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ABSTRACT
An Abstract of a Dissertation Submitted to Nova Southeastern University in Partial
Fulfillment of the Requirements for the Degree of Doctor of Philosophy
MEASURING KNOWLEDGE AND ATTITUDES REGARDING THE USE OF
PHARMACOGENETIC TESTING AMONG PATIENTS AND PRESCRIBERS:
DIFFUSION OF INNOVATION THEORY
By
SUHAIB MOHAMMAD MUFLIH
September 2017
Background: Healthcare providers play a key role in patient care. Their knowledge and
attitudes may play a critical role in the incorporation of pharmacogenetic (PGx) testing into
routine practice. The knowledge and attitudes of patients are also equally important in
determining the rate of diffusion and the adoption of PGx testing. This study aims to test
Rogers’s diffusion of innovation theory to identify and evaluate the influence of
knowledge, attitudes, and sociodemographic characteristics of patients and physicians on
the adoption of PGx testing in current clinical settings.
Method: A cross-sectional, descriptive survey design was implemented. The sample
consisted of patients with chronic diseases and licensed physicians. One-way analysis of
variance (ANOVA), linear regression, and path analysis were performed to test the
research hypotheses.
Results: Limited knowledge regarding PGx testing was prevalent among patients, despite
good attitudes. While the total PGx testing knowledge score was predicted significantly by
levels of education, prior experience, and innovativeness, the total attitude score was
predicted significantly by gender, relative advantage, compatibility, complexity, and
trialability. The acceptance of PGx testing by patients was significantly influenced by their
attitudes towards PGx testing and its perceived characteristics. Physicians expressed low
levels of knowledge regarding PGx testing; however, the majority had favorable attitudes
toward its potential clinical advantages. The total PGx testing knowledge score was
predicted significantly by gender, type of practice setting, and prior experience. Physicians’
attitude score was predicted significantly by gender, relative advantage, and compatibility
of PGx testing. Barriers to the adoption of PGx testing were reported. The acceptance of
PGx testing by physicians was significantly influenced by the perceived characteristics of
PGx testing and the perceived need for testing.

Conclusion: This dissertation successfully evaluated the relationship among several
factors adapted from Rogers’s theory and the adoption of PGx testing. The research is
expected to provide the scientific community with an increased understanding of the
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decision-making process surrounding PGx testing. It will help identify the key factors and
barriers that may have a significant influence on the direction of the future implementation
of PGx testing, which will ultimately assist patients and physicians with therapeutic
decisions.
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Chapter 1
Introduction
Pharmacogenetics (PGx) is a new and dynamic field of medicine. The term PGx was
first coined by the German geneticist Friedrich Vogel (1959) and has recently become an integral
component of clinical practice. This is due to the completion of the Human Genome Project in
2003 and the availability of cutting-edge DNA technology. The major role of PGx testing is to
determine genetic-based variations in drug responses by finding associations between genetic
differences and observable clinical traits in individual patients. This allows for careful clinical
evaluation of potential drug toxicity and effectiveness prior to the initiation of a specific drug
therapy. Yet, despite the prospective benefits of PGx testing in the improvement of both
medication safety and efficacy in many therapeutic areas, its acceptance and use in medical
practice are still limited.
Since physicians play a key role in patient healthcare, their knowledge and attitudes may
play a critical role in the incorporation of PGx testing and genetically recommended therapy into
routine practice. Equally important are the knowledge and attitudes of patients, who may also
affect the rate of diffusion as stated in Rogers’s diffusion of innovation theory and the adoption
of PGx testing (Rogers, 2003).
This dissertation investigates different factors associated with patients’ and physicians’
acceptance of PGx testing. Participants’ knowledge and attitudes toward PGx testing are
evaluated as a set of variables that constitutes the basis of Rogers’s diffusion of innovation
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theory. The research method was a cross-sectional descriptive survey. The surveys of patients’
and physicians’ knowledge and attitudes were derived from the relevant literature and were
tested and developed further to accommodate the framed objectives of this study. Then, eligible
participants were invited to complete the survey. Results were analyzed using a One-way
ANOVA, linear regression, and path analysis models.
This chapter describes the background of the problem and how Rogers’s diffusion of
innovation model can be used to address the statement of the problem. Additionally, the chapter
illustrates the purpose of the study, the research questions and hypotheses, the rationale, and the
need for the study.
Background to the Research Problem
Variations in the human deoxyribonucleic acid (DNA) sequence play a significant role in
the development of diseases. These DNA variations may also cause a differential response to
pathogens, chemicals, drugs, and vaccines (Lazaridis and Petersen, 2005; Zhang et al., 2015).
Each individual has a unique set of genetic markers represented by DNA sequences located in
specific regions of the chromosomes that may help predict his/her response to medications and
the risk of developing a particular disease (Ginsburg and McCarthy, 2001). Research conducted
under the genome-wide association study (GWAS) has helped identify genetic variations that
result in differential health outcomes (Chasman et al., 2004; Shiffman et al., 2012; Srivastava,
2003; Thompson et al., 2005). Researchers have utilized this information to develop efficient
strategies for the detection, treatment, and prevention of various diseases and pathophysiological
conditions. GWAS typically searches the human genome obtained from different individuals for
single-nucleotide polymorphisms (SNPs) associated with defined traits or major diseases. The
role of genetic variability is relevant to medical practice as it eventually enables healthcare
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practitioners to customize treatments and prevention strategies to a patient’s unique genetic
makeup. So far GWAS has successfully identified the association of genetic variations with
many chronic diseases such as type 2 diabetes mellitus (DM), Parkinson's disease, heart
disorders, obesity, Crohn's disease, and prostate cancer (Eeles et al., 2009; Nalls et al., 2013).
Presently the potential benefits of major therapeutic classes (e.g., analgesics,
antipsychotics) have been observed in less than half of patients (Spear et al., 2001). Although
many non-genetic factors such as age, body weight, and disease states cause individual variation
in drug response, the inherited genetic differences among individuals can significantly alter the
pharmacokinetic and pharmacodynamic properties of medications (Roden and George Jr, 2002).
Genetic influences on drug response vary widely among patients. The highest beneficial
response (80%) was expressed among patients receiving selective cyclooxygenase-2 (COX-2)
inhibitors, while the lowest response (25%) was reported among patients receiving
chemotherapeutic medication (Spear et al., 2001).
PGx research is aimed at investigating the roles of genetic differences among individuals
that impact their response to different medications. The ultimate goal of PGx is to determine the
role of genetic variations in drug response by finding associations between genetic differences
(e.g., CYP2C19 *2/2 genotype) and physical changes (e.g., poor metabolizer phenotype) in
individual patients (Hagymási et al., 2011; Tomalik-Scharte et al., 2008). This relatively new
genetic field allows for careful evaluation of potential drug toxicity and effectiveness prior to the
initiation of a specific drug therapy (Benhaim et al., 2012; Kitzmilleret al., 2011; Wang et al.,
2011). For instance, the human genome encoding cytochrome P450 enzymes (CYPs) is
responsible for oxidative metabolism and bio-activation of around 75% of currently prescribed
medications (Guengerich, 2007). Inter-individual variations in the genetic sequences involved in
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coding CYP450 enzymes may result in a reduced, amplified, or complete loss of functionality in
the metabolizing enzymes and, consequently, an alteration in the pharmacokinetics of susceptible
medications and inter-individual variability. According to Lee et al. (2002), the inter-individual
variability of the DNA sequence for the CYP2C9 gene is responsible for about a 30% to 90%
reduction in the enzymatic activity, which typically alters warfarin clearance and the total daily
dose.
Drug-related complications are problematic for patients and healthcare systems. Adverse
drug reactions (ADRs) can result in serious injuries, hospitalizations, and even death. A
combined retrospective patient chart review and patient survey study conducted at eleven general
internal medicine sites in the greater Boston area found that among 2,248 patients who selfreported prescription medication use, 18% indicated ADRs associated with their prescription
medications (Gandhi et al., 2000). Notably, there was no significant association between gender,
age, race, level of education, or insurance status and the reported ADRs. The survey also
revealed that 49%, 48%, and 35% of the 397 patients who experienced ADRs reported
discomfort, seeking medical attention, and interference with daily activities, respectively
(Gandhi et al., 2000).
ADRs are a considerable factor leading to mortality and morbidity. A meta-analysis of
39 prospective studies was conducted to estimate the total incidence of serious ADRs among
patients staying in the hospital and those who were admitted to the hospital due to an ADR in the
US (Lazarou et al., 1998). The study estimated a total of 2,216,000 (6.7%) hospital patients
experienced ADRs and approximately 106,000 (0.32%) death cases were attributed to ADRs in
1994. The study ranked ADRs as the fifth leading cause of death in the U.S. during that year. A
more recent national estimate of annual emergency department visits due to ADRs reported
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approximately 700,000 adverse drug event cases annually between 2004 and 2005, in which
16.7% required hospitalization (Budnitz et al., 2006).
The treatment of chronic diseases often requires long-term use of medications. Patients
with chronic diseases whose physicians do not assess their response to medications are more
likely to have inadequate therapy management (Brown and Bussell, 2011; Gordon et al., 2007).
Moreover, the lack of time and communication between patients with chronic diseases and their
healthcare providers potentially increases patients’ risk of experiencing medication-related
complications (Gandhi et al., 2000; Østbye et al., 2005). Effective chronic disease management
reinforces the need to improve physicians’ knowledge about inter-individual variabilities to
improve quality of prescribing and minimize medication adverse events among patients
responsible for self-administration of their chronic disease medications.
Recent studies have focused on differences in the genetic makeup of individuals that
contribute to variation in therapeutic outcomes and increased susceptibility to adverse effects of
chronic disease medications. Understanding the effect of genetic differences in drug response
among patients enables healthcare providers to select the most appropriate therapeutic choices.
It also helps them reduce side effects that may necessitate urgent medical attention. For
example, variation in metabolism of simvastatin due to genetic differences is associated with
mild to severe myopathy (Owczarek et al., 2005). Likewise, impaired metabolism of clopidogrel
is associated with an increased risk of bleeding (Ma et al., 2011). Currently 150 drugs with PGx
information on their labels (drug package inserts) have been approved by the Food and Drug
Administration (FDA, 2016), indicating that PGx variability should be considered before the
drug is prescribed.
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Various studies have recognized the importance of PGx in personalized medicine and
how the adoption of this tool will primarily help focus on drug selection and dosing (Benhaim et
al., 2012; Ginsburg and McCarthy, 2001; Kitzmiller et al., 2011). The integration of PGx testing
in routine medical practice may help improve clinical outcomes, minimize ADRs, and boost
patients’ perception regarding the safety and efficacy of their medications. Consequently, PGx
can potentially impact patient adherence to chronic disease medications and may result in more
healthcare cost-savings (Haga and LaPointe, 2013; McWilliam et al., 2006).
PGx has become a new field of pediatric research as it has the potential to improve health
outcomes for children. Green et al. (2016) reviewed 65 drugs with FDA-approved PGx
information in search of a safe and effective use of therapeutic medications in children. Out of
the 65 drug package inserts, 28 included prescribing recommendations that were identified based
on specific genetic biomarkers (e.g., glucose-6-phosphate dehydrogenase testing is
recommended before starting treatment with rasburicase). Four drug package inserts indicated
only the availability of genetic tests, three drug package inserts indicated contraindications to use
based on a patient’s genetic makeup, seven drug package inserts mentioned cautions/avoid use or
consider an alternative, and five drug package inserts recommended dosage adjustments.
Finally, nine drug package inserts included more than one prescribing recommendation. The
authors emphasized the role of PGx in rational use of medications to achieve optimal therapeutic
outcomes and decreased ADRs.
Today PGx testing could potentially play a significant role in drug selection and may help
minimize ADRs associated with chemotherapeutics and psychiatric drug use (Kitzmiller et al.,
2011); however, integrating genetic testing more widely into general diagnostic and prescribing
practices has not yet materialized. Studies have shown that lack of awareness and limited
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knowledge among patients and physicians have been two of the most significant factors
contributing to the slow adoption of PGx testing (Rogausch et al., 2006; Stanek et al., 2012).
Unclear ethical guidelines on protection and use of genetic information, unavailability of PGx
tests, lack of evidence supporting the clinical utility, and inefficient administrative and regulatory
policies are also contributing factors to the limited adoption of PGx testing (Ghaddar et al., 2011;
Moaddeb and Haga, 2013).
Theoretical Framework
The Everett Rogers’s diffusion of innovation model has been widely used in several
disciplines such as political science, public health, communications, technology, and education
(Dooley, 1999). It provides an explanatory framework of the domains that have strong
influences on the decision to adopt an innovation or new technology (Rogers, 2003). This theory
explains the reasoning for the adoption of a new technology as well as the rate of adoption. The
present study uses the conceptual framework of Rogers’s diffusion of innovation theory to
examine the impact of factors, in particular innovation decision-making processes, on the
acceptance of PGx testing by patients and physicians.
According to Rogers’s theory, people in any defined population go through five stages of
the innovation-decision process (knowledge, persuasion, adoption, implementation, and
confirmation) as a reaction to an innovation. During the knowledge stage, an individual attempts
to learn more about the innovation: what the innovation is and how and why it works. Following
the knowledge stage, the individual starts developing favorable or unfavorable ideas. According
to Rogers, the formation of a favorable attitude toward an innovation does not always lead
directly or indirectly to an adoption. Knowledge and persuasion are the major stages that
potentially affect an individual’s decision-making regarding adoption or rejection of the
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innovation. If the individual decides to accept the innovation, then it will be put into practice.
After decision-making process and the innovation is already in practice, the confirmation stage
occurs, whereby the individual seeks support for his/her decision to avoid the discontinuance or
rejection of the innovation.
Rogers’s theory provides a number of factors that influence the knowledge and attitude
stages. These factors include prior experience, perceived need for innovation, innovativeness,
rurality, sociodemographic variables (e.g., age, level of education), and communication behavior,
which are knowledge stage attributes. During the knowledge stage and before making the
adoption decision regarding innovations, an individual should become aware of the existence of
the innovation. Prior experience about the innovation helps decrease the uncertainty of that
innovation and facilitate its rate of adoption. While awareness and knowledge regarding a
particular innovation may potentially create a need for it, an individual may also start searching
for an innovation that could meet his/her needs. Furthermore, an individual’s innovativeness
could affect his/her willingness to accept an innovation relatively earlier than other members in
the same social system. According to Rogers, implementing innovations occurs greatly in large
urban areas due to the availability of resources. Sociodemographic variables may also play a
role in the adoption of innovation; Rogers found a positive correlation between education levels
and adoption of innovations. Finally, channels of communication may play a significant role in
creating knowledge and impact the rate of adoption. Individuals usually start seeking
information regarding an innovation only after they become aware of its existence.
The characteristics of innovation (i.e., relative advantage, compatibility, complexity,
trialability, and observability) described by Rogers may explain an individual’s attitudes toward
different innovations and also determine the rate of adoption. Innovations that are perceived as a
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better alternative to existing options will be adopted at a higher rate. Similarly, innovations that
are greatly perceived as well suited with existing values and norms will be accepted faster. Easy
to use and simpler innovations also will be rapidly adopted. Innovations that can be tried and
tested before making the decision to adopt will be adopted at a higher rate. Finally, innovations
that are more visible and noticeable will be more readily adopted. All these factors were
operationalized in this study based on the theoretical lens of Rogers’s theory to generate targetspecific variables that could be assessed from the participants in the sample. Rogers’s diffusion
of innovation model will be further discussed in the next chapter.
Statement of the Problem
Although PGx holds great promise to enhance clinical outcomes of patients and may
assume a key role in predicting ADRs, its integration in medical practice has been implemented
to a limited extent. Aspects beyond medical facts, including knowledge and attitudes of patients
and healthcare professionals, need be addressed. Many studies reported that the lack of adoption
of PGx testing could be due to the fact that patients and physicians are unaware of the need for
testing, do not trust or understand the current evidence of the benefits, or doubt the potential
cost-effectiveness of the testing (Haddy et al., 2010; Perlis et al., 2009; Priest et al., 2006). Other
factors that may also impact the acceptance of PGx testing are the lack of adequate PGx
educational programs and well defined practice guidelines for the use and interpretation of these
tests (Haga et al., 2012a; Rogausch et al., 2006).
A few studies have been conducted to measure patients’ and physicians’ knowledge and
attitudes toward PGx testing. While some recognized a major lack of knowledge and experience
about genetic tests among physicians, others found that physicians were less likely to have
positive attitudes toward the use of PGx testing because of their own concerns about
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understanding phenotyping, patient confidentiality, and patient eligibility for health insurance.
These studies also revealed that some positive advantages of PGx were perceived by physicians
who have more favorable attitudes toward the role of PGx testing in improving general health
and minimizing the frequency of drug-related complications. Similarly, based on existing
studies, there was a lack of knowledge and awareness about genetic testing among patients with
chronic diseases, and this lack of knowledge affected their decision to undergo PGx testing. Yet
most patients expressed positive attitudes, were generally supportive of PGx testing, and felt it
would be of advantage toward their health.
Since individualized medicine is not fully developed for most drugs, PGx testing has not
been recommended by expert committees due to the lack of conclusive and sufficient evidence
that testing improves health outcomes. There have been barriers to the implementation of PGx
testing in clinical settings reported by several studies, especially lack of awareness and limited
knowledge among patients and physicians, lack of clinical practice guidelines that strongly
support the clinical utility of PGx testing, physicians’ concerns about patient confidentiality, and
patients’ ability to afford the testing (Fargher et al., 2007; Ghaddar et al., 2011; Haddy et al.,
2010; Rogausch et al., 2006). Nevertheless, the number of available PGx tests has increased
drastically since 2004, as some ongoing clinical trials are completed (Frueh et al., 2008).
Physicians’ awareness, understanding, and attitudes regarding PGx testing may play a key role in
the rapid diffusion of these genetic tests in clinical practice. Moreover, the knowledge and
attitudes of the general public may play a decisive role in the wider acceptance of PGx testing in
society. Data from previous studies indicate that the public is open to the adoption of new
technology for the betterment of health (Haddy et al., 2010; Rogausch et al., 2006).

11
The lack of knowledge and variable attitudes toward PGx testing appear to be dominant
barriers within healthcare systems. Few studies exist on this topic, and most have been
conducted on patients and physicians outside Florida. Only a few publications have focused on
knowledge and attitude toward PGx testing among patients with chronic diseases (Calsbeek et
al., 2007; Cuffe et al., 2014; Lachance et al., 2015; Morren et al., 2007; Trinidad et al., 2015).
Additionally, there have been very few studies that adequately demonstrate the impact of patients
and physicians knowledge and attitudes on the adoption of PGx testing based on Rogers’s
diffusion of innovation theory (Armstrong et al., 2003; Dressler et al., 2014; Nielsen and
Moldrup, 2007). Relying only on the findings of existing studies to draw broad conclusions
about the knowledge and attitudes towards PGx testing among patients and physicians may not
be representative of the heterogeneous population of Florida.
More research is needed to understand if and how patients’ and physicians’ knowledge
and attitudes contribute to the adoption of PGx testing. Knowledge and attitudes toward PGx
testing are critical to expanding this evolving field of science. The implementation of PGx in
routine medical practice and future personalized medicine will ultimately depend upon patients’
and physicians’ acceptance of these tests and related recommendations.
There is a significant gap concerning knowledge and attitudes toward PGx testing among
patients with chronic diseases and physicians in the State of Florida that may be related to their
uncertainty to adopt PGx testing with promising health outcomes. Due to the relationship among
knowledge, attitudes, and the adoption of innovation explained by Rogers’s diffusion of
innovation theory, this study focused on the measurement of knowledge and attitudes as they
relate to the acceptance of PGx testing.

12
Purpose of the Study
This study aimed to identify and evaluate the influence of knowledge, attitudes, and
sociodemographic characteristics of patients and physicians on the adoption of PGx testing as a
diagnostic tool in the current clinical settings. In order to achieve a better understanding of
decision-making processes toward PGx testing and the strategies that help foster efficient
adoption, this study was based on Rogers’s diffusion of innovation theory, which has been
widely accepted as a theoretical model to explore diffusion and adoption of innovations. The
knowledge and attitudes toward PGx testing were compared among patients filling their
prescriptions for their chronic conditions at the Nova Southeastern University (NSU) Clinic
Pharmacy in Fort Lauderdale, Florida, who would be willing to reject or accept PGx testing, if
available, for one of their chronic disease medications. The knowledge and attitudes toward PGx
testing were also compared among physicians who would be willing to reject or accept PGx
testing, if available.
Research Questions and Hypotheses
Previous scholarly work has independently evaluated patients’ and physicians’
knowledge and attitudes toward PGx testing (Calsbeek et al., 2007; Cuffe et al., 2014; Haga et
al., 2012a; Haga et al., 2012c; Henneman et al., 2006; Kobayashi and Satoh, 2009; Lachance et
al., 2015; Lanktree et al., 2014; Morren et al., 2007; Nielsen and Moldrup, 2007; Stanek et al.,
2012; Stanek et al., 2013; Taber and Dickinson, 2014; Trinidad et al., 2015; Walden et al., 2015).
Pursuing this work, the goal of this study was to increase understanding of several factors
(sociodemographic characteristics, knowledge, and attitudes) that may play a role in the early
adoption of PGx testing among patients and physicians by answering the following research
questions:
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Research Question 1A:
What is the association between patients’ knowledge of PGx testing and their gender,
age, ethnicity, level of education, area of living, prior experience, innovativeness, and perceived
need for innovation?
H0 (1A): Gender, age, ethnicity, level of education, area of living, prior experience,
innovativeness, and perceived need for innovation are not significantly associated with
knowledge of PGx testing among patients.
Research Question 1B:
What is the association between physicians’ knowledge of PGx testing and their gender,
age, ethnicity, medical specialty, type of practice setting, duration of practice, prior experience,
innovativeness, and perceived need for innovation?
H0 (1B): Gender, age, ethnicity, medical specialty, type of practice setting, duration of
practice, prior experience, innovativeness, and perceived need for innovation are not
significantly associated with knowledge of PGx testing among physicians.
Research Question 2A:
What is the association between patients’ attitudes toward PGx testing and relative
advantage, compatibility, complexity, trialability, and observability of PGx testing?
H0 (2A): The relative advantage, compatibility, complexity, trialability, and observability
are not significantly associated with attitudes toward PGx testing among patients.
Research Question 2B:
What is the association between physicians’ attitudes toward PGx testing and relative
advantage, compatibility, complexity, trialability, and observability of PGx testing?
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H0 (2B): The relative advantage, compatibility, complexity, trialability, and observability
are not significantly associated with attitudes toward PGx testing among physicians.
Research Question 3A:
Do knowledge, attitudes, perceived characteristics of innovation, and sociodemographic
characteristics significantly influence the acceptance or rejection of PGx testing among patients?
H0 (3A): There is no relationship between patients’ willingness to accept PGx testing and
their knowledge of PGx testing, attitudes toward PGx testing, perceived characteristics of PGx
testing, and sociodemographic characteristics.
Research Question 3B:
Do knowledge, attitudes, perceived characteristics of innovation, and sociodemographic
characteristics significantly influence the acceptance or rejection of PGx testing among
physicians?
H0 (3B): There is no relationship between physicians’ willingness to accept PGx testing
and their knowledge of PGx testing, attitudes toward PGx testing, perceived characteristics of
PGx testing, and sociodemographic characteristics.
Rationale and Need for the Study
Advances in the knowledge regarding human genetic variation and its relation to drug
responses have increased significantly since the completion of the Human Genome Project in
2003. Yet, despite the prospective benefits of PGx testing in improving both medication safety
and efficacy in many therapeutic areas, the literature shows that the use of PGx testing remains
limited in many clinical settings. Further aspects beyond medical facts, including knowledge
and attitudes of patients and physicians, need be studied. Although the FDA has reviewed more
than 150 labels of prescription medications to include information regarding the impact of
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genetic variation on medication safety and efficacy (FDA, 2016), the integration of more
widespread genetic testing into general diagnostic and prescribing practices has not yet occurred,
possibly due to the limited knowledge and awareness among patients and physicians.
Research is needed to understand if and how patients’ and physicians’ knowledge and
attitudes contribute to the adoption of PGx testing and use of the results to guide prescribing.
Haga et al. (2012a) indicated that 76% of physicians were unaware of the drug package inserts
including PGx information, and only 13% of physicians indicated they felt comfortable ordering
PGx testing. Available studies on sociodemographic characteristics and geographic locations
that did not include Florida were conducted a few years ago; since then, much has changed in the
field of PGx testing.
This study primarily focused on the initial factors that prompt patients or physicians to
either reject or accept the utilization of PGx testing according to Rogers’s theory. A more
thorough understanding of the underlying barriers that influence the decision-making process can
be expected to have important benefits for promoting personalized medicine. Florida has an
increasingly diverse general population; thus, a unique opportunity exists to update the
knowledge on the use of PGx testing and gather information from a culturally diverse population
filling their prescriptions at the NSU Clinic Pharmacy. The contribution of this research is
expected to significantly advance patients’ and physicians’ knowledge, improve their attitudes
toward the use of PGx testing, and encourage them to utilize testing not only for drugs available
with PGx information, but potentially to inform other treatment decisions currently or in the
future. For example, the results of PGx testing for one or more enzymes involved in the
metabolism of a particular drug could possibly inform useful treatment decisions for other future
prescribed medications that share the same metabolic enzymes (Mills et al., 2013). Additionally,
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this study measured the influence of certain sociodemographic factors on the willingness of a
patient to use PGx testing. Thus, it may advance physicians’ understanding of patients’ needs
and subsequently the need for change in their current clinical practice.
Patients with chronic conditions are of a growing concern in the U.S. due to their high
risk of morbidity and mortality responsible for almost 80% of all causes of death in 2010
(Murphy et al., 2012). Studies have shown that patients with chronic diseases who were less
motivated to manage their conditions had a lower rate of medication adherence that impacted
their health outcomes (Balkrishnan, 2005; Kripalani et al., 2007). Moreover, patients’ concerns
regarding the appropriateness of their medications, the possibility of having ADRs, and lack of
communication between patients and physicians could negatively influence the optimal outcome
of their chronic conditions (Gordon et al., 2007; Stevenson et al., 2004). Stevenson et al. (2004)
showed that increasing the role of patients in decision-making and considering patients’
preferences toward treatment options have potential benefits on their health outcomes. As such,
patients’ perceptions of their medication suitability, as well as understanding the rationale behind
switching to other medications and/or different doses, have a favorable impact on their health
(Balkrishnan, 2005; Gordon et al., 2007). Therefore, more careful assessments of chronic
condition medications are needed to provide patients with more information about their therapy
of choice and potential side effects, which could enhance their medication utilization. The
findings of behavioral research on the acceptance of a new clinical tool such as PGx testing
could help support the informed prescribing process.
Definitions of Variables and Concepts
In order to achieve a better understanding of the decision-making process in PGx testing
and which strategies would help foster its efficient adoption, this study aimed to identify and
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evaluate the impact of knowledge and attitudes of patients and physicians in the adoption of PGx
testing as a diagnostic tool in the clinical settings. What follows is a definition of relevant
variables within Rogers’s diffusion of innovation theory.
Knowledge Stage
Individuals become aware of the existence of an innovation and collect more information
to gain a better understanding of its characteristics. The following are antecedents to the
knowledge stage:
● Innovativeness: the degree to which an individual is willing to accept the innovation
relatively earlier than other members in the same social system.
● Prior experience: the degree to which an individual is aware or familiar with the innovation
prior to making an adoption decision.
● Perceived need: the degree to which an individual believes in the utility of the innovation.
● Work environment: the location of an individual workplace (i.e., urban, rural).
● Sociodemographic variables: gender, age, ethnicity, level of education, and area of living.
● Communication channels: the most effective resources of generating knowledge about an
innovation.
Persuasion Stage
Individuals acquire positive and negative attitudes toward the innovation. The following
are attributes of adopters’ attitudes toward the characteristics of innovation:
● Relative advantage: the degree to which an individual believes that the value in the
innovation is higher than what it replaces. Greater perception of advantages leads to a
higher rate of adoption.
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● Compatibility: the degree to which the innovation deviates from the existing values,
practice, and prior experiences. Greater perception of compatibility leads to a higher rate
of adoption.
● Complexity: the degree to which the innovation is perceived as difficult to understand or
use. Simpler innovations are accepted at a relatively higher rate.
● Trialability: the degree to which the innovation can be tested or tried before adoption. The
ability to try an innovation reduces the level of perceived uncertainty and ultimately
increases the rate of adoption.
● Observability: the degree to which the results and effects of the innovation are noticeable
by individuals. Per Rogers’s theory, individuals who can more easily see the results of the
innovation will be more likely to adopt it.
Characteristics of Innovations
The characteristics of innovations perceived by an adopter include relative advantage,
compatibility, complexity, trialability, and observability, which could potentially influence the
rate of adoption of innovations.
Pharmacogenetics
The study of inherited genetic differences that influence an individual’s responses to
drugs (Nebert, 1999). The term is often used interchangeably with the term pharmacogenomics,
but there is a difference. The distinction is fully explored in
Chapter 2.
Pharmacogenomics
A comprehensive study of all genetic variants within an individual or across a population
to relate their multiple effects on drug response (Evans and Relling, 1999).
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Chronic Conditions
A health problem such as cardiovascular disease, asthma, and cancer that lasts for at
least three months (Goodman et al., 2013; National Center for Health Statistics [NCHS], 2011).
Almost 50% of U.S. adults have at least one chronic condition (CDC, 2017; Ward et al., 2014).
Chronic Medications
Medicines prescribed over a long period of time (at least three months) to control or
manage chronic diseases (e.g., antihypertensive and antidiabetic medications).
Summary
PGx testing is a relatively new diagnostic clinical tool. It provides an opportunity to
tailor medications based on an individual’s genetics. Several studies have recognized the
potential benefits of PGx testing to evaluate possible drug toxicity and increase drug
effectiveness; however, the slow uptake of PGx testing in clinical practice has resulted in limited
information about the acceptance of PGx testing among patients and physicians. The objective
of this study was to test Rogers’s diffusion of innovation theory on the adoption of PGx testing.
It is expected to contribute to the existing literature by identifying a set of potentially modifiable
variables that may affect the adoption of PGx testing by patients and physicians, thus increasing
understanding of the decision-making process surrounding PGx testing and identifying the key
factors and barriers that may highly influence the direction of future implementation of PGx
testing in routine clinical practice.
In the next chapter the theoretical framework is discussed. Along with a description of
the potential clinical utility of PGx and pharmacogenomics to inform treatment decisions, a
review of the relevant studies found in the literature is undertaken.
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Chapter 2
Literature Review
Published works related to patients’ and physicians’ knowledge and attitudes
toward PGx testing are presented and discussed in this chapter. Rogers’s diffusion of
innovation theory, which was adopted as the conceptual framework for this research, is
examined in the first part of this review. The concepts of PGx and pharmacogenomics
are described in the second part. The relevant literature is reviewed in the last part of this
chapter to support the current research questions and hypotheses.
Literature Search Method
Potentially relevant studies were identified by searching MEDLINE EBSCO,
EMBASE, and Google Scholar for all articles written in English that reported results
based on surveys, interviews, or focus groups. To narrow the scope of search, the
following keywords that describe the current dissertation project were used: knowledge,
awareness, attitudes, perception, views, perspectives, opinions, adoption,
pharmacogenomics, pharmacogenetics, pharmacogenetic testing, genetic factors,
diffusion of innovation, barriers, drug response physicians, doctors, clinicians, chronic
diseases, patients, and public. These keywords were searched in combination using the
Boolean operators “AND, OR, and NOT.” Then the corresponding titles and abstracts
were carefully reviewed to assess their potential relevance to this dissertation. Included
were all the works conducted on patients and physicians to assess their knowledge and/or
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attitudes toward PGx testing up to 2017. Studies conducted on genetic diseases or
genetic factors linked to diseases were excluded. After applying inclusion and exclusion
criteria, 40 studies were identified. After subsequent scrutiny, 27 studies were selected.
Diffusion of Innovation Theory
Rogers’s diffusion of innovation theory provides a useful framework for
evaluating the factors that might affect acceptance of an innovation such as PGx testing
among patients and physicians (Rogers, 2003). According to Rogers, adoption is defined
as “full use of an innovation as the best course of action available” and rejection is
defined as “not to adopt an innovation.” An innovation is described as “an idea, practice,
or object that is perceived as new by an individual.”
Five distinctive stages are identified: knowledge, persuasion, decision,
implementation, and confirmation (see Figure 2.1). The knowledge and persuasion stages
were operationalized, defined, and measured in this study using patients’ and physicians’
perspectives to generate specific items. Knowledge is gained when an individual learns
of the innovation’s existence and obtains more information to determine how it functions.
Having enough information at this stage helps override the problem of uncertainty about
the mechanism by which the innovation’s capacity solves an individual’s problems.

Figure 2.1: Illustration of the various stages in implementing an innovation as adapted
from Rogers’s diffusion of innovation theory.
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The persuasion stage occurs when an individual’s attitude toward the innovation
changes from positive to negative or vice versa. Availability of new knowledge, along
with the individual’s attitude, plays a critical role in the adoption decision of the
innovation. The decision process takes place when an individual is involved in making
his/her own choice to adopt or reject the innovation. Implementation occurs later when
an individual makes a decision to adopt and utilize the innovation. Afterwards, an
individual starts seeking support for his/her decision. At this point, confirmation occurs
and the individual decides to make full use of the innovation or discontinue it.
Rogers’s diffusion of innovation theory has been applied in several health studies.
Helitzer et al. (2003) applied it to examine the acceptance of telemedicine and its
components for an efficient delivery of healthcare services. Chew et al. (2004) used it to
assess the acceptance by family physicians of the Internet as an innovative tool for
clinical and public health topics. Zhang et al. (2015) applied it to measure patients’
acceptability for consumer e-health services, and Dodson (2012) applied it to measure the
adoption of PGx testing among oncology nurses. These studies demonstrated that
Rogers’s theory provides a useful theoretical framework for promoting health behavior or
adopting relatively new medical tools.
Rogers’s theory identifies five adopter categories based on the number of
individuals who adopt the innovation in a given time period. The adopter categories
include innovators, early adopters, early majority, late majority, and laggards (see
Figure 2.2). These categories are presented as segments of a bell-shaped curve and
indicate innovativeness defined as the extent to which an individual is relatively early in
adopting new ideas. Innovators are the first to try new ideas regardless of the level of
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Figure 2.2: Illustration of a normal distribution encompassing adopter categories as
described by Rogers’s diffusion of innovation theory.
uncertainty. Early adopters come later and serve as role models and opinion leaders for
the remaining categories; their well informed decision-making greatly influences the
majority of the social system. Early majority and late majority adopters represent the
largest section of the social system; they adopt an innovation and start adoption as a
result of interpersonal networking and peer adoption and recommendation. The late
majority is generally skeptical and reluctant to adopt an innovation due to high levels of
perceived uncertainty; however, increasing peer pressure may persuade them to adopt.
Laggards are the last to adopt an innovation; their slow decision to adopt is likely because
they are more suspicious of innovations and have no opinion leadership.
The successful application of Rogers’s theory helps investigate the factors
affecting the rate of adoption among potential adopters; it also helps target those who are
usually classified as the late majority or laggards to shift into an earlier adoption stage for
a more efficient use of the PGx testing tool. A limited number of studies have examined
the rate of PGx testing adoption among physicians. Stanek et al. (2012) conducted a
cross-sectional survey that showed physicians who were early adopters of PGx testing
were more likely to be practicing in an urban setting with a long duration in overall
medical practice (15-29 years) and had previous experience ordering genetic testing. The
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study also found that early adopters of PGx testing were influenced by medical specialty;
the highest adoption rates were reported by oncologists (69%), much higher than those of
family medical practitioners (12%) or nonsurgical specialists (10%). In comparison to
late adopters of PGx testing, a larger percentage of early adopters had received PGx
training in their undergraduate and postgraduate studies. In contrast, late adopters were
more likely to be male, older, and with a longer duration of medical practice than early
adopters. Physician age and gender had no significant association with early adoption of
genetic testing.
This research study focused on the first two stages of the Rogers’s diffusion of
innovation theory. The first step of the decision-making process focused on initial
awareness and knowledge of an innovation. Although knowledge does not guarantee
successful adoption of an innovation, it is essential to motivate individuals to seek more
information relevant to the innovation. Subsequently individuals begin to shape their
own attitudes concerning that innovation. After learning more about the innovation and
becoming more involved with it by forming positive or negative attitudes, the individual
must then be persuaded to choose to accept or reject the innovation. A meta-analysis of
75 studies, conducted and summarized by Tornatzky and Klein (1982), reported that the
more relative advantage, compatible, simple, trialable and visible the innovation is, the
more likely it is to be adopted and put in practice.
Pharmacogenetics and Pharmacogenomics
Recent studies have increasingly focused on the evolving role of both PGx and
pharmacogenomics in dealing with the impact of genetic variations on drug response.
Typical variability in an individual’s response to medications creates challenges in
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prescribing the correct medication and the optimal dosage regimen. The human genome
encodes tens of thousands of proteins. These proteins play a crucial role in several
pathways of drug metabolism, disposition, and therapeutic effects. SNPs, DNA sequence
variants, are considered the inherited basis of inter-individual variability in drug response
(Collins et al., 1998). Across the human genome, the identification of a large number of
SNPs could serve as database of genetic markers to predict an individual’s susceptibility
to diseases or altered drug responses. For instance, SNPs of the genes that encode drug
metabolizing enzymes (e.g., CYP2C9, CYP2D6) have been associated with impaired
metabolism and variable drug responses for warfarin and codeine, respectively (Evans
and Relling, 1999). Therefore, to improve medication safety and efficacy among
genetically susceptible individuals, an adjusted dose of warfarin to achieve the
therapeutic anticoagulant effect can be predicted on CY2C9 SNPs. Similarly, selecting
an individual-specific dose of codeine is important to improve pain relief (Evans and
Relling, 1999).
With the completion of the Human Genome Project in 2003, more information
about the entire collection of human genes has become available for research. To
promote the scientific understanding of human genetics, research has begun to identify
not only common disease-causing genetic variants, but also the relationship between
genetic variants and drug response (Manolio et al., 2008). The field of PGx examines a
single gene-drug interaction, which is determined by the impact of genetic variation (i.e.,
SNPs) on drug metabolism and disposition in the human body. For example, genetic
polymorphism of drug-metabolizing enzymes CYP2C9 could potentially impact the

26
anticoagulant effect of warfarin; similarly, genetic polymorphism of CYP2C19 could
potentially impact the antiplatelet effect of clopidogrel (Roden et al., 2011).
Emerging data about the relationships between phenotypes and genetic variants in
multiple genes have advanced the understanding of variable drug response (Manolio et
al., 2008). Thus, the term pharmacogenomics has become more recently used to indicate
the existence of multiple genetic variants modulating drug response (Roden et al., 2011).
Pharmacogenomics examines multiple genetic variants within an individual or across a
population to relate their multiple effects to drug pharmacokinetics and drug response. In
addition to the genetic variability in drug pharmacokinetics, pharmacogenomics also
investigates additional candidate genes encoding drug molecular targets that control the
effect of drugs on the body (pharmacodynamics). For example, polymorphisms in
CYP4F2, CYP2C18, EPHX1, and GGCX genes may alter the pharmacokinetic and
pharmacodynamics of warfarin and contribute to its heterogeneous response (Roden et
al., 2011).
The majority of prescribers rely on conventional drug therapy, treating patients as
large homogenous groups regardless of whether or not there is a genetic component
influencing the outcome of drug therapy (Vogenberg et al., 2010). When considering a
shift into more accurate prescribing based on the genetic profiles, however, PGx and
pharmacogenomics may help find more appropriate treatment for individual patients
(Vogenberg et al., 2010). PGx and pharmacogenomics should be integrated into current
medical practice, as they continue to hold substantial promise to improve drug
therapeutic outcomes among genetically susceptible patients.
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Patients’ Knowledge of Pharmacogenetic Testing
Studies have shown that unsuccessful implementation and decreased utilization of
genetic testing are linked to the lack of knowledge and negative attitudes toward genetic
testing. For example, Calsbeek et al. (2007) assessed and established that less perceived
medical knowledge about genetic testing and more perceived social knowledge of genetic
testing were responsible for the poor attitudes toward PGx testing in patients with chronic
diseases such as asthma, DM, and cardiovascular disease (CVD). They also found that
perceived genetic knowledge was inadequate, particularly among older and less educated
patients. The authors reported that knowledge and attitudes toward genetic testing did
not significantly change over a follow-up period of two years. It should be noted that the
strength of their study was its longitudinal nature and that its results corresponded with
Rogers’s diffusion of innovation theory. However, the study had limitations that could
compromise its findings. Its sample size might not have been sufficient to detect small
changes in knowledge and attitudes over a period of two years, and it did not clearly
define PGx testing.
These findings were supported by another study in which Morren et al. (2007)
observed that patients with chronic diseases, including CVD, asthma or chronic
obstructive pulmonary disease (COPD), DM, musculoskeletal disease, cancer,
neurological disease, and gastrointestinal disease, were not able to make decisions
regarding genetic testing. This was not due to their uncertainties about the PGx testing,
but the lack of knowledge and awareness about genetic testing that affected their decision
to undergo PGx testing. In contrast, Haga et al. (2012b) found that almost 80% of study
participants heard of the term genetic testing, and less than 2% of them had been ordered
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PGx testing to predict drug response. They also found that White and female
participants, as well as those with a college degree, were more aware of genetic testing
than the rest of the sample.
Utilizing a national representative sample of patients with chronic diseases,
Morren et al. (2007) found that perceived genetic knowledge was limited, particularly
among older and less educated patients. Despite the limited knowledge and low
awareness, more positive attitudes toward genetic testing were found among younger and
more educated patients. One of the strengths of their work was the use of a large sample
size; the study also significantly contributed to the knowledge base by suggesting
variables that might influence the adoption of PGx testing. A limitation, however, was
the use of few response options that might have estimated less accurately participants’
knowledge and attitudes. Another limitation was that it used the term genetic testing in
general and avoided using the term PGx testing.
A study surveying 3,000 patients in Denmark, conducted by Nielsen and Moldrup
(2007), revealed results similar to those of the Morren et al. (2007) study, namely, the
public had poor knowledge but good attitudes toward PGx testing. Nielsen and Moldrup
(2007) also reported that prior use of medical tests and perceived needs for PGx testing
were related to the general knowledge and attitudes toward PGx testing, as well as the
future use of these tests. Their work was influential because it was based on Rogers’s
diffusion of innovation theory and the adapted variables provided consistent results with
the theory. Its weakness, however, was the potential selection bias that might have
occurred, since only individuals with Internet access could participate.
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Understanding factors that could influence the acceptance of well established
innovations may support the design and conduct of this dissertation. Or and Karsh
(2009) performed a systematic review to identify the variables influencing patients’
acceptance of consumer health information technology (IT) applications, which enables
them to electronically manage their health information. The review reported an
association between patient-related factors and their adoption decision. Among the 52
reviewed studies, more than half found that higher education and prior experience were
associated with increased acceptance. Age was examined in 39 studies, and it did not
show a consistent effect on the acceptance of health IT application. Gender demonstrated
no effect in the majority of the studies, either. Six studies reported that lack of familiarity
and perceived benefits were negatively associated with patients’ acceptance of health IT
applications.
In 2015 a qualitative study was conducted to explore patients’ attitudes regarding
the role of PGx testing in reducing ADRs and improving medication efficacy (Trinidad et
al., 2015). Patients taking chronic disease medications for mental health disorders were
recruited. Results showed that the majority of patients were less familiar with the impact
of inter-individual genetic differences in medication response and only a few believed
that this variability was inheritable. The authors reported that participants perceived the
potential benefits of PGx testing on improving their medication response and reducing
the challenges of avoiding ADRs. This project was important because it enriched the
existing literature about PGx testing from the perspective of patients with mental disease.
A cross-sectional study was conducted on cancer patients, evaluating their
willingness to accept and pay for PGx testing (Cuffe et al., 2014). Findings revealed that
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the majority of patients (85%), regardless of their lack of knowledge, perceived that PGx
testing would help in detecting the therapeutic benefit of medications and avoiding
chemotherapy-induced toxicities. The majority of adjuvant and metastatic patients were
willing to accept PGx testing if it was offered free with a one-day waiting period for
testing results. The majority of the participants were also willing to pay out of pocket for
this innovation and devote several weeks of waiting time to receive the testing results.
Almost 15% of the participants were reluctant to accept PGx testing, however, because
they were worried about the potential of these genetic tests to disclose information about
the inheritability of cancer. The strength of this work was the validity of the comparisons
between patient groups to detect the perceived benefits of PGx testing. The reliability of
the findings also was supported by measuring participants’ willingness to pay for PGx
testing. Yet recruiting participants from one cancer center limited the generalizability of
the findings, plus differences in patients groups’ sociodemographic characteristics might
have led to biased statistical results.
Patients’ Attitudes toward Pharmacogenetic Testing
Lachance et al. (2015) conducted a survey among three groups of individuals:
healthy volunteers, heart failure (HF) patients, and heart transplant recipients. The
researchers compared the opinions of each group on PGx testing. All three groups
expressed high expectations and hope about the usefulness of PGx testing, but were
concerned about the confidentiality of the testing results. Healthy volunteers had higher
concerns about confidentiality, employability, and insurability compared to HF and heart
transplant patients, and the majority of participants expressed concerns about undergoing
PGx if there was no suitable alternative drug available. The authors reported that 24%,
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13%, and 17%, respectively of healthy volunteers, HF patients, and heart transplant
recipients were more likely to consider genetic testing only if the targeted disease of
interest was treatable. The study’s strength was providing a valid comparison between
healthy and unhealthy participants’ perspectives toward PGx testing. It also enlightened
future studies to address the need for complete confidentiality, enhanced educational
programs, and public awareness. Its lack of generalizability to the target population was
a limitation. In addition, there might have been a selection bias insofar healthy
individuals might have been less interested in PGx testing than participants with chronic
diseases.
In 2015 a qualitative study showed that participants taking carbamazepine and
antidepressants commonly suffered from multiple drug reactions and reported a lack of
therapeutic benefit. These patients required assurance of the optimal therapeutic outcome
of PGx testing and whether or not they were on the correct medications (Trinidad et al.,
2015). Based on Rogers’s diffusion of innovation theory, the association between
knowledge and attitudes of patients toward PGx testing is vital to achieving effective use
of testing. But the lack of adequate knowledge about PGx testing can lead to
apprehension among patients, even though they may agree with the benefits of testing
(Trinidad et al., 2015). The authors reported that patients expressed positive attitudes
toward the clinical advantages of PGx testing; however, most of them had concerns that
might possibly outweigh the perceived benefit of PGx testing. These concerns included
vulnerability to unauthorized access to genetic information, risk of discrimination in
health insurance, and employability. Similar results were reported by Haddy et al. (2010)
when chronically ill patients emphasized the potential advantage of PGx testing but were

32
worried about the potential discrimination and unauthorized access to genetic
information. Both Trinidad et al. (2015) and Haddy et al. (2010) provided a distinctive
qualitative insight on the potential barriers of accepting the use of PGx testing. Their
findings could not, however, be extended to the whole target population.
Trinidad et al. (2015) also showed that the fear of discrimination and
stigmatization was more prevalent among patients with mental health conditions than
healthy patients. Participants were concerned about not receiving the therapeutic dose or
correct medication if their physicians relied solely on the results of PGx testing and
overlooked their patients’ feedback on prescribed psychotropic medications. Therefore,
some patients perceived PGx testing as an additional source of information about drug
response rather than the only source. The study contributed to the understanding of a
specific population prior to the transition of PGx innovation into practice, as emphasized
by Rogers’s diffusion of innovation theory.
A longitudinal study of undergraduate medicine and science students at three
Canadian universities aimed to assess the students’ attitudes regarding the use of PGx
testing for psychotropic medications, assuming that these tests would result in the best
therapeutic outcomes (Lanktree et al., 2014). Nine out of ten participants expressed
positive attitudes toward PGx testing and its use for the optimal selection of psychotropic
medications. About 78% of participants raised concerns about potential discrimination
and the potential of using the results for non-clinical reasons. Sociodemographic
characteristics such as age, sex, race, and religion group were not significantly associated
with the students’ attitudes. The strength of this work was that it contributed to the
understanding of the use of PGx testing in psychiatric patients who usually experience a
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wide range of ADRs; its weakness was the use of a convenient sample with a potential
selection bias.
In a random digital phone survey among U.S. adults, Haga et al. (2012b)
concluded that people expressed interest in PGx testing to find out about ADRs and seek
help with drug and dosage selection. The authors indicated that White participants with a
higher educational degree and prior experience of side effects expressed greater positive
attitudes toward PGx testing than the rest of the sample. They established that people
would be less likely to use PGx testing if their genetic information was shared for nonclinical purposes. The strengths of this study were its large number of participants and its
novel insight about the association of sociodemographic characteristics and several
benefits of PGx testing as perceived by the public. The limitations included an unclear
definition of PGx testing, lack of a theoretical base, and inadequate description of the
methods.
In a study conducted in Australia, Haddy et al. (2010) enrolled 35 individuals who
personally had, or had an immediate family member with, a chronic medical condition.
Patients were generally positive about PGx testing and were supportive of its use as a
medical tool to help individualize treatment decisions rather than worrying about the
negative effects of medications. Most participants, however, expressed concerns about
the ability of PGx testing to determine future sensitive diseases (e.g., mental diseases)
because of the potential for discrimination by insurance companies and employers. The
study also revealed some potential barriers to the successful implementation of PGx
testing, including concerns regarding storage of PGx testing results, the privacy of
genetic information, and the cost of the test.
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Rogausch et al. (2006) reported that 35% of patients with asthma or COPD
expressed concerns about adverse results of PGx testing if a therapeutic alternative was
not available while the available drugs were ineffective or caused serious ADRs.
Patients’ low expectations regarding PGx testing results were evidenced in that 69% and
44% of patients believed that they would be at a disadvantage with employers and health
insurance companies, respectively. The majority of patients strongly felt that PGx testing
would be advantageous to optimize their medication therapy in terms of avoiding taking
wrong medications (75%), selecting a medication that best worked for them (63%), and
avoiding ADRs (63%). The possibility of unavailable therapeutic options recommended
by the genetic testing worried 72% of patients. Moreover, the study revealed that age and
gender were major predictors of a hopeful attitude. The strength was its use of a large
sample size to assess patients’ and physicians’ opinions regarding the use of PGx testing
in a common chronic disease; however, providing participants with a leaflet explaining
PGx with examples might have created self-report response bias. In addition, the
findings might not have been generalized because the study focused on only two chronic
disorders.
The authors also reported that younger patients were more likely than older
patients to be optimistic about the useful application of PGx testing, while female patients
were more likely than male patients to have fears and anxieties. Approximately one-half
of physicians had favorable attitudes toward recommending PGx testing for their patients
prior to the initiation of the therapy (e.g., anti-asthma medications) only if PGx testing
was covered by health insurance. Additionally, physicians were concerned that patients
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would be discriminated by health insurance companies if undesirable genetic testing
results were disclosed to them.
A qualitative study was conducted in North-West England to explore the views of
patients regarding autoimmune conditions and the views of healthcare professionals on
PGx testing (Fargher et al., 2007). The study revealed that patients eligible to obtain PGx
testing related to their immunosuppressant agents had positive attitudes. Patients also
had high expectations of the benefits of PGx services providing healthcare practitioners
were confident in interpreting and explaining the testing results. The authors suggested
that the gap between patients’ anticipated benefits of PGx testing and barriers to
delivering PGx testing in clinical practice illustrates the need for awareness, educational,
and training programs to facilitate the integration of PGx testing into clinical practice.
Similar findings were reported by Moaddeb et al. (2015), who evaluated the experiences
and feasibility of applying PGx testing in five community pharmacies. They revealed
that offering PGx testing services for patients taking clopidogrel and simvastatin was
feasible; however, additional training and effective communication between patients and
physicians were required for an enhanced clinical use of these genetic tests. The Fargher
et al. (2007) study’s strength was that it helped design future research that would shed
light on the urgent need for PGx education and training programs, and how these factors
may affect the dissemination of PGx testing, although there was a weakness concerning
generalizability of the results.
Patients should be given sufficient details to understand the pros and cons of PGx
testing to assist in decision making. For example, a single gene in the human genome
may influence the therapeutic effects of many prescribed medications; as a result, PGx
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tests could potentially help in choosing the most effective available therapies, with the
correct dose, and reduce the risk of drug-drug interactions for numerous treatments. The
possibility of genetic discrimination, confidentiality of the testing results, the ability of
providers to effectively translate and explain the testing results, feelings of being denied
access to treatment, the cost of the tests, and the lack of evidence-based clinical
information may impact the decision to adopt PGx testing (Fargher et al., 2007; Haddy et
al., 2010; Rogausch et al., 2006).
A study conducted on a sample of Dutch individuals found that the perceived
compatibility and benefits of genetic testing played a role in patients’ decision-making
for accepting these tests (Henneman et al., 2006). The authors revealed that having more
information on genetics or a higher level of education might not increase participants’
attitudes or their acceptance of genetic testing. Supporting the findings by Morren et al.
(2007) and Rogausch et al. (2006), they established that variables such as genetic
knowledge, education, age, and gender were not significantly associated with positive
attitudes regarding PGx testing. This study was informative since it used a representative
random sample of participants as well as valid and reliable instruments to accurately
measure participants’ responses, but it lacked a theoretical framework to evaluate the
relationships among variables linked to the acceptance of these tests; it also had a
selection bias.
Kobayashi and Satoh (2009) surveyed patients in Japan to assess their attitudes
toward PGx and the role of genomic markers associated with ADRs. The majority of
patients (88%) had optimistic attitudes toward the role of PGx in medicine and 75% were
willing to be tested to investigate the effects of genetic differences on drug response.
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Regardless of age and gender, proportionately more patients were likely to have their
DNAs tested in PGx research when expecting severe reactions to drugs than when taking
medications. The authors concluded that positive attitudes and greater perceived needs
for PGx among patients increased their acceptance of PGx research investigating the role
of genetic differences in medication response and medication safety, although concerns
about protecting private health information, utilizing testing results in research, and
finding an association between their genetic structure and the possibility of having ADRs
were expressed by patients. Patients expressed higher perceived benefits and positive
attitudes (81%) toward PGx as a clinical tool than did the general public (70%); however,
they were more reluctant to contribute to the field of PGx by donating their DNAs than
were the general public (Kobayashi and Satoh, 2009). The strength of this study was that
the authors identified several variables influencing patients’ attitudes toward PGx testing,
and thus helped future studies to explore the actual roles of patients’ medical conditions
and severity of experienced side effects in decision-making. Its weakness was that PGx
testing was not well defined in the study, and a potential of selection bias existed.
Summary of Patients’ Knowledge and Attitudes toward Pharmacogenetic Testing
A comprehensive review of the literature reveals a paucity of studies regarding
patients’ knowledge and attitudes toward PGx testing. Lack of awareness and limited
knowledge regarding PGx testing were prevalent among patients despite good attitudes.
Although patients are generally supportive of PGx testing and optimistic about its
potential therapeutic benefits, their concerns about confidentiality, employability,
insurability, and cost are seen as potential barriers to accepting PGx testing. Many
studies have emphasized the need for awareness programs directed at the general patient
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population to facilitate the clinical implementation of these genetic tests. A summary of
the advantages and disadvantages of PGx testing is presented in Table 2.1.
Table 2.1
Summary of Potential Advantages and Disadvantages of PGx Testing from the Patient
Perspective Identified in the Literature Review
Advantages
Disadvantages
- Reducing ADRs
- Negative impact on patients’ insurability
- Preventing ineffective or incorrect
- Negative impact on patients’ employability
medication
- Breach of confidentiality
- Predicting the most effective
- Concerns about physicians’ over-reliance on
medication
testing results
- Restoring patients’ confidence in
- Denial of certain treatment options
the drug-prescribing process
- Increased anxiety about negative testing
results (i.e., unavailability of a suitable drug)
- Increasing patients’ awareness of
their conditions
- Disclosing information about the risk of pre- Improving patients’ adherence to
existing conditions
prescribed medications
Prescribers’ Knowledge of Pharmacogenetic Testing
According to research carried out by Powell et al. (2012) utilizing a sample
of family and internal medicine physicians in North Carolina, 39% of participants were
aware of genetic testing and only 15% felt competent to answer genetics-related
questions. More than half of the physicians who were aware of genetic testing did not
perceive its clinical benefits. The majority of those physicians expressed concerns
regarding unavailability of clinical guidelines, the clinical utility of these tests, and
complexity of testing result interpretation. The likelihood of insurance and employment
discrimination based on genetic testing results were less frequently reported. Physicians
50 years or older were more likely to be cognizant of genetic testing than younger
physicians. Male physicians were more likely to feel comfortable answering geneticsrelated questions than female physicians. This study provided preliminary findings for
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more specific genetic testing such as PGx testing and was based on a relatively large
sample size and appropriate instruments to capture variables of interest. Its weakness
was the use of a convenient sample that limited the generalizability of the findings.
A large, nationally representative survey of U.S. physicians showed that the lack
of adequate knowledge was probably the main factor influencing the implementation of
PGx testing by healthcare providers (Stanek et al., 2012). The study reported that most
physicians across the U.S. had no formal coursework related to PGx during their
educational years. For instance, only 15% and 23% reported receiving information on
PGx during their undergraduate or graduate training, respectively. The authors also
reported that only 10% of physicians believed that they had enough information and
training to introduce PGx testing into clinical practice. Few physicians recognized the
benefits of PGx testing in improving drug effectiveness (9%), adherence (4%), and
lowering ADRs (10%). Almost 10% reported prior experience with ordering PGx testing
for their patients. Physicians who were aware of the availability of PGx testing and who
believed that genetic difference can cause variability in drug response were more likely to
be early adopters of PGx testing. Furthermore, the authors revealed that early adopters
were more likely to be oncologists or surgeons and had intermediate to long years of
medical practice (i.e., 15-29 years). Male physicians 40 years or older and working in
urban areas were more likely to be future adopters. The majority of physicians (67%)
refused to order the test and indicated that they did not have enough information about
PGx. These findings highlight a need to increase physicians’ knowledge and attitudes to
appropriately integrate PGx testing into daily clinical practice and communicate testing
results to their patients in order to help them with decision making. The study was large
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and representative, and indicated reliable results, but it lacked a theoretical framework.
Unfortunately, it did not provide additional clarifications on the relationship between
attitudes and adoption of PGx testing.
Rogausch et al. (2006) showed that physicians’ lack of knowledge and familiarity,
in addition to the fearful attitudes toward PGx testing, may impact their decision to
implement this technology in the future. Inadequate information about the clinical utility
of these tests and the lack of clear clinical guidelines were described as new challenges to
the physicians’ decision-making process to accept PGx testing. In other words,
physicians were portrayed as willing to consider PGx testing as an area of research rather
than its clinical application.
According to research carried out by Haga et al. (2012a), physicians’ levels of
knowledge and experience with PGx testing decreased their preparedness to use genetic
testing for their patients. The study reported that only 16% of participants received
training about PGx in medical school or post-graduate training, and almost 76% were
unaware of PGx information in drug package inserts. Different results were reported by
Stanek et al. (2012): a small percentage of physicians (29%) received training about PGx
in medical school or post-graduate training, and 39% indicated learning about PGx from
drug package inserts. Haga et al. (2012a) also reported that only 13% of physicians felt
comfortable ordering PGx testing. Physicians had other concerns related to
communicating confounded testing results, reimbursement issues, and the lack of practice
guidelines and recommendations regarding PGx testing. This study was enlightening
because its major findings have been reported by other studies and it supported the need
for incorporating PGx into educational curricula and training programs, but it had a

41
selection bias and an incomplete and inadequate description of the statistical analyses
performed.
Shields et al. (2005) conducted a national survey to assess the adoption of geneticbased smoking cessation treatment among 1,120 U.S. primary physicians. The study
aimed to predict physicians’ attitudes and decision-making about the future use of PGx
testing that may become available in individualized treatment cessation therapy. Most
participants were in practice with fewer than five other physicians and in urban areas.
Over 75% of respondents received some formal training in clinical genetics from
different sources such as medical school (57%), continuing medical education (CME)
courses (47%), clinical genetics rotation in medical school (16%), and genetics rotation in
residency (4%). Approximately 15% reported that they were early adopters and another
14% were very optimistic about the benefits of PGx testing on the treatment outcomes of
nicotine replacement therapy. Although only 4% reported being well prepared for these
types of tests, almost 69% of participants were willing to adopt PGx testing for smoking
cessation treatment. The study’s strength was that it relied on a large sample randomly
selected from all U.S. primary care providers (PCPs). The study method, however, was
based on a patient scenario rather than on investigating an existing PGx testing, which
might have underestimated or overestimated the factors influencing the uptake of genetic
testing into practice. The underrepresentation of some medical specialties also might
have limited the generalizability of the findings.
In a landmark work conducted by Taber and Dickinson (2014) on physicians from
different specialties, only 13% of participants reported being extremely or very familiar
with PGx. Similar results were also reported by others (Haga et al., 2012a; Stanek et al.,

42
2012). Only 11% reported receiving formal training in PGx. Nearly 32% of
cardiologists and 12% of psychiatrists had ordered a PGx test. Barriers to ordering PGx
testing identified by participants included not knowing what test to order (70%), lack of
insurance coverage for the PGx tests (53%), uncertainty about the clinical utility of the
test (52%), and cases in which PGx testing was not applicable (18%). The study had a
strong description of methods and provided an updated finding on knowledge deficit,
which was a major gap in previous studies, but it had a small sample and a possible
selection bias.
Genetic differences account for 35-50% of inter-individual variability in warfarin
anticoagulant responses (Wen and Lee, 2013). Anticoagulation providers deal with a
wide range of warfarin dosing requirements that dictate finding an adequate patientspecific and regular monitoring to avoid serious side effects. Kadafour et al. (2009)
assessed the clinical use of PGx testing among anticoagulation providers in North
America by comparing their knowledge and attitudes. Most participants (80%) indicated
that warfarin PGx testing was not available at their sites. Only about 12% reported using
these tests. The study also found that anticoagulation providers’ knowledge was not
significantly correlated with their attitudes. Participants who had warfarin PGx testing
available in their practice sites had a significantly higher knowledge score than those who
did not. Similarly, participants who previously used warfarin PGx testing had a
significantly higher knowledge score than those who had not.
The authors reported several potential barriers to the acceptance of warfarin PGx
testing, including the lack of clear evidence of clinical utility, unavailability of the test,
and lack of PGx knowledge among physicians and patients. Similarly, Shishko et al.
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(2015) reported that inadequate educational and training programs for healthcare
professionals and insufficient education of patients are barriers to the uptake of PGx into
clinical practice. The Kadafour et al. (2009) work was one of the largest studies that
contributed to the literature by addressing the challenges for integrating PGx testing in
warfarin therapy. Its weakness was the improper representation of anticoagulation
healthcare providers in North America.
Dressler et al. (2014) studied factors that influence the adoption of PGx testing in
cancer treatment. They conducted a survey of 94 North Carolina oncologists and
indicated that most of them believed in the beneficial outcomes of using PGx testing;
however, only 33% of them were comfortable with their knowledge about PGx testing
and 37% felt confident in interpreting testing results. Oncologists in a community setting
were more likely than oncologists in an academic setting to be early adopters of new PGx
testing (Oncotype Dx™) that potentially determine the benefit of using chemotherapy, as
well as more likely to be future adopters of cancer PGx testing. The authors reported that
oncologists with more than ten years of medical experience were more likely to be early
adopters of PGx testing than the rest, although those with fewer years of experience were
more comfortable about their PGx testing knowledge. The authors identified the main
factors that enhance acceptance of cancer PGx testing among oncologists, including
availability of well-conducted prospective clinical trials, evidence-based studies, and
professional guidelines. This study provided additional clarification about the need for
optimal communication channels and educational programs to appropriately disseminate
PGx information and influence the acceptance of PGx testing in the clinical practice. Its
major limitation was a relatively small sample size.
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Knowledge should not necessarily be limited to PGx testing only. Knowledge
about basic genetic variation underlying some health conditions is also imperative to
optimize the benefits of PGx testing and meet the current standard of care. For example,
genetic variants of the β-fibrinogen gene may increase the progression of coronary heart
disease; more importantly, knowledge about these genetic variations has been useful in
predicting patients’ responses to statin therapy and improving the overall health outcome
(Dornbrook-Lavender and Pieper, 2003).
Genetic testing in the screening and potentially directing the clinical management
of patients with mutations in the breast cancer genes 1 and 2 (BRCA1 and BRCA2) has
proven to be one of the most successful tests available (Miki et al., 1994; Smith and
Isaacs, 2011). Armstrong et al. (2003) studied how the adoption of BRCA1/2 genetic
testing initially started and what factors contributed to its subsequent acceptance among
women who underwent genetic counseling. The study results reported that only 7% of
study participants were recommended by physicians to undergo BRCA1/2 screening.
Most participants excluded physicians as a source of information about BRCA1/2 testing,
which showed the lack of physicians’ awareness about BRCA1/2 screening tests. The
study concluded that participants’ innovativeness and perceptions about compatibility
(i.e., whether the test fits well with patients’ personal values), not complexity, and
advantage of the test influenced the adoption of BRCA1/2 genetic testing. Although
BRCA1/2 mutations are relatively rare, having a family medical history is a strong
predictor of the need for BRCA1/2 screening; other factors that might have influenced
acceptance of genetic testing could have been previously overlooked.
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This study was influential because it utilized a relatively large sample size and
was guided by Rogers’s diffusion of innovation theory to explain the factors that
influence the early acceptance of genetic testing. In addition, the study demonstrated the
significance of communication channels in participants’ awareness about an innovation.
Its major limitation was unavailability of a control group (i.e., women who had not
undergone genetic counseling), which was required to determine whether the diffusion of
innovation theory adequately explained the acceptance of genetic testing. In addition,
there was a high risk of selection bias.
Klitzman et al. (2013) surveyed 220 internal medicine physicians to assess their
use of genetic testing, including PGx testing. The majority of participants rated their
knowledge of genetics as very or somewhat poor (74%). Most participants indicated a
need for more training relevant to ordering genetic testing (79%), patient genetic
counseling (82%), interpretation of genetic results (77%), and maintaining patient genetic
privacy (81%). The most frequent genetic tests ordered by internists were for Factor V
Leiden thrombophilia (15%), breast and ovarian cancers (17%), and cardiomyopathy
(8%). Only 6% used PGx testing to prevent drug toxicity. The authors also reported the
factors that significantly influenced the use of genetic testing: patients’ request to use the
tests (62%), working in large practices with more than 1,000 patients (67%), availability
of a genetic counselor for patient referral (62%), and having fewer numbers of AfricanAmerican patients in their practice (56%). Most physicians who adopted genetic testing
were White, male, 50-59 years old, and had more White patients in their practice.
This study was important because it included a wide range of genetic tests to
assess physicians’ acceptance. The study also revealed that African-Americans might
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have been deprived of the potential benefits of genetic testing. The major limitation was
its use of a non-representative sample. The study also failed to conduct subgroup
analysis in order to show the impact of rurality and area of practice on the adoption of
genetic testing.
Kudzi et al. (2015) conducted a semi-structured survey study in seven health
institutions and four academic institutions in Ghana in which the knowledge of PGx
among healthcare professionals and faculty members was evaluated. The authors showed
that the majority of participating physicians were aware of PGx testing as a new clinical
tool and heard about it from several resources (i.e., colleagues, schools, the Internet).
While most healthcare professionals rated their perceived knowledge of PGx as good or
very good, most faculty members rated their perceived knowledge as poor or very poor.
The study also showed that most healthcare professionals with prior awareness about
PGx testing were 25-29 years old with five years or less of practice. Most healthcare
professionals agreed on the potential benefits of PGx testing in ensuring drug safety and
improving efficacy, but they were uncertain about its role in cost saving and drug
discovery.
The strength of this work was that it interviewed healthcare professionals and
faculty members to better assess the need for continuous and updated PGx educational
programs in medical school curricula. Its main limitation was its reliance on a small and
selective sample of participants. A selection bias also might have occurred.
Prescribers’ Attitudes toward Pharmacogenetic Testing
Rogausch et al. (2006) showed that while patients were excited to undergo PGx
testing because of the possibility of being given a suitable anti-asthma drug with fewer
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ADRs, both physicians and patients were concerned about the confidentiality of genetic
information. Physicians also were concerned about the cost of these PGx tests and feared
that results would be reported to patients’ insurance companies and workplaces, raising
the possibility of discrimination. In addition, physicians working in rural areas had more
fearful attitudes toward PGx testing than physicians working in urban areas. The authors
reported that age, gender, and size of practice were not significantly associated with
physicians’ views regarding PGx testing. In line with other reports of healthcare
providers’ attitudes toward PGx testing (Fargher et al., 2007; Haga et al., 2012c;
Klitzman et al., 2013; Lanktree et al., 2014; Shields et al., 2005; Stanek et al., 2013;
Walden et al., 2015), the authors expressed fears toward the potential disadvantages of
PGx testing in disclosing pre-existing conditions, exposing patients to potential
discrimination at insurance or workplace, and privacy of genetic health information.
Fargher et al. (2007) conducted a focus group study of healthcare professionals to
assess their knowledge, attitudes, and experiences of PGx testing. Most participants
agreed on the perceived benefits of PGx testing to guide treatment decisions, although
they were worried about the possibility of excluding a patient from a specific treatment
option based on testing results. Participants also believed that they had a limited role in
utilizing PGx testing. Supporting the finding of other studies (Haga et al., 2012c;
Rogausch et al., 2006), the authors noted that physicians were concerned about the
potential of identifying a genetic biomarker that might be used as an indicator of
susceptibility to a particular disease. They explored healthcare professionals’ views and
opinions about PGx testing at an early stage to help future studies focus on the
application of PGx testing in clinical practice. The major limitations of this study were

48
underrepresentation of some medical specialties in the sample, limited generalizability of
the findings, and failure to explore the reasons why participants did not feel that they had
a role in utilizing PGx testing.
Haga et al. (2012c) found that many physicians and genetic experts had more
favorable attitudes toward currently prescribing practices than PGx testing. Respondents
felt that traditional clinical methods were the most effective technique to determine
optimal warfarin dosage. Some physicians raised concerns about the cost of PGx testing
and insurance coverage. Yet these physicians showed interest in PGx because of the
possibility of avoiding severe adverse effects, especially when drugs with a narrow
therapeutic index such as warfarin were recommended. Other physicians were concerned
about the lack of adequate evidence regarding the clinical utility of PGx testing. Similar
to other studies (Fargher et al., 2007; Kadafour et al., 2009; Lanktree et al., 2014;
Rogausch et al., 2006; Walden et al., 2015), the researchers indicated that the paucity of
test interpretation skills, lack of insurance coverage of PGx testing, delay of treatment,
and unclear guidelines for the use and regulation of PGx testing might have a negative
impact on its effective clinical implementation. The strength of the study was that it
involved three focus groups to gain more detailed information (i.e., ancillary disease risk
information) about health professionals’ interest regarding the use of PGx testing. Its
limitation was that its small and convenient sample might not have been representative of
the target population.
The Kadafour et al. (2009) survey study of anticoagulation providers reported that
half of the participants agreed or strongly agreed that they were adequately informed
about warfarin PGx; about half of them responded that they were comfortable
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interpreting warfarin PGx testing results. Nearly 26% of the participants agreed or
strongly agreed about potential clinical benefits of warfarin PGx testing in reducing
ADRs, and 32% expressed this view regarding achieving a therapeutic outcome quickly.
Overall, the lack of confidence regarding interpretation of genetic results was associated
with the lack of PGx knowledge. A small fraction indicated willingness to recommend
warfarin PGx testing to their colleagues. The strengths of the study were the use of a
large sample size and a real case scenario to better capture the factors influencing the
uptake of currently existing warfarin PGx testing into practice; the use of tailored
scenarios helped resolve conflicts among previous studies findings. However, the study
might not have accurately reflected the actual knowledge and attitudes of the target
population of anticoagulation providers.
The results of a national survey conducted on 597 internists and family medicine
practitioners showed that over 70% were aware of the availability of PGx testing prior to
taking the survey, but most felt that they were insufficiently trained to order or use these
genetic tests (Haga et al., 2012a). Respondents felt that CME, grand rounds, and training
in residency were the best sources to learn about PGx testing. In contrast to the findings
of the Fargher et al. (2007) study, these researchers reported that the majority of
participants felt responsible for increasing patients’ awareness of PGx testing, discussing
testing results with their patients, and integrating the testing results in their patients’
medical records. Only 10% agreed on pharmacists’ roles in determining the optimal
therapeutic regimen based on PGx testing results. The study was significant because it
used a large randomized sample to provide additional clarification about more efficient
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communication channels and addressed barriers to early adoption of PGx testing, but it
was susceptible to a form of selection bias.
A survey conducted on 10,303 physicians in the U.S. reported that virtually all
respondents believed that genetic testing could influence individual drug response
(Stanek et al., 2013). About 42% relied on FDA-approved PGx information in package
inserts to predict or improve response to medications, and 10% felt that adequate
knowledge about PGx and its application was acquired. Out of 1,319 physicians who had
ordered PGx testing for their patients, 73% believed that PGx testing improved drug
effectiveness, 80% believed that it reduced toxicity, 61% said that it improved patient
understanding of their health conditions, and 31% agreed that it improved patient
adherence to medications.
This study also reported that physicians who relied on drug package inserts to
learn more about PGx had significantly greater prior education and adequate PGx
information than those who did not rely on drug package inserts as a direct source of
information. The results also showed that 39% of physicians obtained information on
PGx testing from drug package inserts and 42% relied on FDA-approved
recommendations. As a result, adoption of PGx testing in clinical practice was higher
among physicians who obtained PGx information from drug package inserts and those
with prior testing experience. The study also showed that adoption of PGx testing in
clinical practice was higher among physicians who perceived the potential benefit of PGx
testing to their patients. Other factors associated with obtaining PGx information from
drug package inserts included older age, greater years of postgraduate experience, using
the Internet or other colleagues as genetic information sources, and greater stability in
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their practice careers. The study was able to explore additional factors associated with
the dissemination of PGx testing; it provided new findings of the use of FDA-approved
PGx information in drug package inserts. The risk of selection bias and inclusion of
underrepresented groups of physicians limited generalizability of its results.
Walden et al. (2015) conducted a survey study to assess the opinions of Canadian
physicians regarding the use of PGx testing to guide the selection and dosing of
antidepressant and antipsychotic medications. The study found that 80% of respondents
expressed optimistic attitudes toward the future of PGx testing as the standard of practice
for antipsychotic treatment and 76% reported satisfaction for being able to understand
and interpret the PGx report provided. There were no gender differences in attitudes
toward the clinical application of PGx testing; a similar finding was reported by Klitzman
et al. (2013). Supporting the findings of Haga et al. (2012c) and Kadafour et al. (2009),
these researchers reported that the cost of PGx testing and the time needed to receive the
results were obstacles to accepting the procedure. The study contributed to the literature
by proving up-to-date information about physicians’ attitudes toward the use of PGx
testing after receiving a PGx report for real clinical situations; the small sample size and
the possibility of selection bias might have limited statistical inference.
Summary of Prescribers’ Knowledge and Attitudes toward Pharmacogenetic
Testing
Only a few studies focus on physicians’ knowledge and attitudes toward PGx
testing. Physicians did not feel well informed about the procedure. Most physicians had
favorable attitudes toward PGx testing and its perceived benefits in different therapeutic
areas, but expressed concerns about their inadequate knowledge, ability to interpret
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genetic testing results, lack of clear clinical guidelines, and patients’ confidentiality. The
need for educational initiatives focused on training physicians to increase their
knowledge base and competency in interpreting and communicating PGx testing results
to patients. A summary of the advantages and disadvantages of PGx testing is presented
in Table 2.2.
Table 2.2
Summary of Potential Advantages and Disadvantages of PGx Testing from the Prescriber
Perspective Identified in the Literature Review
Advantage
Disadvantage
- Determining the appropriate dose or
- Negative impact on patient health
drug selection
insurance eligibility
- Explaining individual variation in drug
- Negative impact on employment
response
requirements
- Predicting the most effective
- Risk of treatment delay
medication
- Breaches of confidentiality
- Reducing serious ADRs
- Risk of unintentional disclosure of
information about disease susceptibility
- Improving patient adherence to
prescribed medications
- Lack of insurance coverage
- Reducing the overall cost of treatment
- Lack of clinical guidelines
- Uncertainty about clinical utility
The research methods applied in this dissertation are discussed in Chapter 3.
Development of the questionnaire, inclusion criteria, the recruitment process, and data
collection are described. A summary of concrete analytical procedures used to address
the research questions also is presented.
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Chapter 3
Methodology
The methodology used in this study is presented in this chapter to assess and
evaluate the effect of knowledge and attitudes on acceptance of PGx testing using a
convenient sample of patients and physicians. The setting in which the study took place
and the participant pool are described. Also described are the instruments developed and
used to collect the data. Justification of the sample size, the data analysis plan, and
ethical considerations are discussed.
Research Design
A cross-sectional, descriptive survey design was implemented to assess the
knowledge and attitudes of patients and physicians toward PGx testing. Cross-sectional
studies are often used to gain information and answer specific research questions based
on data collected from a subset of a population at only one point in time (Birch and
Malim, 1988). The data collection instrument was a questionnaire containing variables of
interest. According to Rogers’s diffusion of innovation theory, several independent
factors, such as sociodemographic variables (e.g., gender, age, level of education, area of
living, current practice setting), prior experience with PGx testing, and perceived need for
innovation and innovativeness can influence an individual’s knowledge of PGx testing.
Other variables, including relative advantage, compatibility, complexity, trialability, and
observability, also work as independent variables that may affect an individual’s attitude
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toward PGx testing. Knowledge and attitudes toward PGx testing are independent
variables that can influence the acceptance of PGx testing.
A large, representative sample was planned for the study. The probabilities of
type I and type II errors were set in advance to determine an adequate sample size. A
type I error (α) occurs when a researcher rejects a true null hypothesis; failing to reject a
false null hypothesis is called a type II error (β). Based on the value of β, a power
analysis was conducted; power equals to 1 – β.
G*Power 3.1 was utilized to calculate the appropriate sample size required to
achieve a sufficient power (Faul et al., 2009). Cohen’s f 2 was utilized for calculating the
effect size within a multiple regression model in which the independent and the
dependent variables are continuous (Cohen, 1977). Cohen’s f 2 value, calculated by
R2 / (1-R2), is an adjusted coefficient of determination indicator of how well a regression
equation fits the data values. A medium effect size value of f 2 = 0.15 in the analysis of
variance context was selected. Using significance level α = 0.05, the minimum sample
size was determined to consist of 120 observations with up to ten predictors and an actual
power of 0.80. Due to the lack of studies that consider the effect size required for this
type of research, the necessary sample size required to detect a significant effect with
enough statistical power using a 5% to 7% margin of error and a significance level of
0.05 was estimated to range between 126 and 180 participants.
Population and Recruitment of Patients
Patient recruitment took place at the Nova Southeastern University (NSU) Clinic
Pharmacy located in Fort Lauderdale, Florida. Potential participants filling a prescription
for a chronic disease were personally invited by the author of this dissertation to be part
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of the study. A flyer with a brief description of the study was given to patients who
showed interest in participating. The eligibility criteria were that potential participants
had to fill their prescription for at least one chronic disease, were aged 18 years or older,
spoke English fluently, and were willing and able to provide informed consent (see
Figure 3.1). If a patient self-reported at least one chronic disease, more about the
research project and possible benefits and risks were explained. If the patient was still
interested, he/she was given the opportunity to participate in the study and asked to read
and sign the consent form. All eligible participants were assured that their decision to
participate (or not) would not affect their relationship with the NSU Clinic Pharmacy or
other healthcare providers. If the potential participant signed the consent form, the
survey was then administered.

Figure 3.1: Illustration of inclusion criteria for patient recruitment.
Population and Recruitment of Prescribers
NSU physicians, as well as community physicians involved in medication therapy
decisions, were asked to participate in an online survey. A letter was emailed with the
survey to eligible physicians. Eligible community physicians were also recruited in
person from three medical conferences held in Florida. If a potential participant was
interested, he/she was offered the opportunity to participate in the study using a tablet
computer to sign the online participating letter and subsequently fill out the
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questionnaire. Prescribers’ inclusion criteria included being a physician licensed to
practice in Florida and currently involved in medication therapy decisions, willing to sign
the participation letter, and willing to complete the survey online (see Figure 3.2).
Respondents who successfully completed the survey were offered an incentive ($5 or $10
gift card) as a token of appreciation. The first 60 respondents were given $10-gift cards
and $5-gift cards were assigned to the next 90 expected respondents.

Figure 3.2: Illustration of inclusion criteria for prescriber recruitment.
Development of Patient Survey
The questionnaire survey used in this study was configured following the format
of similar studies (Calsbeek et al., 2007; Dodson, 2012; Nielsen and Moldrup, 2007;
Lachance et al., 2015; Roederer et al., 2012; Rogausch et al., 2006; Zhang et al., 2014).
Several concepts adapted from Rogers’s diffusion of innovation theory were
incorporated. The patient questionnaire had 46 questions. A copy of the patient
questionnaire is presented in Appendix A.
Once the questionnaire was configured, it was tested with nine persons to
examine the validity of the items. The results showed an average completion time of nine
minutes. Subsequently the format of several questions was changed to make them more
understandable. A brief description of PGx testing was provided in the final version.
The final patient questionnaire began with seven items assessing participants’ knowledge
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about PGx testing. This section was followed by 18 items assessing participants’
preferences about the use of PGx testing. Questions about patients’ prior experience with
genetic testing and their willingness to accept the testing were asked. The survey
concluded with sociodemographic items. Patient survey questions and corresponding
citations are listed in Appendix B. The attitude items showed an internal consistency or
reliability (Cronbach's alpha) score of 0.72, while the knowledge items showed a
Cronbach's alpha score of 0.65.
Development of Prescriber Survey
The questions posed to prescribers also were configured following the instruments
of previous studies (Dodson, 2012; Roederer et al., 2012; Rogausch et al., 2006; Shaw et
al., 2011; Taber and Dickinson, 2014). Several concepts adapted from Rogers’s diffusion
of innovation theory were incorporated as well. The prescriber questionnaire had 42
questions. A copy of the prescriber questionnaire is presented in Appendix C.
Six healthcare professionals agreed to participate in testing the survey. For face
and content validity purposes, they were asked to explain their reactions to the wording,
order, and clarity of the questions. An average completion time of 6.5 minutes was
reported. Changes to the questionnaire were made based on the feedback provided; these
reduced average time of completion to four minutes. The final prescriber questionnaire
began with six items assessing participants’ knowledge about PGx testing. This section
was followed by 16 items designed to assess participants’ preferences about the use of
PGx testing. Questions about prescribers’ prior experience with genetic testing and their
willingness to accept the testing were asked. The survey concluded with
sociodemographic items. Prescriber survey questions and corresponding citations are
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listed in Appendix B. The attitude and knowledge items showed Cronbach’s alpha scores
of 0.78 and 0.60, respectively.
Collection of Patient Data
The original plan for patient data collection was to offer the option of either a
paper-based or web-based survey. None of the potential participants showed any interest
in using a tablet computer to answer the web-based questionnaire. Thus, after participant
number 60 was recruited, the option of answering online was no longer offered. Each
participant received the questionnaire on a clipboard. The materials included an adult
consent form with a general overview of the study and the two-page, 46-item
questionnaire. To protect participants’ confidentiality, separate folders were used to
collect the consent forms and the questionnaires. After collecting all the survey
materials, the data were organized with Research Electronic Data Capture (REDCap)
software, leaving only numbers and variable names to be utilized in the analysis. This
software was created by a group of clinical researchers in 2004 at Vanderbilt University
as a user-friendly data collection tool. REDcap opens a secure survey page and allows
researchers to have their participant data auto-populated in the server; it also allows
manual data entry. The data collected in this study were entered electronically. Prior to
data analysis, a data reconciliation process was conducted to verify the accuracy of the
entered data. Data analyses were performed using IBM ® Statistical Package for the
Social Sciences (SPSS), version 24.0 and Stata version 14.
Collection of Prescriber Data
All prescriber questionnaires were administered and answered online. The
questions were programmed into the Snap Survey software (Snap Surveys Ltd.). NSU
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physicians and community physicians were invited to complete an online survey about
PGx testing from July through October 2016. The survey was terminated after receiving
150 responses. The prescriber survey was anonymous; respondents’ identifiable
information was removed from the responses before downloading them.
Measurement of Variables
Patient Variables
Patients’ knowledge of PGx testing was measured as the number of PGx testing
questions answered correctly. Within Rogers’s diffusion of innovation theory,
knowledge as a dependent variable is influenced by several antecedents, which in this
study were treated as independent variables. These included prior experience, perceived
need for innovation, innovativeness, area of living, sociodemographic variables (e.g., age,
level of education), and communication channels. Attitude toward an innovation was
measured by the number of favorable responses toward PGx testing. According to
Rogers’s diffusion of innovation theory, attitude as a dependent variable was influenced
by several independent variables including relative advantage, compatibility, complexity,
trialability, and observability of PGx testing (see Table 3.1).
Prescriber Variables
Physicians’ knowledge of PGx testing was measured as the number of PGx
testing questions answered correctly. Within Rogers’s innovation of diffusion theory,
knowledge as a dependent variable is influenced by independent variables such as prior
experience, perceived need for innovation, innovativeness, area of current setting,
sociodemographic variables (e.g., age, ethnicity), and communication channels. Attitude
toward PGx testing was measured by the number of favorable responses toward PGx
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Table 3.1
Measurement of Concepts Utilized in the Patient Survey
Construct/Variable
Measurement
Question(s)
Knowledge of PGx
Number of correct answers related to the
1-7
testing
influence of genetic differences on individual’s
responsiveness to different medications
Attitudes toward
Number of positive responses toward the use of
11-17, 20,
PGx testing
PGx testing
23, 24
Prior experience
Whether the adopter is awareness of the
8, 9
innovation before adoption
Innovativeness
Whether the patient is reluctant to adopt PGx
25
testing until he/she sees it providing useful
results for other patients
Perceived need
Whether an individual feels that there is a useful
18, 19
need for the innovation
Sociodemographic
Gender, age, ethnicity, and level of education
31-35
variables
Communication
Most effective channels of generating knowledge 30
behavior
about the innovation
Relative Advantage
Whether the adopter sees a higher value in the
21, 22
innovation than what it replaces
Compatibility
Whether the innovation is consistent with the
26
existing values and norms
Complexity
Whether the innovation is difficult to understand
27
or use
Trialability
Whether the innovation can be tested to reduce
28
the uncertainty
Observability
Whether the results and effects of an innovation
29
are visible
Willingness to take
Whether patients would like to take PGx testing
10
PGx testing
for one of their chronic disease medications
testing. According to Rogers’s diffusion of innovation theory, attitude as a dependent
variable was influenced by several independent variables including relative advantage,
compatibility, complexity, trialability, and observability of PGx testing (see Table 3.2).
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Table 3.2
Measurement of Concepts Utilized in the Prescriber Survey
Construct/Variable
Measurement
Question(s)
Duration of
Duration of overall medical practice
1
practice
Knowledge of PGx Number of correct answers related to the influence
2-7
testing
of genetic differences on individual’s
responsiveness to different medications
Attitudes toward
Number of positive responses toward the use of
8-12, 15,
PGx testing
PGx testing
17, 19
Prior experience
Whether the physician has ever ordered PGx
25
testing for a patient
Innovativeness
Whether the physician is reluctant to adopt PGx
14
testing until he/she sees it working for patients
Perceived need
Physician’s acknowledgement that there is a useful 21a, 12b
need for the PGx testing in several instances such
as a high risk of genetic variant
Area of current
Rural, Suburban, or Urban
32
setting
Sociodemographic
Gender, age, ethnicity, and medical specialty
28-31
variables
Communication
Most effective channels of generating knowledge
22
behavior
about PGx
Relative advantage Whether the physician believes that PGx testing is
20a, 20b
beneficial for his/her patients in the selection of a
medication that would better control their health
condition in several situations
Compatibility
Whether the physician believes that PGx testing is
13
compatible with his/her personal values
Complexity
Whether the physician believes that the application
18
of PGx testing adds more complexity to the drug
prescribing process
Trialability
Whether the physician believes that PGx testing is
16
worth trying
Observability
Whether the physician has ever talked with a
23
patient about PGx testing
The willingness to
Whether the physician is willing to recommend
24
recommend PGx
PGx testing to his/her patients
Factors affecting
Factors that influence physician’s acceptance of
26
PGx adoption
PGx testing
Pharmacist role in
Whether the physician prefers a pharmacist to
27
PGx testing
order and interpret PGx testing
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Data Analysis
Descriptive Statistics
Univariate analysis was conducted to describe and summarize nominal, ordinal,
and continuous data. Measures of central tendency, variation, and normality were used
for continuous variables, while counts and percentages were used for categorical
variables. Seven testing patient knowledge questions and six testing prescriber
knowledge questions utilized yes/no/not sure responses. The correct answer for all
knowledge subscale responses was recoded as one, while the incorrect or “not sure”
answers were recoded as zero. Ten testing patient attitude questions and eight testing
prescriber attitude questions were in the form of a 5-point Likert scale, with 5 being the
most favorable answer. Additionally, questions 13-16, 20, and 25-27 (patient data) and
13, 14, and 17-19 (prescriber data) were reverse coded so that larger values for all the
questions had the same direction, indicating a more positive attitude. All Likert scale
item responses to the attitude statements “Strongly Disagree” or “Disagree” were recoded
as zero. The “Neutral” response was recoded as one. All the “Agree” or “Strongly
Agree” responses were recoded as two. Since there were very few responses on some of
the choices provided for some categorical variables, including age, education, ethnicity,
and area of living, some levels were merged based on the results appearing in the
frequency tables. Similarly, due to a lack of responses in some of the provided choices,
the options in the variable “communication channels” were also collapsed.
The PGx testing knowledge subscale, the PGx testing attitude subscale, and the
perceived characteristics of innovation subscale were created using the Rasch model.
The Rasch model is a one-parameter logistic model that applies the principles of item
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response theory (IRT). This logistic model relates the difficulty of an item to the ability
of a respondent to answer that item in order to obtain an interval-level score (An and
Yung, 2014). Estimates of item difficulty and respondents’ ability are independent of
each other, making the scale score relatively distribution-free. After assessing the
subscales using the Rasch model, some weak items were removed to better measure the
constructs of interest and ensure validity. The total summative scores for the PGx testing
knowledge, attitude, and perceived characteristics of innovation questions were
calculated for each respondent. Finally, the reliability of the study constructs (subscales)
was calculated using Cronbach’s Alpha to examine the internal consistency of each
subscale. The extent to which each subscale data deviated from normality was also
measured (see Tables 3.3 and 3.4).
Table 3.3
Cronbach’s Alpha and Shapiro-Wilk (SWilk) Scores for Each Patient
Cronbach’s SWilk Test
Subscale
No. of Items
Alpha
(Signif.)
Knowledge*
7
0.65
0.072
Attitude
10
0.71
0.600
Perceived characteristics of innovation**
6
0.69
0.340
Note. Significance value of the Shapiro-Wilk Test is greater than 0.05; the data are
normally distributed. *log10 transformation; ** Square transformation
Table 3.4
Cronbach’s Alpha and Shapiro-Wilk (SWilk) Scores for Each Prescriber Subscale
Cronbach’s SWilk-Test
Subscale
No. of items
Alpha
(Signif.)
Knowledge
6
0.60
0.700
Attitude*
8
0.78
0.074
Perceived characteristics of innovation
6
0.60
0.066
*log10 transformation
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The gender variable for both patient and physician data was recoded into two
categories: male or female. The age variable was recoded into five categories (18-29
years, 30-39 years, 40-49 years, 50-59 years, and 60 years or older) for patient data and
four categories (25-39 years, 40-49 years, 50-59 years, and 60 years or older) for
physician data. The ethnicity variable was recoded into four categories:
White/Caucasian, Hispanic/Latino, Black or African American, and other. The area of
living variable and the type of practice setting variable were recoded into three
categories: urban, suburban, and rural. The prior experience variable was recoded into
two categories: yes or no.
In the patient data set, the level of education variable was recoded into five
categories: high school or GED, associate degree, baccalaureate degree, master's degree,
and doctorate or professional degree. The communication channel variable for patients
was recoded into four categories: one source, two sources, three sources, and four or
more sources. The physicians’ medical specialty variable was recoded into three
categories: internal medicine, family medicine, and others. The communication channel
variable for prescribers was recoded into four categories: zero source, one source, two
sources, and three or more sources. The duration of practice variable was recoded into
three categories: 1-10 years, 11-20 years, and 21 years or more.
Inferential Statistics
Statistical packages IBM® SPSS version 24.0 and Stata version 14 were utilized
to check all the assumptions of the One-way analysis of variance (ANOVA) and the
linear regression models. One-way ANOVA analysis was performed to address patients’
knowledge and identify significant differences within gender, age, ethnicity, level of
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education, area of living, innovativeness, prior experience, perceived need for innovation,
and sources of communication. A similar analysis was conducted for prescribers’
knowledge, plus two predictor variables: duration of practice and medical specialty. A
power analysis was conducted to determine the minimum sample size required to achieve
a power of 0.8.
The assumptions of the One-way ANOVA model were assessed to determine the
validity of the procedure. Statistical tests for a normal distribution of errors (ShapiroWilk’s test) and homoscedasticity (Levene’s test) across two or more groups (Levene,
1960; Shaphiro and Wilk, 1965) were conducted. The presence of asymmetry was
addressed and handled using transformations (log10). The presence of influential outliers
in a set of independent variables was assessed using Cook’s distance (Cook and
Weisberg, 1982).
A multiple linear regression model was generated to predict the strength of the
relationship between the overall PGx testing knowledge score and the significant
predictor variables identified in the ANOVA model. The assumptions of linear
regression were assessed, including linearity (using a normal Q-Q scatterplot),
autocorrelation (using the Durbin-Watson test), homoscedasticity (using Levene’s test),
multicollinearity (using the variance inflation factor), and normality (using the ShapiroWilk’s test).
The multiple regression model was formulated separately for patients and
physicians to estimate the overall knowledge and attitudes toward PGx testing as
functions of sociodemographic variables and attributes of knowledge and attitude stages
as follows:
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Yijk = αij + Xijkl βlji + Aijkl λlji + εijk
where
Yijk was a vector of scores for the ith indicator and jth type of participant reported by the
kth respondent;
Xijkl was a matrix of values of sociodemographic variables (l = 6 including gender, age,
ethnicity, level of education, area of living/type of practice setting, and duration of
practice) reported by the kth respondent of the jth type of participant for the ith indicator;
Aijkl was a matrix of attribute values for the ith indicator (when i = 1, then l = 4 including
prior experience, innovativeness, perceived need, and communication behavior; when
i = 2, then l = 5 including relative advantage, compatibility, complexity, trialability, and
observability) reported by the kth respondent of the jth type of participant;
αij was the independent term for the ith indicator and jth type of participant;
βlji and λlji were vectors of l parameters for the jth type of participant for the ith indicator
estimated within their respective matrix;
εijk was a vector of normally and independently distributed stochastic error terms
pertaining to the kth respondent of the jth type of participant for the ith indicator;
i = 1 for knowledge and i = 2 for attitude;
j = 1 for patients and j = 2 for physicians;
k = 1, … , nj; and
nj was the number of respondents in the jth type of participant category (n1 = 192 and
n2 = 148).
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One-way ANOVA and multiple regression models were also conducted to probe
the association between patients’ and physicians’ attitudes toward PGx testing and
relative advantage, compatibility, complexity, trialability, and observability of PGx
testing. Afterwards, sensitivity analysis using an alternative assumption (i.e., count data)
was conducted to validate the findings of the linear regression model. The possibility of
measuring the outcome variables by counting the number of correct answers (i.e., the
overall knowledge equals the number of correct answers, as shown in Table 4.2 and
Table 4.14) explains the use of the Poisson model for count data. The key assumption
that the mean of the Poisson distribution should equal its variance was assessed in order
to determine the goodness of fit of the Poisson model. An ordered Probit model was also
utilized since the categories of the dependent variables of this study were ranking with an
arbitrary interval between the scores.
Path analysis was performed to explore the influence of knowledge, attitudes,
perceived characteristics of innovation, and sociodemographic characteristics on the
acceptance or rejection of PGx testing among patients and physicians. The implications
of Rogers’s theory are based on the prediction of an individual’s decisions to either
accept or reject an innovation; the decision-making process depends on the magnitude of
the relationship between the individual’s knowledge and attitudes toward the innovation
as well as the antecedent variables that potentially influence knowledge and attitudes.
Considering only the direct effect of one variable on another (e.g., the relationship
between attitude toward PGx testing and the adoption decision) may not be optimal; the
relationship between two variables could influence or be influenced by a third variable.
Therefore, to measure the total effect of a variable (e.g., level of education) on another
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variable (e.g., attitude), both the direct and indirect effects of level of education must be
considered.
A generalized path analysis was created with a Probit link function and robust
standard errors to examine the effect of the subscales (knowledge, attitude, and perceived
characteristics of innovation), and demographic characteristics on the outcome variable
(accept or reject PGx testing). This analysis offered a better methodological tool to
establish causality in correlated variables in a model (Wright, 1921). (The following are
assumptions of path analysis: linear and additive relations among variables that should be
presented in the path diagram, the causal flow between independent and dependent
variables should be one-way, the error terms should not be correlated with the
independent variables in the model or among themselves, and the errors should be
normally distributed.)
Finally, the hypothesized causal relationships were evaluated using the overall
goodness of fit. The following tests were conducted: likelihood ratio chi-square (X 2); the
root mean square error of approximation (RMSEA), which according to Brown and
Cudeck (1993) should be less than 0.08, but according to Steiger (2007) it is preferred
when it is less than 0.07; and the Tucker-Lewis Index (TLI) and Comparative Fit Index
(CFI), which compare the model of interest to a null model that assumes no correlation
among variables. As the values of both the TLI and CFI approach 1.0, the model
represents a better fit than the null alternative model; a value of 0.90 is required for the
model to be a more acceptable fit (Hu and Bentler, 1999).
Based on Rogers’s theory-driven path, demographic characteristics, prior
experiences, innovativeness, perceived need for innovation, communication channels,
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were perceived characteristics of the innovation are exogenous variables that causally
precede all dependent variables in the model. Conversely, knowledge and attitudes were
endogenous variables, and they might be either dependent or independent. The adoption
or rejection of PGx testing was the main outcome variable.
Ethical Considerations
After reviewing the study design, an exemption was granted from the Institutional
Review Board (IRB) at NSU (see Appendix D). The patient and prescriber surveys (see
Appendices A and C), informed consent, promotional flyer, invitation e-mail, and
participation letter were submitted and approved by NSU (see Appendix E) before the
implementation of the study in compliance with the Health Insurance Portability and
Accountability Act (HIPAA). The data did not include direct patient or physicians
identifiers.
Summary
A cross-sectional design was utilized in this study using data obtained from a
convenient sample of patients and physicians. Patients 18 years or older who selfreported at least one chronic disease and physicians licensed to practice in Florida who
were involved in medication therapy decisions were included. Paper-based and online
survey questionnaires were used to collect data from patients and physicians,
respectively. Several concepts (e.g., perceived need, relative advantage, compatibility,
complexity, trialability, observability) adapted from Rogers’s diffusion of innovation
theory were incorporated into the survey questions. Statistical analyses including Oneway ANOVA and linear regression were performed to test the hypothesized relationships
among the main concepts adapted from Rogers’s theory. Then a generalized path
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analysis was conducted to predict the factors that influence the acceptance of PGx testing
among patients and physicians. The results obtained from these procedures are presented
in the next chapter.
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Chapter 4
Results
The purpose of this chapter is to report the results of the statistical analysis
performed in this study. The characteristics of the sample are provided and the
relationship between demographic variables and both knowledge and attitudes toward
PGx testing is discussed. The results from the various inferential analyses used to
addresses the research questions are also presented. Results are reported separately for
patients and prescribers.
Patient Descriptive Statistics
Sample Characteristics
The sample consisted of 192 patients with several chronic diseases. Their
distribution of selected demographic characteristics is presented in Table 4.1. Most of
them were women and the 40-59 age groups were the most numerous.
Patients’ Knowledge of Pharmacogenetic Testing
Seven questions were used to assess patients’ knowledge about PGx testing. The
mean score was 3.83 out of 7.00, with a standard deviation of 1.62. Younger, White, and
male participants with higher education had the highest mean scores. A Cronbach’s
alpha value of 0.65 was calculated for the PGx testing knowledge subscale, which
indicated moderate internal consistency.
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Table 4.1
Percentage Distribution of Selected Demographic Variables
of Patients in the Sample
Variables
Frequency (%)
Gender
Male
39.1
Female
61.9
Age (years)
18-29
14.6
30-39
19.3
40-49
21.4
50-59
25.0
60 or older
19.7
Ethnicity
White/Caucasian
45.3
Hispanic/Latino
25.0
Black or African American
19.3
Other
10.4
Level of education
High school or GED
13.5
Associate degree
21.9
Baccalaureate degree
25.5
Master's degree
16.7
Doctorate or professional degree
22.4
Area of living
Urban
38.0
Suburban
58.8
Rural
3.2
More than 70% of patients were informed about general aspects of genetics and
PGx testing, such as knowing that carrying a gene linked to a disease does not necessarily
affect health status, and that the genetic makeup can influence drug response among
different individuals. Less than 70% correctly answered the question that assessed the
association of genetic make-up with the severity of medication side effects, and less than
50% correctly answered knowledge questions regarding availability of PGx testing and
its ability to detect medication side effects (see Table 4.2).
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Table 4.2
Percentage of Correct Responses by Patients Pertaining to Knowledge of PGx Testing
Correct
Answer (%)
Questions
A person who carries a gene associated with a disease may be healthy
74.5
A person's genetic make-up can influence how he or she responds to
72.9
medicines
People with genetic differences can respond differently to the same
78.1
medication (e.g., some patients may benefit; others may not)
A test that looks at an individual's genes will likely reveal whether a
7.3
particular medicine would cause side effects for that person
A test that takes a cotton swab from the mouth of an individual and looks
34.9
at genes is currently available for some medications (e.g., simvastatin,
clopidogrel)
A test that looks at a person's genes will likely reveal whether a particular
46.9
medicine would work for that person
The severity of side effects of some medications may depend on a person's
68.2
genetic make-up
Patients’ Attitudes toward Pharmacogenetic Testing
Ten questions were used to assess patients’ attitudes toward PGx testing. The
mean score was 4.80 out of 9.00, with a standard deviation of 2.17. Female and White
participants with higher education showed higher mean scores. A Cronbach’s alpha
value of 0.71 was calculated for the PGx testing attitude subscale, which indicated
moderately high internal consistency.
The majority of patients expressed favorable attitudes toward PGx testing and its
perceived benefits on health. Patients indicated willingness to take these tests as they
believed the results would help their physicians make better treatment options. There
were concerns, however, about the financial cost of the testing as well as the potential for
discrimination in health insurance and on the job (see Table 4.3).
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Table 4.3
Percentage of Favorable Responses by Patients Pertaining to Attitudes toward PGx
Testing
Answers (%)
Questions
SD or D N A or SA
It is important to look at my genes in order to know what
7.8
29.2
63.0
is best for my health
I am willing to take a test that measures how a medicine
17.7
24.0
58.3
works, based on my genes
It is not useful to take genetic tests because my family
52.6
28.1
19.3
physician may not know how to use my tests results
If I had to pay for the genetic test myself, financial cost
7.8
9.4
82.8
would be one of my concerns for taking these tests
If I underwent testing, I would be concerned about the
12.5
17.2
70.3
effect of the test results on my eligibility for private health
insurance
If I underwent testing, I would be concerned about the
29.1
21.4
49.5
effect of the test results on my employment opportunities
I believe that physicians should have PGx testing
2.2
25.5
72.3
information in their clinical practice
If I took the test, I would be concerned that unauthorized
27.0
14.2
58.8
persons may gain access to the results of that test
PGx testing is a promising innovation in medicine
1.0
16.7
82.3
PGx testing can help my physicians to make the right
4.1
21.4
74.5
decisions about my health
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D),
Neutral (N), Agree (A), and Strongly Agree (SA).
Rogers’s Diffusion of Innovation-Based Questions
This study adapted several variables within the content of Rogers’s diffusion of
innovation theory. These variables were prior experience, innovativeness, perceived
need of adopters, and area of living. The variables were included and measured as a
subset of the knowledge stage. The knowledge stage begins when an individual becomes
interested in gathering more information about an innovation to develop a better
understanding of what the innovation is and how and why it works. According to
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Rogers’s theory, the knowledge stage is influenced by demographic characteristics (e.g.,
age and education) and communication channels. Other variables, including relative
advantage, compatibility, complexity, trialability, and observability, were included as a
subset of the persuasion stage.
Almost 78% of participants indicated that they had never heard the term PGx
testing, and only 11% had had their genes tested. Many patients perceived the need for
PGx testing in two different clinical situations. Most views on relative advantages of
PGx testing were positive. Attitudes related specifically to the perceived need, relative
advantage, compatibility, and trialability of PGx testing had more favorable responses
than attitudes connected to the complexity and observability of PGx testing in general
(see Table 4.4).
The majority of participants reported that physicians and physician assistants were
the major sources to obtain information about health issues. The Internet was ranked
second, followed by pharmacists. Most participants relied on three or more sources of
health information.
Patient Inferential Statistics
Research Question 1A Analysis
In this section the findings pertaining to research question 1A, namely, the
association between patients’ knowledge of PGx testing and their gender, age, ethnicity,
level of education, area of living, prior experience, innovativeness, and perceived need
for innovation, are reported. Prior to conducting ANOVA tests, the results showed a
violation of the normality assumption of ANOVA (i.e., Shapiro-Wilk’s p < 0.05, JarqueBera test for Skewness-Kurtosis p < 0.05) due to negatively skewed data. Consequently,
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Table 4.4
Percentage of Favorable Responses by Patients Pertaining to Rogers’s Theory-Based
Questions about PGx Testing
Answers (%)
Questions
SD or D N A or SA
Innovativeness
I will be reluctant about accepting PGx testing until I
31.3
24.5
44.2
see it providing useful results for people around me
Perceived need
7.3
28.6
64.1
I think that PGx testing may prevent me from taking the
wrong medicine
I believe that PGx testing will help reduce my current
8.3
35.4
56.3
medications' side effects
Relative advantage
I believe that PGx testing can help in the selection of
0.5
25.0
74.5
medication that would better improve my medical
condition
PGx testing can offer to me a useful alternative to the
7.8
31.2
61.0
way that a physician usually prescribes medications
Compatibility
PGx testing is a type of test that can invade my privacy
35.9
23.5
40.6
Complexity
The term “Pharmacogenetic Testing” is difficult to
53.0
26.2
20.8
understand
Trialability
I won't lose much by trying PGx testing, even if it
12.5
28.7
58.8
doesn't benefit me directly
Observability
I have discussed (at least once) PGx testing with my
86.0
9.9
4.1
healthcare provider
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D),
Neutral (N), Agree (A), and Strongly Agree (SA).
the data were transformed using base 10 logarithms in order to bring the skewness score
back to zero or close to normality.
The One-way ANOVA results showed a significant effect of age, ethnicity, and
level of education on the overall knowledge score. There was also a significant effect of
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prior experience, innovativeness, and perceived need. The estimated F values are
presented in Table 4.5.
Table 4.5
Estimated F Statistic Values of the One-Way ANOVA Model
Pertaining to Patients’ Knowledge of PGx Testing
Variables
F Statistic
Gender
0.56
Age
2.76*
Ethnicity
3.30*
Level of education
11.50**
Area of living
1.37
Prior experience
22.00**
Innovativeness
15.80**
Perceived need
9.60*
Communication channels
1.28
* p < 0.05, ** p < 0.01
Post-hoc Tukey tests were performed after completing the ANOVA tests to
determine which groups differed from each other. These showed that the mean score of
White participants was significantly higher than the score of Black or African Americans.
The mean score of participants who held a doctorate degree was significantly higher than
those of the other levels of education. The mean scores of participants who perceived
one need or two needs were significantly higher than patients who did not express any
need. Mean difference scores and levels of significance are presented in Table 4.6.
A multiple linear regression model was generated using the significant predictors
found in the One-way ANOVA tests (age, ethnicity, level of education, prior experience,
innovativeness, and perceived need). Assumptions for normality, multicollinearity,
autocorrelation, and homoscedasticity were tested prior to estimating the regression
equation. The results revealed that level of education, innovativeness, and prior
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Table 4.6
Results of Post-Hoc Pairwise Comparison of ANOVA Model Results Pertaining to
Patients’ Knowledge of PGx Testing
Mean
Standard
Variables
Difference
Error
Age (years)
18-29 vs. 40-49
0.114
0.041
Ethnicity
White/Caucasian vs. Black or African American
0.098 *
0.033
Level of education
High school or GED vs. doctorate degree
-0.159**
0.039
Associate degree vs. master's degree
-0.109*
0.037
**
Associate degree vs. doctorate degree
-0.220
0.034
Baccalaureate degree vs. doctorate degree
-0.145**
0.033
*
Master's degree vs. doctorate degree
-0.112
0.036
Innovativeness
Disagree/strongly disagree vs. agree/strongly agree
-0.152**
0.027
*
Neutral vs. agree/strongly agree
-0.084
0.034
Perceived need
No need vs. one need
-0.084*
0.033
No need vs. two needs
-0.039**
0.028
* p < 0.05, ** p < 0.01
experience best fit the data (see Table 4.7). The adjusted coefficient of multiple
determination value was 0.31. Stepwise regression was performed and similar results
were found. The results of sensitivity analysis using Poisson and ordered Probit models
showed comparable results to the linear models (see Appendix F).
Research Question 2A Analysis
The statistical analysis in this section was designed to address the association
between patients’ attitudes toward PGx testing and relative advantage, compatibility,
complexity, trialability, and observability of PGx testing. One-way ANOVA tests were
conducted to determine whether attitudes toward PGx testing differed significantly for
each of the variables adapted from Rogers’s theory. Gender and level of education
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Table 4.7
Predictors of Patients’ Knowledge of PGx Testing
Regression Standard
Predictors
Coefficient
Error
Age
-0.003
0.008
Ethnicity
-0.018
0.011
**
Level of education
0.036
0.008
**
Prior experience
0.075
0.027
Innovativeness
0.043**
0.014
Perceived need
0.027
0.014
Independent term
-0.785
0.052
* p < 0.05, ** p < 0.01
yielded significant differences. Relative advantage, compatibility, complexity,
trialability, and observability of PGx testing were also significantly related to the total
attitude score (see Table 4.8).
Table 4.8
Estimated F Statistic Values of the One-Way ANOVA Model
Pertaining to Patients’ Attitudes toward PGx Testing
F Statistic
Variables
Gender
10.10**
Age
0.96
Ethnicity
1.99
Level of education
4.27**
Area of living
1.25
Communication channels
0.04
Relative advantage
44.00**
Compatibility
28.30**
Complexity
25.80**
Trialability
39.30**
Observability
5.75**
* p < 0.05, ** p < 0.01
Post-hoc Tukey tests were performed for pairwise comparisons of means.
These showed that master’s degree holders had higher attitude scores than those with
associate degree or baccalaureate degree. The mean score of participants who agreed on
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two relative advantages of the testing was significantly higher than those who perceived
only one advantage or did not perceive any advantages. Additionally, participants who
agreed or strongly agreed on the compatibility, easiness of PGx testing, and trialability
showed significantly higher attitude mean scores than those who were neutral or
disagreed. The results of the post-hoc Tukey tests are presented in Table 4.9.
Table 4.9
Results of Post-Hoc Pairwise Comparison of ANOVA Model Results Pertaining to
Patients’ Attitudes toward PGx Testing
Mean
Standard
Variables
Difference
Error
Level of education
Master's degree vs. associate degree
1.835**
0.494
Master's degree vs. baccalaureate degree
1.437*
0.479
Relative advantage
Two relative advantages vs. no relative advantage
2.903**
0.346
Two relative advantages vs. one relative advantage
1.996 **
0.311
Compatibility
Agree/strongly agree vs. disagree/strongly disagree
2.326**
0.317
**
Agree/strongly agree vs. neutral
1.782
0.368
Complexity
Agree/strongly agree vs. disagree/strongly disagree
2.185**
0.362
**
Agree/strongly agree vs. neutral
1.855
0.335
Trialability
Agree/strongly agree vs. disagree/strongly
2.770**
0.413
disagree
Agree/strongly agree vs. neutral
2.188**
0.302
Observability
Agree/strongly agree vs. disagree/strongly disagree
2.150*
0.769
* p < 0.05, ** p < 0.01
A regression equation was estimated for the PGx testing attitude scores after
evaluating the underlying assumptions of normality, multicollinearity, autocorrelation,
and homoscedasticity. The significant predictors found in the One-way ANOVA models
were included as independent variables. The forward selection, backward elimination,
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and stepwise models showed similar results. Gender, relative advantage, compatibility,
complexity, and trialability were statistically significant (see Table 4.10). The adjusted
coefficient of multiple determination value was 0.50. The results of sensitivity analysis
using Poisson and ordered Probit models showed comparable results (see Appendix F).
Table 4.10
Predictors of Patients’ Attitudes toward PGx Testing
Regression
Standard
Predictors
Coefficient
Error
*
Gender
-0.569
0.234
Level of education
0.100
0.087
Relative advantage
0.948**
0.161
Compatibility
0.548**
0.148
*
Complexity
-0.354
0.162
Trialability
0.637**
0.191
Observability
0.409
0.237
Independent term
-0.520
0.530
* p < 0.05, ** p < 0.01
Research Question 3A Analysis
The analysis in this section was designed to assess whether knowledge, attitudes,
perceived characteristics of innovation, and sociodemographic characteristics
significantly influence the acceptance or rejection of PGx testing among patients.
A generalized path analysis was conducted to determine the causal effect between
knowledge, attitude, perceived characteristics of innovation, demographic characteristics,
and the outcome variable, namely, acceptance or rejection of PGx testing. Based on the
initial model guided by Rogers’s theory, some reproduced correlations were not
significant at the 0.05 level. Finding the possible missing paths in the initial model
showed that five additional paths significantly contributed to the model. Two nonsignificant paths to the adoption of PGx testing were removed. The revised model was
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statistically significant at the 0.05 level. Computation of the reproduced direct, indirect,
and total causal effects of the revised model indicated a good fit model for the collected
data. The coefficient of multiple determination values for the predictors were as follows:
0.32 for knowledge, 0.52 for attitudes, and 0.38 for adoption of PGx testing. The
goodness of fit scores are presented in Table 4.11.
Table 4.11
Goodness of Fit Scores for Statistics Pertaining to Path
Analysis of Patients’ Adoption of PGx Testing
Goodness of Fit Test
Value
2
Likelihood Ratio
chi _ms
7.550
2
p > chi
0.374
Population Error
RMSEA
0.020
Baseline Comparison
CFI
0.998
TLI
0.996
The results of the path analysis showed that the overall attitude score and the total
perceived innovation characteristic score were significant predictors of patients’ adoption
of PGx testing (see Table 4.12). Participants who scored higher on the attitude subscale
and on the perceived characteristics of innovation subscale were more likely to accept
PGx testing.
Prescriber Descriptive Statistics
Sample Characteristics
Of the initial 1,000 physicians contacted via email, there were 850 deliverable
messages and 60 participants successfully completed and submitted the online survey. In
addition, 70 physicians were contacted at regional conferences and 20 were contacted at
NSU’s Health Professions Division. In two surveys, the majority of the questions were
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Table 4.12
Predictors of Patients’ Adoption of PGx Testing
Predictors
Knowledge
Level of education
Prior experience
Innovativeness
Perceived characteristics of innovation
Independent term
Attitude
Perceived need
Perceived characteristics of innovation
Independent term
Adoption of PGx testing
Knowledge
Attitude
Perceived characteristics of innovation
Independent term
* p < 0.05, ** p < 0.01

Regression
Coefficient

Standard
Error

0.249**
0.148*
0.122
0.281**
-5.606

0.062
0.064
0.073
0.076
0.360

0.201**
0.706**
-1.404

0.059
0.036
0.223

0.112
0.348**
0.258**
-0.661

0.064
0.078
0.084
0.480

blank, either due to a software error or due to lost Internet connection that led to data
loss. These surveys were deleted. A total of 148 physicians completed the online survey
for a response rate of 15.7%. Most of them were men and White, and they were evenly
distributed in terms of age groups. The most numerous group had been in practice for
over 20 years (see Table 4.13).
Prescribers’ Knowledge of Pharmacogenetic Testing
Six questions were used to assess physicians’ knowledge about PGx testing. The
mean score was 3.40 out of 6.00, with a standard deviation of 1.53. Younger, non-White
and female respondents practicing in suburban areas had higher mean scores than their
counterparts. A Cronbach’s alpha value of 0.60 was calculated for the PGx testing
knowledge subscale, which indicated moderate internal consistency. The majority of
physicians answered correctly that PGx testing can determine whether people with
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Table 4.13
Percentage Distribution of Selected Demographic Variables
of Prescribers in the Sample
Variables
Frequency (%)
Gender
Male
66.4
Female
33.6
Age (years)
25-39
18.4
40-49
24.7
50-59
29.5
60 or older
27.4
Ethnicity
White/Caucasian
71.7
Hispanic/Latino
10.3
Black or African American
10.0
Other
8.0
Medical specialty
Internal Medicine
18.4
Family Medicine
31.3
Others
50.3
Type of practice setting
Urban
45.3
Suburban
48.7
Rural
6.0
Duration of practice (years)
1-10
25.0
11-20
31.1
21or more
43.9
genetic differences can respond differently to the same medication. Almost one-half felt
challenged to find the correct answer about the availability of PGx testing (see
Table 4.14).
Prescribers’ Attitudes toward Pharmacogenetic Testing
Eight questions were used to assess prescribers’ attitudes toward PGx testing.
The mean score was 4.97 out of 8.00, with a standard deviation of 2.04. Older, White,
and female participants practicing in urban areas had relatively higher mean attitude
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Table 4.14
Percentage of Correct Responses by Prescribers Pertaining to Knowledge of PGx
Testing
Correct
Questions
Answers (%)
Genetic variations account for as much as 95% of the variability of an
43.2
individual's response to a medication
PGx testing can determine whether people with genetic differences can
89.2
respond differently to the same medication
PGx testing of an individual's genes guarantees whether a particular
52.0
medicine would cause adverse events for that person
PGx testing is currently available for all medications
59.5
Some medications have FDA-approved PGx information in their
50.7
package inserts
The package insert for clopidogrel (Plavix ®) includes a warning about
44.6
possible worse outcomes in individuals who have specific genetic
variants
scores. A Cronbach’s alpha value of 0.78 was calculated for the PGx testing attitude
subscale, which indicated high internal consistency for this subscale.
The majority of physicians expressed favorable attitudes toward the perceived
benefits of PGx testing in prescribing effective medication, reducing medications side
effects, and educating patients regarding PGx testing. However, physicians expressed
concerns about potential discrimination for their patients by health insurance companies
and unauthorized access to testing results (see Table 4.15).
Inhibitors of Recommending Pharmacogenetic Testing
Physicians who had never ordered PGx testing for their patients or were not
willing to accept it in routine medical practice identified several reasons for their
response. The most common reasons were lack of insurance support for these tests,
unavailability of PGx testing at the workplace, and uncertainty about the clinical utility of
these tests (see Table 4.16).
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Table 4.15
Percentage of Favorable Responses by Prescribers Pertaining to Attitudes toward PGx
Testing
Answers (%)
Questions
SD or D
N A or SA
Prescribers should use PGx testing information in clinical
8.1
33.8
58.1
practice
Patients should be educated about the purpose, benefits,
5.4
16.9
77.7
limitations, and risks of PGx testing
PGx testing will potentially help decrease the number of
4.7
21.0
74.3
adverse drug events
PGx testing may prevent me from prescribing an
8.1
17.5
74.4
ineffective medicine
PGx testing is a promising innovation in medicine
5.4
14.9
79.7
PGx testing can offer a useful tool to the way I usually
8.1
25.0
66.9
prescribe/recommend medications
I am concerned about the effect of the test results on my
26.4
27.7
45.9
patients' eligibility for private health insurance
I am concerned that unauthorized personnel may gain
39.9
27.7
32.4
access to the results of that test
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D),
Neutral (N), Agree (A), and Strongly Agree (SA).
Table 4.16
Barriers to Implementing PGx Testing in Clinical Practice Identified by
Prescribers
Barriers
Frequency (%)
60.6
PGx testing is not available at workplace
Concerns about patient confidentiality
19.7
Concerns about patients' employment opportunities
9.8
Not enough time to order
16.4
Waiting for PGx testing results would delay treatment
32.7
Uncertain about the clinical utility of the test
55.7
Insurance does not cover test
62.3
Not applicable for my patients
14.8
Patient refused test
14.8
Other
6.6
Respondents were allowed to answer one or more than one reason.
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Rogers’s Diffusion of Innovation-Based Questions
This study adapted several variables within the context of Rogers’s diffusion of
innovation theory. These variables were prior experience, innovativeness, perceived
need of adopters, demographic characteristics (e.g., gender, age, ethnicity, and site of
practice), and communication channels. In addition, relative advantage, compatibility,
complexity, trialability, and observability were included as a subset of the persuasion
attitude stage.
Only a fraction of respondents said that they had ever ordered PGx testing for a
patient, and only about a third replied that they had ever talked with a patient about PGx
testing. Most participants expressed the need for PGx testing when information about the
test is included in the package inserts and when the practice guidelines for the use and
interpretation of these tests become available. Likewise, the majority of prescriber
agreed on the relative advantages of using PGx testing to avoid the risk of non-response
to an essential drug and to select a medication that better controls a patient's health
condition. In general, attitudes toward the perceived need, relative advantage, and
compatibility of PGx testing had more favorable responses than attitudes toward its
trialability and complexity (see Table 4.17).
Almost 16% of respondents reported that they had not received education in
genetics, and about one-half identified the use of only one source of information about
PGx testing. Sources included genetics training in medical/pharmacy school, CME
courses, graduate or undergraduate genetics courses, genetics-related seminars or
workshops, grand rounds, genetics training in residency, and other sources such as direct
experience, the Internet, and scientific articles (see Table 4.18).
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Table 4.17
Percentage of Favorable Responses by Prescribers Pertaining to Rogers’s TheoryBased Questions about PGx Testing
Answers (%)
Questions
SD or D N
A or SA
Innovativeness
I will be reluctant to adopt PGx testing until I see it
39.0
26.0
35.0
working for patients
Perceived need
When information about the test is included in the
14.2
25.7
60.1
package inserts
When practice guidelines for the use and interpretation
4.7
16.2
79.1
of these tests are available
Relative advantage
In case of non-response to an essential drug (e.g.,
4.1
10.8
85.1
analgesic) / Refractory patients
In the selection of medication that better controls a
11.5
16.9
71.6
patient's health condition
Compatibility
PGx testing is not compatible with my personal values
78.0
12.0
10.0
Complexity
The application of PGx testing adds more complexity
13.0
15.0
72.0
to the drug prescribing process
Trialability
I would like to try PGx testing on some patients before
23.0
26.0
51.0
I decide whether I will adopt it or not
Observability
Have you ever talked with a patient about PGx
67.0
0.0
33.0
testing?
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D), Neutral
(N), Agree (A), and Strongly Agree (SA).
Prescriber Inferential Statistics
Research Question 1B Analysis
In this section, the findings pertaining to research question 1B, namely, the
association between physicians’ knowledge of PGx testing and their gender, age,
ethnicity, medical specialty, practice setting, duration of practice, prior experience,
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Table 4.18
Percentage Distribution of Sources of Genetic Information Reported
by Prescribers
Source
Frequency (%)
Genetics training in medical school
33.1
Genetics training in residency
8.1
Undergraduate genetics course
19.6
Genetics course in graduate school
8.1
Grand Rounds
15.6
CME course
31.8
Genetics-related seminar or workshop
17.6
Other
18.2
Respondents were allowed to answer one or more than one source.
innovativeness, and perceived need for innovation, are reported. As in the data analysis
section, the assumptions of One-way ANOVA were tested to determine the applicability
of the model. The empirical evidence indicated that gender, type of practice setting, prior
experience, perceived need, and sources of communication showed significant
differences in scores of knowledge about PGx testing by physicians (see
Table 4.19).
Table 4.19
Estimated F Statistic Values of the One-Way ANOVA Model
Pertaining to Prescribers’ Knowledge of PGx Testing
Variables
F Statistic
Gender
5.39*
Age
0.21
Ethnicity
0.39
Medical specialty
1.94
Type of practice setting
4.81*
Duration of practice
1.66
Prior experience
8.38**
Innovativeness
1.79
Perceived need
3.40*
Communication channels
4.50**
* p < 0.05, ** p < 0.01
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Post-hoc Tukey tests were performed to determine which groups differed from
each other. The results showed that the mean PGx testing knowledge score of
participants who perceived two needs was significantly higher than the score of those
who expressed no need, and the mean scores of participants who used one or two
resources were significantly greater than those who did not report any source of heath
information (see Table 4.20).
Table 4.20
Results of Post-Hoc Pairwise Comparison of ANOVA Model Results
Pertaining to Prescribers’ Knowledge of PGx Testing
Mean
Standard
Variables
Difference
Error
Perceived need
Two needs vs. no need
0.900*
0.135
Communication channels
One source of information vs. no source
1.178 **
0.359
**
Two sources of information vs. no source
1.383
0.407
* p < 0.05, ** p < 0.01
A multiple linear regression model was generated using the significant predictors
found in the One-way ANOVA tests (gender, type of practice setting, prior experience,
perceived need, and sources of communication). The forward, backward, and stepwise
regression versions revealed that gender, type of practice setting, and prior experience
were significant variables that best fit the data (see Table 4.21). The adjusted coefficient
of multiple determination value was 0.22. The results of sensitivity analysis using
Poisson and ordered Probit models showed comparable results to the linear models (see
Appendix F).
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Table 4.21
Predictors of Prescribers’ Knowledge of PGx Testing
Regression
Standard
Predictors
Coefficient
Error
**
Gender
0.798
0.267
Type of practice setting
-0.742**
0.255
*
Prior experience
0.771
0.314
Perceived need
0.255
0.179
Communication channels
0.159
0.134
Independent term
3.500
0.374
* p < 0.05, ** p < 0.01
Research Question 2B Analysis
The statistical analysis in this section was designed to address the association
between physicians’ attitudes toward PGx testing and relative advantage, compatibility,
complexity, trialability, and observability of PGx testing. One-way ANOVA tests were
conducted to determine whether attitudes toward PGx testing differed significantly for
each of the variables adapted from Rogers’s diffusion of innovation theory. Gender,
relative advantage, compatibility, and observability were significantly related to the total
attitude score (see Table 4.22).
Post-hoc Tukey tests were performed to determine which groups differed from
each other. They showed that the mean score of participants who agreed on two relative
advantages of PGx testing was significantly higher than the mean of those who did not
report advantages. The mean score of participants who agreed or strongly agreed with
the statement about compatibility of PGx testing was significantly higher than the mean
of those who disagreed or strongly disagreed. The results of the post-hoc Tukey tests are
presented in Table 4.23.

92
Table 4.22
Estimated F Statistic Values of the One-Way ANOVA Model
Pertaining to Prescribers’ Attitudes toward PGx Testing
Variables
F Statistic
Gender
5.98*
Age
0.53
Ethnicity
0.83
Medical specialty
0.32
Type of practice setting
0.78
Duration of practice
1.93
Prior experience
2.42
Relative advantage
6.52**
Compatibility
11.50**
Complexity
1.02
Trialability
1.62
Observability
6.52*
Communication channels
0.76
* p < 0.05, ** p < 0.01
Table 4.23
Results of Post-Hoc Pairwise Comparison of ANOVA Model Pertaining to Prescribers’
Attitudes toward PGx Testing
Mean
Standard
Variables
Difference
Error
Relative advantage
Two relative advantages vs. no relative advantage
0.180**
0.057
Compatibility
Agree/strongly agree vs. disagree/strongly disagree
0.140**
0.056
* p < 0.05, ** p < 0.01
The predictors found to be significant in the One-way ANOVA tests were utilized
as independent variables in the estimation of a regression equation. Forward selection,
backward elimination, and stepwise regressions were conducted. All three models
revealed that coefficients for gender, relative advantage, and compatibility were
significant (see Table 4.24). The adjusted coefficient of multiple determination value
was 0.21. The results of sensitivity analysis using Poisson and ordered Probit models
showed comparable results (see Appendix F).
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Table 4.24
Predictors of Prescribers’ Attitudes toward PGx Testing
Regression
Standard
Predictors
Coefficient
Error
*
Gender
0.078
0.037
Relative advantage
0.061*
0.026
Compatibility
0.155**
0.044
Observability
0.061
0.038
Independent term
-0.730
0.060
* p < 0.05, ** p < 0.01
Research Question 3B Analysis
The analysis in this section was designed to assess whether knowledge, attitudes,
perceived characteristics of innovation, and sociodemographic characteristics
significantly influence the acceptance or rejection of PGx testing among physicians.
A generalized path analysis was conducted to determine the causal effect among
knowledge, attitude, perceived characteristics of innovation, demographic characteristics,
and the outcome variable, namely, acceptance or rejection of PGx testing. Based on the
initial model guided by Rogers’s theory, some reproduced correlations were not
significant at the 0.05 level. Finding the possible missing paths in the initial model
indicated that seven additional paths significantly contributed to the model. Two nonsignificant paths to the adoption of PGx testing were removed from the model.
Computation of the reproduced direct, indirect, and total causal effects of the revised
model indicated a good fit model for the collected data. The coefficient of multiple
determination values for the predictors were as follows: 0.19 for knowledge, 0.23 for
attitudes, and 0.18 for adoption of PGx testing. The goodness of fit scores are presented
in Table 4.25.
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Table 4.25
Goodness of Fit Scores for Statistics Pertaining to Path
Analysis of Prescribers’ Adoption of PGx Testing
Goodness of Fit Test
Value
2
Likelihood ratio
chi _ms
12.75
2
p > chi
0.388
Population error
RMSEA
0.021
Baseline comparison
CFI
0.998
TLI
0.997
The results of the path analysis showed that the total perceived innovation
characteristic score and the total perceived need score were significant predictors of
prescribers’ adoption of PGx testing (see Table 4.26). Participants who scored higher on
the perceived characteristics of innovation subscale and on the perceived need items were
more likely to accept PGx testing.
Table 4.26
Predictors of Prescribers’ Adoption of PGx Testing
Regression
Predictors
Coefficient
Knowledge
Age (years)
-0.359**
Type of practice setting
-0.196**
Duration of practice
0.401**
Perceived need
0.151*
Perceived characteristics of innovation
0.146
Independent term
2.617
Attitude
Innovativeness
0.320**
Perceived characteristics of innovation
0.261**
Independent term
-1.732
Adoption of PGx testing
Knowledge
-0.028
Attitude
0.128
Perceived need
0.261**
Perceived characteristics of innovation
0.197*
Independent term
1.756
* p < 0.05, ** p < 0.01

Standard
Error
0.129
0.074
0.128
0.080
0.079
0.439
0.075
0.076
0.339
0.079
0.081
0.079
0.086
0.445
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In the next chapter, a discussion of the empirical findings of this dissertation is
undertaken. Also discussed is the applicability of the adapted theoretical framework and
how the evidence relates to previous scholarly works. Limitations and recommendations
for future research are addressed.
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Chapter 5
Discussion and Conclusions
This study was guided by Rogers’s diffusion of innovation theory to test the
relationship between patients’ and physicians’ willingness to use PGx testing and their
knowledge of PGx testing, attitudes toward PGx testing, and sociodemographic
characteristics. Understanding these relationships may help promote the diffusion of
these genetic tests, which may potentially predict medication response and improve
medication safety in clinical practice. In this chapter key findings and conclusions are
addressed for both patients and physicians, along with the results of path analysis
describing the relative importance of model-based relationships to the decision to adopt
PGx testing. Study limitations and recommendations for future research are also
discussed.
Patients’ Knowledge of PGx Testing
In contrast with findings from previous studies that included patients with chronic
diseases (Calsbeek et al., 2007; Cuffe et al., 2014; Morren et al., 2007; Nielsen and
Moldrup, 2007; Rogausch et al., 2006), most patients here were knowledgeable about
general aspects of genetics and PGx testing, although less than half were familiar with the
availability of PGx testing and its potential to detect medication side effects. Education
and prior experience were significantly correlated with knowledge of PGx testing;
educated patients with prior experience of PGx testing had greater overall knowledge of
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it. The relatively higher overall knowledge of patients who participated in this study
might have reflected their higher level of education compared to participants in other
studies. In addition, patients’ knowledge about PGx testing might have been influenced
by their previous awareness regarding PGx testing as a new clinical tool.
Another explanation for the relatively higher knowledge scores observed in this
study might have been the use of more than one resource of health information by
patients to find out more about PGx testing. The results indicated that healthcare
professionals, including physicians, physicians’ assistants, and pharmacists, as well as the
Internet, were the most popular sources of health information for patients.
Variables Associated with Patients’ Knowledge
Patients’ knowledge of PGx testing showed strong association with several factors
of the Rogers’s diffusion of innovation theory such as prior experience, age, ethnicity,
level of education, perceived need, and innovativeness. Prior experience was associated
with more knowledge about PGx testing; this finding was consistent with previous works
that showed prior experience was related to patients’ acceptance of consumer health
information technology applications (Or and Karsh, 2009), genetic knowledge
(Henneman et al., 2004), patients’ support to PGx testing (Haga et al., 2012b), and better
understanding of personalized medicine (Haddy et al., 2010). The findings also revealed
that young, White, and more educated patients were more knowledgeable about PGx
testing than older, Blacks or African Americans, and those with lower levels of
education. Gender and area of living were not associated with overall knowledge of PGx
testing.
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The fact that gender was not associated with overall knowledge might be a sign
that neither males nor females were aware of PGx testing. Although the majority of
studies reviewed by Or and Karsh (2009) showed that gender had no effect on the
acceptance of health IT application, other studies reported that women had a higher level
of genetic knowledge than men (Haga et al., 2012b; Henneman et al., 2004; Morren et al.,
2007).
This study found no association between channels of communication of health
information and patients’ knowledge of PGx testing. The importance of effective
communication in understanding the barriers to actual implementation of PGx testing,
however, has been recognized in other studies, especially between patients and their
healthcare providers (Haddy et al., 2010; Haga et al., 2012b; Henneman et al., 2006).
Since PGx testing has been slowly integrated into clinical practice, it was not expected to
be widely known among non-adopter medical groups and appear as a central issue in
social media. Additionally, evidence-based guidelines for PGx testing have not yet been
developed for the majority of chronic medications. Therefore, healthcare providers may
not consider it to be a relevant point of discussion with patients. Communication
channels might have provided a better measurement if patients had been asked to mention
the sources from which they received information about personalized medicine.
No association between patients’ overall knowledge of PGx testing and area of
living was found either. This might have been due to the fact that most patients lived in
either urban or suburban areas, so access to health information resources might have been
equal across different areas; this would accord with Rogers’s diffusion of innovation
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expectation about innovations occurring in large urban centers/hospitals due to greater
availability of resources.
This study also found a significant association between patients’ perceived need
for PGx testing and their knowledge of it. Most patients agreed on the need for PGx
testing in order to avoid being prescribed the wrong medication and reduce ADRs that
might be associated with their chronic medications. Although this association has not
been specifically addressed in the literature, several studies have reported that the
perceived need among patients regarding genetic testing or other health-related
innovations influenced the adoption of the studied innovations. Several studies stressed
the importance of perceived need in decision-making. For example, Shah (2004)
expressed the medical need to improve patient’s quality of life as one of the criteria for
the medical use of PGx testing. Henneman et al. (2006) showed that less than half of
participants in their study perceived a need for genetic testing; the perceived usefulness
of these tests were linked with patients’ acceptance of genetic testing. Cuffe et al. (2014)
showed that the majority of cancer patients wanted PGx testing due to their high need to
detect the risk of severe toxicity associated with chemotherapy. Furthermore, Or and
Karsh (2009) concluded that meeting patients’ needs was of great importance to
implement and accept telemedicine among patients. These studies support the view that
increased perceived need for PGx testing as an antecedent of knowledge may play a
pivotal role in decision making as described by Rogers’s theory.
Another independent variable investigated here was innovativeness. The
empirical evidence revealed that patients who were more willing to adopt PGx testing
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also were more knowledgeable, a clear illustration of adopters’ behavior as described by
Rogers’s theory.
Patients’ Attitudes toward PGx Testing
The overall attitudes of patients with chronic diseases toward PGx testing were
positive. In line with previous studies (Fargher et al., 2007; Haga et al., 2013; Kobayashi
and Satoh, 2009; Lachance et al., 2015), patients expressed high expectations and hopes
regarding the benefits of PGx testing and its potential role in preventing medications
prescribed erroneously and enhancing medication safety. Most participants felt
optimistic and preferred to have their genes tested to find the medications that best
worked for them, and nearly all patients agreed or strongly agreed that PGx testing was a
promising innovation in medicine that could eventually help physicians make educated
decisions about their health.
Yet most participants expressed concerns regarding the cost of testing, the
handling of confidential testing results (e.g., unauthorized access to the results),
employment opportunities, and their eligibility to purchase a health insurance plan.
Previous studies also reported that patients were worried about confidentiality issues, the
impact of testing results on their eligibility to private health insurance, and employment
opportunities (Fargher et al., 2007; Haga et al., 2013; Kobayashi and Satoh, 2009;
Lachance et al., 2015; Rogausch et al., 2006). Patients from other studies were also
concerned about the possibility of disclosing a future risk of chronic diseases after
undergoing genetic tests (Cuffe et al., 2014; Rogausch et al., 2006).
The optimistic attitudes revealed here indicated that patients’ high expectations of
advancements in the field of genetics were not necessarily dependent on their knowledge.
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According to Rogers’s diffusion of innovation theory, knowledge and comprehension
among patients about PGx testing should precede the attitude stage; in this study,
however, although patients’ knowledge of PGx testing was positively correlated with
their attitudes, their high expectations of the role that PGx testing could play in effective
therapeutic options seemed to be overrated because other factors (e.g., age, type of
disease, health status) that also influence drug response were not studied. This finding
was consistent with the conclusions of Rogausch et al. (2006), who reported that patients
were optimistic about the benefit of PGx testing but more than half of them would not
change their ineffective current therapy if the PGx-recommended optimal therapy was
not available. Since this dissertation did not specifically measure patients’ overall
knowledge of non-genetic factors that might also impact therapeutic outcomes, which is a
fundamental concept of Rogers’s diffusion of innovation theory, the potential effect of
this type of knowledge on patient attitudes cannot be overlooked.
Variables Associated with Patients’ Attitudes
The empirical evidence showed that patients’ overall attitudes toward PGx testing
were correlated with the factors originated in Rogers’s diffusion of innovation theory.
Women were more likely to have positive attitudes toward PGx testing than men.
Women also were less likely to be concerned with the perceived disadvantages of PGx
testing (i.e., cost of testing, confidentiality, insurability, employability). This is the
opposite of findings in other studies (Haga et al., 2013; Henneman et al., 2006; Rogausch
et al., 2006). The discrepancy might be explained by a higher percentage of women in
this dissertation having attained higher levels of education. The findings here were also
consistent with previous studies (Haga et al., 2013; Haga et al., 2012b) insofar as more

102
educated patients expressed more positive attitudes toward PGx testing than those with a
lower level of education.
No significant association was found between patients’ attitudes toward PGx
testing and either age or ethnicity. Similar findings were reported in other studies
(Henneman et al., 2006; Lanktree et al., 2014; Or and Karsh, 2009). In line with the
findings of Rogausch et al. (2006), area of living had no influence on patients’ attitudes
toward PGx testing; the absence of a link might be attributed to 97% participants living in
urban and suburban areas, with approximately the same access to resources and
innovation.
The results of this study revealed a significant relationship between patients’
attitudes toward PGx testing and relative advantage, complexity of understanding the
term of PGx testing, compatibility, trialability, and observability of PGx testing. This
study showed that patients who agreed on at least one relative advantage (i.e., PGx
testing may help in prescribing the best available treatment for chronic conditions) had
more positive attitudes than those who did not perceive PGx testing as advantageous.
Rogausch et al. (2006) also revealed that patients who perceived the potential advantages
of PGx testing (e.g., reducing side effects, avoiding ineffective medications) were more
optimistic about the advantages of PGx testing.
Patients who were able to understand the term PGx testing expressed more
positive attitudes toward PGx testing than those patients who perceived it as a complex
concept. Comparable results on adopting different innovation were reported by Or and
Karsh (2009). A strong correlation also was found between patients’ favorable attitudes
towards PGx testing and standards of care that maintain health information privacy.
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Similarly, Henneman et al. (2006) reported that compatibility of PGx testing with moral
values played a role in patients’ acceptance of PGx testing. Moreover, this dissertation
illustrated the degree to which PGx testing could be tried by patients. Patients willing to
try PGx testing expressed more positive attitudes. When measuring the level of
observability, almost 86% of patients never had a discussion with their healthcare
providers about PGx testing. The observability of PGx testing was significantly
associated with patients’ hopeful attitudes toward PGx testing. Yet after conducting
regression analysis, observability was not a significant predictor of patients’ attitudes
toward PGx testing.
Adoption of PGx Testing among Patients
A distinguishing feature if this study is that different PGx testing predictors were
measured to determine the factors that influence patients’ acceptance of PGx testing.
A generalized path analysis was conducted to assess the factors that predict acceptance of
PGx testing. Path analysis is a subset of structural equation modeling that uniquely
provides information about the strength of causal relationships between factors of a
hypothesized model. The results showed that more than 50% of patients with chronic
conditions were willing to undergo PGx testing. When path analysis was originally
applied based on the initial model guided by Rogers’s diffusion of innovation theory,
some reproduced correlations did not appear to be significantly associated with the
acceptance of PGx testing; however, finding the possible missing correlations (i.e., direct
and indirect pathways) using a path analysis model between the defined factors and the
outcome variable (i.e., willingness to accept PGx testing) resulted in a well fit model for
the collected data.
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Patients’ attitudes, as well as the perceived characteristics of PGx testing (e.g.,
relative advantage, compatibility, complexity, trialability, and observability), had a direct
and indirect influence on the acceptance of PGx testing, while knowledge was not
significantly related to the outcome variable. Rogers’s diffusion of innovation theory
provides a plausible explanation for these findings about the relationship between
attitudes toward PGx testing and the decision to adopt; the lack of association between
the two reported in this study might be attributed to patients’ non-involvement in decision
making about their healthcare needs that might affect their actual knowledge. The
association between knowledge and adoption may appear after patients acquire more
detailed knowledge about PGx testing.
Prescribers’ Knowledge of PGx Testing
Most physicians knew that PGx testing can determine whether people with
genetic differences respond differently to the same medication; they also were aware that
PGx testing is not available for all medications. Relatively few, however, knew about the
impact of genetic variability on an individual's response to a medication or were familiar
with the availability of PGx testing for Plavix ® (clopidogrel). Younger, non-White, and
female participants practicing in suburban areas had the highest mean knowledge scores.
Physicians’ overall knowledge of PGx testing in the sample was greater than the
knowledge of physicians who participated in other studies (Dressler et al., 2014; Haga et
al., 2012a; Powell et al., 2012; Rogausch et al., 2006; Stanek et al., 2013; Taber and
Dickinson, 2014). Perhaps this differential reflects an ongoing trend in the growth of the
PGx field and the surge in interest to know more about PGx testing.
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Variables Associated with Prescribers’ Knowledge
Physicians’ overall knowledge of PGx testing was significantly associated with
gender, perceived need, prior experience, type of practice setting, and sources of
communication. The absence of association with age, ethnicity, and duration of practice
might be explained by the fact that participants received similar education and training
programs in genetics. The lack of correlation between overall knowledge of PGx testing
and type of specialty may reflect uniform genetics education and training across
specialties.
Physicians made conscious efforts to gain more information about genetics from a
variety of sources. Compared to other studies (Dressler et al., 2014; Haga et al., 2012a;
Shields et al., 2005; Stanek et al., 2012), the percentage of physicians who reported
receiving formal education in genetics was higher. The majority reported using two or
more sources of genetic information and testing. These sources included genetics
training in medical school, CME courses, undergraduate genetics courses, geneticsrelated seminars or workshops, and grand rounds.
Physicians who relied on at least one source of genetic information had a higher
level of overall PGx knowledge than physicians who did not report any source. This was
consistent with other studies (Dressler et al., 2014; Haga et al., 2012a, Stanek et al., 2012,
2013; Taber and Dickinson, 2014). Physicians who perceived the need for PGx testing in
reducing ADRs and preventing ineffective therapies were more knowledgeable about
PGx testing than those who did not perceive the need. Stanek et al. (2012), Stanek et al.
(2013), and Haga et al. (2012a) reported similar findings.
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Finally, the strength of the relationship between overall knowledge of PGx testing
and the significant factors identified in the One-way ANOVA model was probed using a
multiple linear regression model. Forward selection and backward elimination regression
models yielded similar results, with three significant predictors: gender, prior experience,
and type of practice setting. Female physicians practicing in suburban areas with prior
experience had a higher overall PGx testing knowledge score. Participants practicing in
suburban areas might have had better access/exposure to educational resources regarding
PGx testing. More research is needed to confirm this finding and further investigate
whether suburban-practice physicians are more likely to have longer interaction with
patients over a longer period of time, which might lead to increased awareness of interindividual variation in drug response.
Other studies showed findings different from those reported here. Walden et al.
(2015) found that more male than female physicians believed that they had a better
understanding of the PGx report. Klitzman et al. (2013) found that White and male
physicians were associated with increased ordering of genetic testing. Stanek et al.
(2012) reported that physicians who were willing to accept PGx testing were more likely
to be male, older, having practiced 30 years or more since graduation, practicing in urban
settings, and working in general/family practice settings.
Similar to the findings of this work, several studies revealed an association
between lack of prior experience with PGx testing and the knowledge gap that influenced
decision making toward the adoption of PGx testing (Haga et al., 2012a; Stanek et al.,
2012; Stanek et al., 2013). According to these studies, physicians’ levels of knowledge
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of PGx testing and experience with patients who undergo genetic tests might significantly
impact their preparedness for accepting genetic tests.
Prescribers’ Attitudes toward PGx Testing
Physicians’ overall attitudes toward PGx testing were positive, which was
consistent with the findings of other studies (Dressler et al., 2014; Haga et al., 2012a;
Moaddeb et al., 2015; Shields et al., 2005; Walden et al., 2015). Rogausch et al. (2006)
revealed more reserved attitudes toward PGx testing among healthcare professionals
when considering the potential discrimination by health insurance companies as well as
employers; in this dissertation, however, the levels of concern shared by physicians were
much lower.
The findings here suggest that physicians’ attitudes toward PGx testing are
becoming increasingly receptive, and this may be due to more perceived benefits of
genetic tests in improving medication safety and efficacy. Supporting the findings of
other studies (Fargher et al., 2007; Haga et al., 2012a; Haga et al., 2012c; Rogausch et al.,
2006; Stanek et al., 2012) regarding physicians’ concerns about PGx testing, the results
showed that some concern existed about the cost of PGx testing, patients' confidentiality,
and the uncertainty about the clinical utility of these tests.
Variables Associated with Prescribers’ Attitudes
The regression model indicated that physicians’ total attitude score toward PGx
testing was predicted significantly by gender, relative advantage, and compatibility.
Duration of practice, medical specialty, and urban-rural practice setting were not
significantly associated with attitudes toward PGx testing. The lack of statistical
significance of duration of practice might be due to a low comfort level of physicians’
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knowledge about these tests, regardless of years of practice, because of lack of exposure
to, and experience with, PGx testing. The lack of statistical significance of medical
specialty might be due to a possible selection bias or because participants did not
perceive the benefits of PGx to be directly related to their specialties. The lack of
statistical significance of practice setting might be attributed to the absence of substantial
differences among rural, suburban, and urban areas in terms of accessibility to genetic
information and/or type of patients encountered.
The findings of this study did not accord with the results of Klitzman et al. (2013)
and Walden et al. (2015), who showed that male physicians had more favorable attitudes
than female physicians toward the clinical application of PGx testing. This discrepancy
might be due to the fact that female physicians in this study had higher level of
knowledge about PGx testing than their male counterparts.
A significant relationship was found between attitudes toward PGx testing and
relative advantage, compatibility, and observability. The significant effect of the
observability variable, however, disappeared after conducting regression analysis. Haga
et al. (2012a) also reported an impact of the relative advantage of PGx testing toward
predicting potential ADRs and improving therapeutic outcomes on physicians’ attitudes
and their decision to accept PGx testing. In this dissertation trialability and complexity
were not significantly associated with attitudes toward PGx testing. In contrast, Taber
and Dickinson (2014) and Fargher et al. (2007) indicated that the complexity perceived
by physicians in terms of describing the role of PGx testing in healthcare, ordering the
tests and interpreting the results, and unperceived clinical benefits negatively impacted
attitudes and the ordering of these tests. Stanek et al. (2012) also indicated that the
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complexity of multiple genetic predictors involved in the variability of drug response
might present a barrier to adoption.
Adoption of PGx Testing among Physicians
The adoption of PGx testing by physicians was significantly influenced by the
perceived characteristics of PGx testing as well as the perceived need for innovation.
Along with the initial path-analysis model guided by Rogers’s diffusion of innovation
theory, some reproduced correlations between variables were not significant. After
finding the possible missing correlations in the initial model and computing the direct,
indirect, and total causal effects of the revised model, however, the model provided a
good fit for the data.
Over 50% of physicians were willing to accept PGx testing. Supporting the
results of other studies (Dressler et al., 2014; Haga et al., 2012a; Stanek et al., 2012;
Taber and Dickinson, 2014), this dissertation showed that lack of knowledge and poor
attitudes toward PGx testing negatively impacts the PGx-based prescribing decisions
among physicians. Other factors contributing to the low use of PGx tests included
availability of PGx testing, the cost of testing, privacy issues, and absence of clinical
guidelines. Almost half of physicians agreed that pharmacists’ role was crucial in the
process of ordering PGx testing and interpreting results.
Limitations
Although the response rate of patient participants was high, the convenient nature
of the sample might limit the generalizability of the findings. Underrepresentation of
Hispanics/Latinos also might have affected the results. Using flyers to recruit patients
might have resulted in patients’ self-selection; thus the likelihood of selection bias should
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be taken into consideration. Finally, the knowledge instrument had a slightly lower than
adequate internal reliability (Cronbach’s alpha) score. Avoiding an excessively long
questionnaire that might have limited participants’ response and caused survey fatigue
was important; therefore, several redundant items, which might have increased the
Cronbach’s alpha score but not necessarily provided additional information, were
removed from the scale.
The relatively low response rate of physicians might have limited the
generalizability of the findings. Since physicians had to answer and submit the
questionnaires on line, some might not have participated due to the inconvenience of
responding via e-mail. Underrepresentation in some medical specialties was a limitation.
Finally, using a relatively low reliability knowledge instrument also might have affected
the findings.
Recommendations for Future Research
As the number of drug package inserts with FDA-approved PGx information
increases, the need to measure physicians’ knowledge and attitudes becomes imperative.
More accurate findings may be obtained from replicating this study, applying Rogers’s
diffusion of innovation theory or other models to a larger sample of physicians from a
wider variety of specialties. It is also important to recruit a representative sample of
patients with a wide array of chronic diseases to assess their knowledge of PGx testing.
Different measurement instruments may be used to capture accurately separate factors
such as trialability, observability, innovativeness, area of practice/living, and
communication channels.
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Future research should be geared toward recruiting physicians working in medical
settings in which PGx testing is available and proportionately include minority
ethnic/racial groups. Younger and older physicians practicing in both rural and urban
areas should be included. Using a larger sample size would allow conducting additional
subgroup analysis that may provide a better insight into the adoption behavior of patients
and physicians as well as the predictors of knowledge and attitudes. A mixed-methods
approach using qualitative and quantitative data collected simultaneously may be best
suited to provide a deeper understanding of the acceptance of PGx testing in medical
practice.
Significance of the Findings in the Field of Pharmacy
Pharmacists play a key role in patient care through a wide array of services that
focus on monitoring the prescription process and optimizing drug utilization to ensure the
safety and effectiveness of prescribed medications (Bush and Daniels, 2017). The unique
position of pharmacists as access points to care has several advantages leading to the
integration of patients’ health information with rational drug use. As the focus of health
care shifts into personalized medicine, pharmacists’ knowledge and awareness about
genetic-based treatment have become a necessity. The FDA has already approved more
than 150 drug package inserts with pharmacogenetic information, and the Clinical
Pharmacogenetics Implementation Consortium (CPIC) has published therapeutic
guidelines based on individual genetic differences (Relling and Klein, 2011) that mandate
healthcare providers, including pharmacists, to take the lead, seek education, and gain
experience in the field of genetics.
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Integrating genetic information with other health information may maximize the
benefits of medications that patients should receive as well as diminish the occurrence of
ADRs (Ma et al., 2011; Owczarek et al., 2005). To fulfill the Accreditation Council for
Pharmacy Education (ACPE) Standards, several pharmacy schools have included genetic
courses in their curricula to fortify the level of knowledge pertaining to medication
response (ACPE, 2015; Adams et al., 2016). These pharmacogenetic courses are
designed to familiarize future pharmacists with the genetic basis of diseases as well as the
role of metabolizing enzymes, which are susceptible to inter-individual genetic variation
in medication response.
The American Society of Health-System Pharmacists (ASHP) has emphasized the
role of pharmacists in promoting personalized medicine and taking the lead in
understanding genetic variability among individuals responsible for aggravating the
burden of preventable side effects (ASHP, 2015). To maintain the ongoing responsibility
of pharmacists toward optimizing therapeutic benefits and minimizing adverse drug
reactions, the barriers to adopting PGx testing as a diagnostic tool should be studied
further. In addition, the interpretation of testing results and the most effective ways of
communicating these results to patients and other healthcare providers should be
investigated and evaluated. The work described in this dissertation has revealed several
factors that significantly influence acceptance of genetic tests by both physicians and
patients. In the presence of clinical guidelines (Relling and Klein, 2011; Swen et al.,
2011), the ability of a pharmacist to understand both physicians’ and patients’ motives
and concerns regarding acceptance of PGx testing may help advocate its application in
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practice and promote the optimal use of PGx testing in order to achieve positive health
outcomes.
Conclusion
Advances in the field of PGx in modern medicine are increasingly becoming a
transforming point in the way chronic conditions are treated, medications are prescribed,
and in developing trusting relationships among patients, pharmacists, and physicians. In
a preliminary step toward searching for a more extensive acceptance of PGx testing in
clinical practice, this study carefully assessed the decision-making process and
subsequently provided a significant insight into factors pertaining to enhancing the rate of
adoption of PGx testing among patients and prescribers.
Incorporating patients’ genetic information as part of their medical history will
optimize the use, safety, and effectiveness of many medications. However, transforming
this technology into practice can only be accompanied with increased knowledge and
more positive attitudes among patients and physicians alike, as they play a key role in its
diffusion. This dissertation considered the fact that participating patients suffered from
several chronic conditions that have a genetic predisposition. Therefore, the research
focused on measuring actual knowledge of genetics and PGx testing rather than perceived
knowledge, and it was found predictive for less reluctance toward accepting the tests.
This conclusion highlights the need for establishing educational programs and revising
existing medical curricula geared toward gaining knowledge as a precedent factor to the
formation of favorable attitudes toward PGx testing.
This study measured the influence of sociodemographic characteristics on
patients’ willingness to accept PGx testing and on prescribers’ understanding of patients’
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medical needs and the need for change in their current clinical practices. It strongly
suggested that obtaining higher levels of education, being innovative, and gaining prior
experience with genetic testing should ultimately improve patients’ acceptance of this
diagnostic tool. The empirical evidence showed an increase in patients’ awareness and
attitudes regarding genetic testing. In addition, several factors connected to the
characteristics of PGx testing were significantly linked to its future acceptance. Thus,
this study provided a thorough understanding of society’s need and opinions toward PGx
testing. Patients believed that PGx testing helps select the effective medication, avoid
wrong medications, and reduce potential adverse events. Several barriers reported here
could contribute to reforming institutional policies regarding patients’ confidentiality and
potential for discrimination that might impact patient’s attitudes and subsequently the
decision to adopt.
The findings also showed that general knowledge of, and attitudes toward, the use
of PGx testing increased physicians’ tendency to select the technique and implement it on
their patients to improve health outcomes. Physicians’ acceptance of these tests was
exclusively linked to their prior experience with, and perceived need for, genetic testing
as well as perceived characteristics of PGx testing. Also identified were several barriers
for the adoption decision that need be considered by the medical community and
healthcare systems to meet society’s need for PGx testing and reduce healthcare costs,
unnecessary medications, and ADRs that will ultimately improve patient adherence.
Moreover, the findings may help develop clinical trials and conduct epidemiological
studies to promote the uptake of genetic tests and overcome the key barriers.
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This dissertation added an additional value by delineating factors that need be
addressed to foster PGx implementation in a clinical setting. It may have a large impact
on developing education and training programs, mitigating future concerns, and on PGx
companies that could improve the characteristics of PGx testing and alleviate currently
foreseen barriers. It provided an insight into the perception of patients with chronic
diseases that might represent and reflect comparable results drawn from a larger
population. The extent of the findings may be expanded to include pharmacoeconomic
and health outcome measures. The findings also may be used to assess the inhibitors of
accepting individual PGx tests in different clinical settings and may be applied to other
healthcare professionals and their response to health-related innovations.
The theoretical framework, Rogers’s diffusion of innovation theory, was a useful
and highly reproducible model. A generalized path analysis method posed new correlates
among different sets of adapted variables. The modified data collecting instruments
validated and used in this research significantly contributed to capturing patients’ and
physicians’ factors that have not been investigated in prior studies.
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Appendix A
Research Questionnaire (Patient Version)
Knowledge
For each of the following items check (X) if you think it is true or false:
1. A person who carries a gene associated with a disease may be healthy
 True
 False
 Not Sure
2. A person's genetic make-up can influence how he or she responds to medicines
 True
 False
 Not Sure
3. People with genetic differences can respond differently to the same medication (e.g.,
some patients may benefit; others may not)
 True
 False
 Not Sure
4. A test that looks at an individual's genes will likely reveal whether a particular
medicine would cause side effects for that person
 True
 False
 Not Sure
5. A test that takes a cotton swab from the mouth of an individual and looks at genes is
currently available for some medications (e.g. simvastatin, clopidogrel)
 True
 False
 Not Sure
6. A test that looks at a person's genes will likely reveal whether a particular medicine
would work for that person
 True
 False
 Not Sure
7. The severity of side effects of some medications may depend on a person's genetic
make-up
 True
 False
 Not Sure
8. Before this survey, have you ever heard about the term "Pharmacogenetic Testing"?
 True
 False
 Not Sure
9. Have you ever had your gene(s) tested?
 True
 False
 Not Sure
10. Would you agree to take a pharmacogenetic test (via cotton swab from the mouth) for
one of your chronic medications?
 Yes
 I already have one
 No
 Not Sure
Attitude
This survey asks about your preference with regard to the following statements:
11. It is important to look at my genes in order to know what is best for my health
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 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
12. I am willing to take a test that measures how a medicine works, based on my genes
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
13. It is not useful to take genetic tests because my family physician may not know how
to use my tests results
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
14. If I had to pay for the genetic test myself, financial cost would be one of my concerns
for taking these tests
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
15. If I underwent testing, I would be concerned about the effect of the test results on my
eligibility for private health insurance
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
16. If I underwent testing, I would be concerned about the effect of the test results on my
employment opportunities
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
17. I believe that physicians should have pharmacogenetic testing information in their
clinical practice
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
18. I think that pharmacogenetic testing may prevent me from taking the wrong medicine
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
19. I believe that pharmacogenetic testing will help reduce my current medications' side
effects
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
20. If I took the test, I would be concerned that unauthorized persons may gain access to
the results of that test
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
21. I believe that pharmacogenetic testing can help in the selection of a medication that
would better improve my medical condition
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
22. Pharmacogenetic testing can offer me a useful alternative to the way that a physician
usually prescribes medications
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
23. Pharmacogenetic testing is a promising innovation in medicine
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
24. Pharmacogenetic testing can help my physicians to make the right decisions about my
health
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
25. I will be reluctant about accepting pharmacogenetic testing until I see it providing
useful results for people around me
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
26. Pharmacogenetic testing is a type of test that can invade my privacy
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
27. The term pharmacogenetic testing is difficult to understand
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 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
28. I won't lose much by trying pharmacogenetic testing, even if it doesn't benefit me
directly
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
29. I have discussed (at least once) pharmacogenetic testing with my healthcare provider
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
30. Which of the following sources, if any, do you usually use to get information about
health issues (for example, medications, treatment, and side Internet effects)? (Check
all that apply)
 TV  Radio
 Internet
 Newspapers
 Magazines
 Physicians/Physician Assistants  Nurses
 Pharmacists
31. Gender
 Male
 Female
32. Ethnic Group
 White/Caucasian  Hispanic/Latino
 Black or African American
 Others
33. Age Group (years)
 18-29
 30-39
 40-49
 50-59
 60+
34. Education
 High School or GED
 Associate Degree  Bachelor's Degree
 Master's Degree
 Doctorate or Professional Degree
35. Area where you live
 Urban
 Suburban  Rural
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Appendix B
Study Constructs and Corresponding Sources
Table B.1
Patient Survey Constructs
Construct/Variable
Knowledge of PGx testing

Survey Items
Reference
1
(Calsbeek et al., 2007)
2,3, 5
(Roederer et al., 2012)
4, 6, 7
(Lachance et al., 2014)
Attitudes toward PGx testing
11, 17, 23, 24
Self-developed
12, 20
(Rogausch et al., 2006)
13 - 16
(Zhang et al., 2014)
Prior experience
8, 9
Self-developed
Perceived need
18, 19
(Rogausch et al., 2006)
Innovativeness
25
Self-developed
Area of living
35
(Dodson et al., 2012)
Sociodemographic variables
31 - 34
Self-developed
Communication channels
30
(Nielsen et al., 2007)
Relative advantage
21, 22
Self-developed
Compatibility
26
Self-developed
Complexity
27
(Dodson et al., 2012)
Trialability
28
Self-developed
Observability
29
Self-developed
Willingness to take the test
10
Self-developed
Note. The patient survey used in this study was developed and modified from previously
published studies to collect information about patients’ knowledge and attitudes toward
PGx testing. Several survey questions were adapted from the above authors.
*PGx = Pharmacogenetic

120
Table B.2
Prescriber Survey Constructs
Construct/Variable
Duration of practice
Knowledge of PGx testing

Survey Items
Reference
1
Self-developed
2, 3, 5 - 7
(Roederer et al., 2012)
4
(Shaw et al., 2011)
Attitudes toward PGx testing
11
(Rogausch et al., 2006)
10,17,19
(Roederer et al., 2012)
9
(Dodson et al., 2012)
8, 12, 15
Self-developed
Prior experience
25
(Taber et al., 2014)
Perceived need
21a, 21b
(Rogausch et al., 2006)
Area of Current Setting
32
(Dodson et al., 2012)
Sociodemographic variables
28-31
Self-developed
Communication channels
22
(Taber et al., 2014)
Relative advantage
20a, 20b
Self-developed
Innovativeness
14
Self-developed
Compatibility
13
Self-developed
Complexity
18
Self-developed
Trialability
16
Self-developed
Observability
23
Self-developed
Willingness to recommend PGx
24
Self-developed
Factors affecting PGx adoption
26
(Taber et al., 2014)
Pharmacist role in PGx testing
27
Self-developed
Note. The prescriber survey used in this study was developed and modified from the
relevant literature to collect information about physicians’ knowledge and attitudes
toward PGx testing. Several survey questions were adapted from the above authors.
*PGx = Pharmacogenetic
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Appendix C
Research Questionnaire (Prescriber Version)
1. How long have you been in practice (years)?
 1-10
 11-20
 21 years or more
Knowledge
For each of the following items, check if you think it is true or false.
2. Genetic variations account for as much as 95% of the variability of an individual's
response to a medication.
 True
 False
 Not Sure
3. Pharmacogenetic testing can determine whether people with genetic differences can
respond differently to the same medication.
 True
 False
 Not Sure
4. Pharmacogenetic testing of an individual's genes guarantees whether a particular
medicine would cause adverse events for that person.
 True
 False
 Not Sure
5. Pharmacogenetic testing is currently available for all medications.
 True
 False
 Not Sure
6. Some medications have FDA-approved pharmacogenetic information in their package
inserts.
 True
 False
 Not Sure
7. The package insert for clopidogrel (Plavix®) includes a warning about possible worse
outcomes in individuals who have specific genetic variants.
 True
 False
 Not Sure
Attitudes
On a scale from 1 to 5, indicate your agreement with the following items:
8. Prescribers should use pharmacogenetic testing information in clinical practice
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
9. Patients should be educated about the purpose, benefits, limitations and risks of
pharmacogenetic testing.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
10. Pharmacogenetic testing will potentially help to decrease the number of adverse drug
events.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
11. Pharmacogenetic testing may prevent me from prescribing an ineffective medicine.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
12. Pharmacogenetic testing is a promising innovation in medicine.
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 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
13. Pharmacogenetic testing is not compatible with my personal values.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
14. I will be reluctant to adopt pharmacogenetic testing until I see it working for patients.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
15. Pharmacogenetic testing can offer a useful tool to the way I usually
prescribe/recommended medications.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
16. I would like to try pharmacogenetic testing on some patients before I decide whether I
will adopt it or not.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
17. I am concerned about the effect of the test results on my patients' eligibility for
private health insurance.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
18. The application of pharmacogenetic testing adds more complexity to the drug
prescribing process.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
19. I am concerned that unauthorized personnel may gain access to the results of that test.
 Strongly Disagree/Disagree
 Neutral
 Agree/Strongly Agree
20. There is a relative advantage for pharmacogenetic testing in the following cases:
a. Non-response to an essential drug (e.g., analgesic) / Refractory patients
 Yes
 No
 Not Sure
b. Selection of medication that better controls a patient's health condition
 Yes
 No
 Not Sure
21. There is a need for pharmacogenetic testing in the following situations:
a. When information about the test is included in the package inserts
 Yes
 No
 Not Sure
b. When practice guidelines for the use and interpretation of these tests are available.
 Yes
 No
 Not Sure
22. How/where have you learned about genetics and genetic testing? [Please select all
that apply.]
 No, I have not received education in genetics
 Genetics training in medical/pharmacy school
 Genetics training in residency
 Undergraduate genetics course
 Genetics course in graduate school
 Grand Rounds
 CME course
 Genetics-related seminar or workshop
 Other
23. Have you ever talked with a patient about pharmacogenetic testing?
 Yes
 No
 Not Sure
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24. Would you recommend pharmacogenetic testing for medications that recommend
such tests in their package inserts?
 Yes
 No
 Not Sure
25. Have you ever ordered pharmacogenetic testing for a patient?
 Yes
 No
26. Which of the following factors would inhibit you from ordering/recommending
pharmacogenetic testing for a patient? [Please select all that apply.]
 Pharmacogenetic-testing is not available at my work place
 Concerns about patients' confidentiality
 Concerts about patients' employment opportunity
 Not enough time to order
 Waiting for pharmacogenetic testing results would delay treatment
 Uncertain about the clinical utility of the test
 Insurance doesn't cover test
 Not applicable for my patients
 Patient refused test
27. Would you prefer a pharmacist order, interpret, and send you a report about your
patients' pharmacogenetic testing results?
 Yes
 No
 Not Sure
28. Gender
 Male
 Female
29. Ethnic Group:
 White/Caucasian
 Hispanic/Latino
 Black or African American
 Other
30. Age Group (year)
 25-39
 40-49
 50-59
 60+
31. What is your medical specialty?
 Internal Medicine
 Family Medicine
 Other
32. Type of current setting: [Please select all that apply]
 Urban
 Suburban
 Rural
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Appendix D
NSU-Institutional Review Board Approval Memorandum and Amendment Approval
Letter
D.1. MEMORANDUM
To:
Suhaib Muflih Muflih
College of Pharmacy
From:
William "Bill" R Wolowich, Pharm.D.,
Center Representative, Institutional Review Board
Date:
March 22, 2016
Re:
IRB #: 2016-77; Title, “Measuring Knowledge and Attitudes Regarding
The Use of Pharmacogenetic Testing Among Patients and Prescribers:
Diffusion of Innovation Theory”
I have reviewed the above-referenced research protocol at the center level. Based on the
information provided, I have determined that this study is exempt from further IRB review
under 45 CFR 46.101(b) (Exempt Category 2). You may proceed with your study as
described to the IRB. As principal investigator, you must adhere to the following
requirements:
1)

CONSENT: If recruitment procedures include consent forms, they must be
obtained in such a manner that they are clearly understood by the subjects and the
process affords subjects the opportunity to ask questions, obtain detailed answers
from those directly involved in the research, and have sufficient time to consider
their participation after they have been provided this information. The subjects
must be given a copy of the signed consent document, and a copy must be placed
in a secure file separate from de-identified participant information. Record of
informed consent must be retained for a minimum of three years from the
conclusion of the study.

2)

ADVERSE EVENTS/UNANTICIPATED PROBLEMS: The principal
investigator is required to notify the IRB chair and me (954-262-5369 and
William "Bill" R Wolowich, Pharm.D., respectively) of any adverse reactions or
unanticipated events that may develop as a result of this study. Reactions or
events may include, but are not limited to, injury, depression as a result of
participation in the study, life-threatening situation, death, or loss of
confidentiality/anonymity of subject. Approval may be withdrawn if the problem
is serious.

3)

AMENDMENTS: Any changes in the study (e.g., procedures, number or types of
subjects, consent forms, investigators, etc.) must be approved by the IRB prior to
implementation. Please be advised that changes in a study may require further
review depending on the nature of the change. Please contact me with any
questions regarding amendments or changes to your study.
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The NSU IRB is in compliance with the requirements for the protection of human
subjects prescribed in Part 46 of Title 45 of the Code of Federal Regulations (45
CFR 46) revised June 18, 1991.
cc:
Barry A. Bleidt, PhD, PharmD
D.2. Amendment Approval Letter
To: Suhaib Muflih, College of Pharmacy
From: William Smith, JD Director, Institutional Review Board
Date: August 3, 2016
Re: 2016-77-Measuring Knowledge and Attitudes Regarding The Use of
Pharmacogenetic Testing Among Patients and Prescribers: Diffusion of Innovation
Theory
I have reviewed the amendment to the above-referenced research protocol. On behalf of
the Institutional Review Board of Nova Southeastern University, the amendment to
Measuring Knowledge and Attitudes Regarding The Use of Pharmacogenetic Testing
Among Patients and Prescribers: Diffusion of Innovation Theory is approved and the
study is still EXEMPT.
cc: Barry A Bleidt, PhD, PharmD; Matthew Seamon, JD, PharmD
Institutional Review Board
3301 College Avenue Ft. Lauderdale, Florida 33314-7796
Phone: (954) 262-5369 Fax: (954) 262-3977 Email: irb@nova.edu Web Site:
www.nova.edu/irb
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Appendix E
Adult Informed Consent, Promotional Flyer for Recruiting Patients, Prescriber Invitation
E-Mail, Prescriber Participation Letter
E.1. Adult Informed Consent
Consent Form for Participation in the Research Study Entitled “Measuring
Knowledge and Attitudes Regarding the Use of Pharmacogenetic Testing Among
Patients and Prescribers: Diffusion of Innovation Theory”
Funding Source: HPD Grant
IRB protocol #: 2016-77
Name
Complete mailing address
Contact phone number
E-mail
Degree

Name
Mailing Address
Contact Phone Number
Email Address
Degree/Academic Information

Principal Investigator
Suhaib Muflih
3301 College Avenue, Fort Lauderdale, Florida
33314-7796
954-980-3890
sm231@nova.edu
PharmD
Co-Investigator 1 (Faculty Advisor)
Barry Bleidt
3301 College Avenue, Fort Lauderdale, Florida
33314-7796
954-262-1855
bbleidt@nova.edu
PhD, PharmD, FAPhA

For questions/concerns about your research rights, contact:
Human Research Oversight Board (Institutional Review Board or IRB)
Nova Southeastern University
954-262-5369/Toll Free: 866-499-0790
IRB@nsu.nova.edu
Site Information:
NSU Clinic Pharmacy
3200 S. University Drive
Ft. Lauderdale, FL 33328
Tel.: 954-262-4550
Fax: 954-262-3865
Why are you asking me?
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You are invited to participate in a research study. Your participation is voluntary
which means you can decide whether to participate. If you choose not to participate, there
will be no loss of benefit to which you might otherwise be entitled. Before you can make
your decision, you will need to know what the study is about, the possible risks and benefits
of participating in this study, and what you will have to do in this study. If you decide to
participate, you will be asked to sign this form.
The purpose of this consent form is to provide you information so that you can
decide whether you want to provide information about yourself, your knowledge and
attitude toward the use of pharmacogenetic testing. The Principle Investigator (the
researcher) will collect the information about you through a survey questionnaire. There
are a particular number of participants expected to participate in this research, but we are
aiming to recruit over 120 participants.
What will I be doing if I agree to be in the study?
If you agree to participate in the study and sign this informed consent, you will fill
out a survey questionnaire (using clipboard survey or tablet computer) that will collect data
that will assess your level of knowledge and attitude toward pharmacogenetic testing. After
you complete the survey (the clipboard survey), please put it in the envelope and give it
back to the Principle Investigator.
Is there any audio or video recording?
No
What are the dangers to me?
We do not anticipate any risks to your participating in this study by filling out a
survey questionnaire. However, if you feel uncomfortable with any question in the survey,
you don’t have to answer it.
Are there any benefits for taking part in this research study?
Although it is not anticipated that there will be any direct benefit to you as a result
of your participation in this study, your participation may contribute to an increase in the
knowledge and understanding of how different individuals pharmacogenetic testing.
Will I get paid for being in the study? Will it cost me anything?
You will not be compensated for you participation in this study. There are no costs
associated with participating in the survey.

How will you keep my information private?
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The Principle Investigator is the only person who will know who you are and any
personally identifiable information about you. We will not share any information that you
give us. The Principle Investigator will replace your personal information with a coded
identification number. All of your information will be stored in a database which is
password-protected and secure. Only the Principle Investigator will have the access to the
database. The researcher will not use any information to identify or contact you.
What if I do not want to participate or I want to leave the study?
You have the right to leave this study at any time or refuse to participate. If you do decide
to leave or you decide not to participate, you will not experience any penalty or loss of
services you have a right to receive.
Other Considerations:
“If significant new information relating to the study becomes available, which may
relate to your willingness to continue to participate, this information will be provided to
you by the investigators.”
Voluntary Consent by Participant:
By signing below, you indicate that
●
●
●
●

this study has been explained to you
you have read this document or it has been read to you
your questions about this research study have been answered
you have been told that you may ask the researchers any study related questions in
the future or contact them in the event of a research-related injury
● you have been told that you may ask Institutional Review Board (IRB) personnel
questions about your study rights
● you are entitled to a copy of this form after you have read and signed it
● you voluntarily agree to participate in the study entitled “Measuring Knowledge
and Attitudes Regarding the Use of Pharmacogenetic Testing Among Patients and
Prescribers: Diffusion of Innovation Theory”
Participant's Signature: ___________________________ Date: ________________
Participant’s Name: ______________________________ Date: ________________
Signature of Person Obtaining Consent: _____________________________
Date: _________________________________
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E.2. Promotional Flyer for Recruiting Patients

E.3. Prescriber Invitation E-Mail
Dear Physician,
The link below will direct you to a survey on pharmacogenetic testing. The
information this survey will collect is vital for an important research project regarding
pharmacogenetic testing/patient personalized medicine. Your answers are important to
publish and totally confidential. Please see the participation letter at the beginning of the
survey for further information on IRB.
Thank you for taking the time to answer this 4-minute survey.
Please note that the survey should be completed in one sitting, and a $10 Starbucks code
will be sent directly via email to the first 120 participants.
Here is the URL:
http://www.nova.edu/~snap/pharmacogenicprescriber.htm
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E. 4. Prescriber Participation Letter
Research Explanation and Letter of Consent
Title of Study: Measuring Knowledge and Attitudes Regarding the Use of
Pharmacogenetic Testing Among Patients and Prescribers: Diffusion of Innovation
Theory.
Principal Investigator: Suhaib Muflih
Complete mailing address: 3301 College Avenue, Fort Lauderdale, Florida 33314-7796
Contact phone number: 954-980-3890
E-mail: sm231@nova.edu
Degree: PharmD
Co-Investigator (Faculty Advisor): Barry Bleidt
Mailing Address: 3301 College Avenue, Fort Lauderdale, Florida 33314-7796
Contact Phone Number: 954-262-1855
Email: bbleidt@nova.edu
Degree/Academic Information: PhD, PharmD, FAPhA
Institutional Review Board
Nova Southeastern University
Office of Grants and Contracts
(954) 262-5369/Toll Free: 866-499-0790
IRB@nsu.nova.edu
IRB #: 2016-77
Site Information:
NSU Clinic pharmacy
3200 S. University Drive
Ft. Lauderdale, FL 33328
Tel.: 954-262-4550
Fax: 954-262-3865
Description of Study:
Dr. Suhaib Muflih is a doctoral student at Nova Southeastern University engaged
in research for the purpose of satisfying the requirements for a Doctor of Philosophy
degree. The goal of this dissertation is to increase our understanding of several factors
(e.g., sociodemographic knowledge, and attitudes) that may play a key role in the
acceptance or rejection of pharmacogenetic testing among patients and prescribers. The
process by which pharmacogenetics will be implemented in the future of both
personalized medicine and routine medical practice will ultimately depend upon patients'
and physicians' acceptance of these tests and related recommendations. If you agree to
participate, you will be asked to complete the survey questionnaire below. The
questionnaire will help the researcher assess prescribers' knowledge and attitudes toward
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pharmacogenetics testing, and the barriers that interfere with its uptake in the routine
clinical practice as a new diagnostic tool. The questionnaire will take approximately four
minutes to complete.
Risks/Benefits to the Participant:
We do not anticipate any risks to your participation in this study. There are no
direct benefits to you for agreeing to be in this study. Please understand that while you
may not benefit directly from participation in this study, you have the opportunity to
enhance the serious gap in our knowledge about the barriers that may prevent the
adoption of pharmacogenetic testing. There is a growing body of evidence that
pharmacogenetics will allow you as a prescriber to make improved prescribing choices
that will increase drug efficacy and minimize adverse effects. If you have any concerns
about the risks/benefits of participating in this study, you may contact the Principle
Investigator and/or the university's human research oversight board Institutional Review
Board at the numbers listed above.
Cost and Payments to the Participant:
There is no cost for participation in this study. Participation is completely
voluntary, however, an incentive will be provided as a token of appreciation for giving
your valuable time to complete the survey.
Confidentiality:
Information obtained in this study is strictly confidential unless disclosure is
required by law. All data will be secured in password-protected computer. Your name
will not be used in the reporting of information in publications or conference
presentations.
Participant's Right to Withdraw from the Study: You have the right to refuse to
participate in this study and the right to withdraw from the study at any time without
penalty.
I have read this letter and I fully understand the contents of this document and
voluntarily consent to participate. All of my questions concerning this research have been
answered. If I have any questions in the future about this study, they will be answered by
the investigator listed above or his/her staff.
I understand that the completion of this questionnaire implies my consent to participate in
this study.
Please initial in the space provided below
______________
Please provide the consent date in the space provided below
______________
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Appendix F
Sensitivity Analyses Using Count Models
Table F.1
Patient Data. Poisson Regression Model
Knowledge
95% Conf. Interval
Variable
IRR
SE
p-value
LL
UL
Gender (Male)
1.020
0.079
0.797
0.877
1.186
Age
0.986
0.028
0.623
0.933
1.043
Ethnicity
0.955
0.037
0.236
0.886
1.030
Level of education
1.089
0.032
0.004
1.028
1.153
Area of living
1.048
0.074
0.506
0.913
1.202
Perceived need
1.080
0.055
0.131
0.977
1.193
Innovativeness
1.119
0.056
0.024
1.015
1.233
Prior experience
1.146
0.102
0.127
0.962
1.364
Cons
2.154
0.502
0.001
1.364
3.402
Note. Knowledge of PGx testing is the response variable in the Poisson regression. IRR:
incidence rate ratios for the Poisson model; SE: standard errors of the individual regression
coefficients; LL: Lower limit; UL: Upper limit. As a patient’s level of education increased
by one unit, his/her knowledge of PGx testing would be expected to increase by a factor
1.089, while holding all other variables in the model constant. Similarly, as a patient’s
innovativeness score increased by one unit, his/her knowledge of PGx testing would be
expected to increase by a factor 1.12, while holding all other variables in the model
constant.
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Table F.2.
Patient Data. Ordinal Dependent Variable Regression Model
Knowledge
95% Conf. Interval
Variables
B
SEB
p-value
LL
UL
Gender (Male)
0.090
0.157
0.565
-0.217
0.398
Age
-0.024
0.059
0.679
0.139
0.091
Ethnicity
-0.135
0.078
0.082
0.287
0.017
Level of education
0.263
0.061
0.000
0.144
0.383
Area of living
0.090
0.142
0.524
0.188
0.368
Perceived need
0.208
0.100
0.038
0.012
0.405
Innovativeness
0.322
0.103
0.002
0.120
0.524
Prior experience
0.520
0.199
0.009
0.131
0.910
Note. B: Standard interpretation of the ordered logit coefficient; SEB: Standard error of
regression coefficients. Ordinal Probit Model is used when the dependent variable
(knowledge) is neither interval nor ratio; the distances between different levels of
knowledge are not equal. For a one unit increase in the level of education, the log-odds
of having a higher level of knowledge would increase by 0.26, given that all of the other
variables in the model are held constant. A one unit increase in the perceived need score
would result in a 0.21 increase in the log-odds of having a higher level of knowledge. A
one unit increase in the innovativeness score would result in a 0.32 increase in the logodds of having a higher level of knowledge, given that all of the other variables in the
model are held constant. The log odds of having a higher level of knowledge is 0.52
greater among patient with a prior experience of PGx testing than those have no prior
experience, given that all of the other variables in the model are held constant.
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Table F.3
Patient Data. Poisson Regression Model
Attitudes
95% Conf. Interval
Variables
IRR
SE
p-value
LL
UL
Gender (Male)
0.883
0.063
0.082
0.767
1.016
Level of education
1.023
0.026
0.365
0.973
1.076
Relative Advantage
1.249
0.066
0.000
1.126
1.386
Compatibility
1.112
0.048
0.014
1.021
1.210
Complexity
0.915
0.054
0.075
0.991
1.205
Trialability
1.187
0.076
0.007
1.047
1.344
Observability
1.059
0.065
0.349
0.939
1.195
Cons
1.323
0.239
0.121
0.929
1.885
Note. Attitude toward PGx testing is the response variable in the Poisson regression. IRR:
incidence rate ratios for the Poisson model; SE: standard errors of the individual
regression coefficients; LL: Lower limit; UL: Upper limit. As the relative advantage score
increased by one unit, the patient’s attitude toward PGx testing would be expected to
increase by a factor 1.25, while holding all other variables in the model constant. As
compatibility score increased by one unit, the patient’s attitude would be expected to
increase by a factor 1.11, while holding all other variables in the model constant. As
trialability score increased by one unit, the patient’s attitude would be expected to increase
by a factor 1.19, while holding all other variables in the model constant.
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Table F.4
Patient Data. Ordinal Dependent Variable Regression Model
Attitudes
95% Conf. Interval
Variables
B
SEB p-value
LL
UL
Gender (Male)
-0.408
0.158
0.010
-0.718
-0.099
Level of education
0.070
0.059
0.233
-0.045
0.185
Relative Advantage
0.629
0.113
0.000
0.408
0.849
Compatibility
0.375
0.101
0.000
0.177
0.573
Complexity
-0.210
0.109
0.054
-0.424
0.004
Trialability
0.434
0.130
0.001
0.179
0.689
Observability
0.268
0.160
0.094
-0.046
0.582
Note. B: Standard interpretation of the ordered logit coefficient; SEB: Standard error of
regression coefficients. Ordinal Probit Model is used when the dependent variable
(knowledge) is neither interval nor ratio; the distances between different levels of
attitude are not equal. The log-odds estimate for males being in a higher level of attitude
is -0.41 less than females when the other variables in the model are held constant. A one
unit increase in the relative advantage score, the log-odds of having a higher level of
attitude would increase by 0.63, given that all of the other variables in the model are
held constant. A one unit increase in the compatibility score would result in a 0.38
increase in the log-odds of having a higher level of attitude. A one unit increase in the
complexity score would result in a 0.21 decrease in the log-odds of being having a higher
level of knowledge, given that all of the other variables in the model are held constant.
A one unit increase in the trialability score would result in a 0.43 increase in the logodds of being having a higher level of knowledge, given that all of the other variables
in the model are held constant.
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Table F.5
Prescriber Data. Poisson Regression Model
Knowledge
95% Conf. Interval
Variables
IRR
SE
p-value
LL
UL
Gender (Male)
0.777
0.078
0.013
0.638
0.948
Type of practice setting
1.248
0.102
0.007
1.063
1.465
Prior-experience
1.257
0.143
0.044
1.006
1.571
Perceived need
1.087
0.077
0.238
0.947
1.247
Communication Channels
1.039
0.054
0.462
0.938
1.150
Cons
2.179
0.407
0.000
1.512
3.142
Note. Knowledge of PGx testing is the response variable in the Poisson regression. IRR:
incidence rate ratios for the Poisson model; SE: standard errors of the individual
regression coefficients; LL: Lower limit; UL: Upper limit. The knowledge scores among
male physicians would be expected to decrease by a factor 0.78 compared to female
physicians, while holding the other variable constant in the model. Knowledge among
physicians who practiced in non-urban areas would be expected to increase by a factor
1.25 compared to physicians who practiced in urban areas, while holding the other
variable constant in the model. Knowledge among physicians who had prior experience
with PGx testing would be expected to increase by a factor 1.26 compared to physicians
with no experience, while holding the other variable constant in the model.
Table F.6
Prescriber Data. Poisson Regression Model
Attitude
95% Conf. Interval
Variables
IRR
SE
p-value
LL
UL
Gender (Male)
0.876
0.068
0.087
0.753
1.020
Relative Advantage
1.160
0.071
0.016
1.029
1.308
Compatibility
1.195
0.079
0.007
1.049
1.361
Observability
1.049
0.042
0.229
0.970
1.135
Cons
3.063
0.495
0.000
2.231
4.205
Note. Attitude toward PGx testing is the response variable in the Poisson regression. IRR:
incidence rate ratios for the Poisson model; SE: standard errors of the individual regression
coefficients; LL: Lower limit; UL: Upper limit. The attitude scores among male physicians
would be expected to decrease by a factor 0.88 compared to female physicians, while
holding the other variable constant in the model. As the relative advantage score increased
by one unit, the physician’s attitude toward PGx testing would be expected to increase by
a factor 1.16, while holding all other variables in the model constant. As compatibility
score increased by one unit, the physician’s attitude would be expected to increase by a
factor 1.20, while holding all other variables in the model constant.
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Appendix G
FDA-Approved Drugs with Package Inserts Containing PGx Information in Warnings
and Precaution Labeling Sections
Table G
Examples of Medications with FDA-Approved PGx information
Drug
Therapeutic Area
Abacavir
Infectious Diseases
Amitriptyline
Psychiatry
Atomoxetine
Psychiatry
Azathioprine
Rheumatology
Capecitabine
Oncology
Carbamazepine
Neurology
Carbamazepine
Neurology
Cetuximab
Oncology
Cetuximab
Oncology
Cevimeline
Dental
Chloroquine
Infectious Diseases
Chlorpropamide
Endocrinology
Citalopram
Psychiatry
Clomipramine
Psychiatry
Clopidogrel
Cardiology
Codeine
Anesthesiology
Dabrafenib
Oncology
Dabrafenib
Oncology
Dapsone
Dermatology
Dapsone
Infectious Diseases
Denileukin Diftitox
Oncology
Desipramine
Psychiatry
Dextromethorphan and
Neurology
Quinidine
Eltrombopag
Hematology
Erythromycin and
Infectious Diseases
Sulfisoxazole
Everolimus
Oncology
Everolimus
Oncology
Fluorouracil
Dermatology
Fluorouracil
Oncology
Fluoxetine
Psychiatry
Glimepiride
Endocrinology

Biomarker
HLA-B*57:01
CYP2D6
CYP2D6
TPMT
DPYD
HLA-B*15:02
HLA-A*31:01
EGFR
EGFR
CYP2D6
G6PD
G6PD
CYP2C19
CYP2D6
CYP2C19
CYP2D6
BRAF
G6PD
G6PD
G6PD
IL2RA (CD25 antigen)
CYP2D6
CYP2D6
F5 (Factor V Leiden)
G6PD
ERBB2 (HER2)
ESR1
DPYD
DPYD
CYP2D6
G6PD
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Glipizide
Glyburide
Iloperidone
Imipramine
Irinotecan
Lenalidomide
Lidocaine and Prilocaine
Lidocaine and Prilocaine
Lomitapide
Mafenide
Mercaptopurine
Methylene Blue
Metoclopramide
Mipomersen
Mycophenolic Acid
Nalidixic Acid
Nefazodone
Nitrofurantoin
Nortriptyline
Olaparib
Oxcarbazepine
Pegloticase
Perphenazine
Pertuzumab
Phenytoin
Pimozide
Primaquine
Propafenone
Protriptyline
Quinidine
Rasburicase
Sevoflurane
Sodium Nitrite
Sulfasalazine
Tamoxifen
Tamoxifen
Tetrabenazine
Thioguanine
Thioridazine
Tolterodine
Trastuzumab
Tretinoin
Trimipramine
Valproic Acid
Vemurafenib

Endocrinology
Endocrinology
Psychiatry
Psychiatry
Oncology
Hematology
Anesthesiology
Anesthesiology
Endocrinology
Infectious Diseases
Oncology
Hematology
Gastroenterology
Endocrinology
Transplantation
Infectious Diseases
Psychiatry
Infectious Diseases
Psychiatry
Oncology
Neurology
Rheumatology
Psychiatry
Oncology
Neurology
Psychiatry
Infectious Diseases
Cardiology
Psychiatry
Cardiology
Oncology
Anesthesiology
Toxicology
Gastroenterology
Oncology
Oncology
Neurology
Oncology
Psychiatry
Urology
Oncology
Oncology
Psychiatry
Neurology
Oncology

G6PD
G6PD
CYP2D6
CYP2D6
UGT1A1
del (5q)
Not specified
G6PD
Not specified
G6PD
TPMT
G6PD
G6PD
Not specified
HPRT1
G6PD
CYP2D6
G6PD
CYP2D6
BRCA1, BRCA2
HLA-B*15:02
G6PD
CYP2D6
ERBB2 (HER2)
HLA-B*15:02
CYP2D6
G6PD
CYP2D6
CYP2D6
CYP2D6
G6PD
RYR1
G6PD
G6PD
F5 (Factor V Leiden)
F2 (Prothrombin)
CYP2D6
TPMT
CYP2D6
CYP2D6
ERBB2 (HER2)
PML-RARA
CYP2D6
POLG
BRAF
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Vemurafenib
Venlafaxine
Warfarin
Warfarin

Oncology
Psychiatry
Hematology
Hematology

NRAS
CYP2D6
PROS1
PROC

140

References
Accreditation Council for Pharmacy Education (2015). Accreditation standards and key
elements for the professional program in pharmacy leading to the doctor of
pharmacy degree. Retrieved from https://www.acpe-accredit.org/pdf/ Standards
2016FINAL.pdf
Adams, S. M., Anderson, K. B., Coons, J. C., Smith, R. B., Meyer, S. M., Parker, L. S., et
al. (2016). Advancing pharmacogenomics education in the core PharmD
curriculum through student personal genomic testing. American Journal of
Pharmaceutical Education, 80(1), 3.
American Society of Health-System Pharmacists (2015). ASHP statement on the
pharmacist’s role in clinical pharmacogenomics. American Journal of HealthSystem Pharmacy, 72(7), 579-581.
An, X. & Yung, Y. (2014). Item response theory: What it is and how you can use the IRT
procedure to apply it. SAS Institute Inc. SAS364-2014.
Armstrong, K., Weiner, J., Weber, B., & Asch, D. A. (2003). Early adoption of BRCA1/2
testing: Who and why. Genetics in Medicine, 5(2), 92-98.
Aron, A. & Aron, E. N. (2003). Statistics for Psychology (3rd ed.). Upper Saddle River,
NJ: Prentice Hall/Pearson Education.
Balkrishnan, R. (2005). The importance of medication adherence in improving chronicdisease related outcomes: What we know and what we need to further know.
Medical Care, 43(6), 517-520.
Benhaim, L., LaBonte, M. J., & Lenz, H.-J. (2012). Pharmacogenomics and metastatic
colorectal cancer: Current knowledge and perspectives. Scandinavian Journal of
Gastroenterology, 47(3), 325-339.
Birch, A. & Malim, T. (1988). Research methods in developmental psychology. In
Developmental Psychology: From Infancy to Adulthood. London, UK: Palgrave
Macmillan, pp. 1-6.
Blankfield, R. P., Goodwin, M., Jaén, C. R., & Stange, K. C. (2002). Addressing the
unique challenges of inner-city practice: A direct observation study of inner-city,
rural, and suburban family practices. Journal of Urban Health, 79(2), 173-185.
Brown, M. T. & Bussell, J. K. (2011). Medication adherence: WHO cares? Mayo Clinic
Proceedings, 86(4), 304-314.
Brown, M. W. & Cudeck, R. (1993). Alternative ways of assessing model fit.
Sociological Methods & Research, 154, 136-162.

141
Budnitz, D. S., Pollock, D. A., Weidenbach, K. N., Mendelsohn, A. B., Schroeder, T. J.,
& Annest, J. L. (2006). National surveillance of emergency department visits for
outpatient adverse drug events. Journal of the American Medical Association,
296(15), 1858-1866.
Bush, P. W. & Daniels, R. (2017). Health care systems and transitions of care implication
on interdisciplinary pharmacy services. North Carolina Medical Journal, 78(3),
177-180.
Calsbeek, H., Morren, M., Bensing, J., & Rijken, M. (2007). Knowledge and attitudes
towards genetic testing: A two year follow-up study in patients with asthma,
diabetes mellitus and cardiovascular disease. Journal of Genetic Counseling,
16(4), 493-504.
Centers for Disease Control and Prevention (2017). Chronic diseases: The leading causes
of death and disability in the United States. Retrieved from https://www.cdc.gov/
chronicdisease/overview/index.htm
Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R., Stanton Jr, V. P., & Ridker,
P. M. (2004). Pharmacogenetic study of statin therapy and cholesterol reduction.
Journal of the American Medical Association, 291(23), 2821-2827.
Chew, F., Grant, W., & Tote, R. (2004). Doctors on-line: Using diffusion of innovations
theory to understand internet use. Family Medicine, 36(9), 645-650.
Cohen, J. (1977). Statistical Power Analysis for the Behavioral Sciences (revised ed.).
New York, NY: Academic Press.
Collins, F. S., Brooks, L. D., & Chakravarti, A. (1998). A DNA polymorphism discovery
resource for research on human genetic variation. Genome Research, 8(12), 12291231.
Cook, R. D. & Weisberg, S. (1982). Residuals and Influence in Regression. New York,
NY: Chapman and Hall.
Cuffe, S., Hon, H., Qiu, X., Tobros, K., Wong, C., De Souza, B., et al. (2014). Cancer
patients’ acceptance, understanding, and willingness-to-pay for pharmacogenomic
testing. Pharmacogenetics and Genomics, 24(7), 348-355.
Desta, Z., Zhao, X., Shin, J., & Flockhart, D. A. (2002). Clinical significance of the
cytochrome P450 2C19 genetic polymorphism. Clinical Pharmacokinetics,
41(12), 913-958.
Dodson, C. (2012). Diffusion of innovation: Knowledge and attitudes of oncology nurses
regarding pharmacogenomic testing. (Doctoral dissertation), The University of
North Carolina at Chapel Hill, Carolina Digital Repository. Retrieved from

142
https://cdr.lib.unc.edu/indexablecontent/uuid:a9f34e42-d78f-4f52-94741e766ae48bf2
Dooley, K. E. (1999). Towards a holistic model for the diffusion of educational
technologies: An integrative review of educational innovation studies.
Educational Technology & Society, 2(4), 35-45.
Dornbrook-Lavender, K. A. & Pieper, J. A. (2003). Genetic polymorphisms in emerging
cardiovascular risk factors and response to statin therapy. Cardiovascular Drugs
and Therapy, 17(1), 75-82.
Dressler, L. G., Deal, A. M., Patel, J., Markey, J., Riper, M. V., & McLeod, H. L. (2014).
Cancer pharmacogenomics, adoption by oncologists and patient benefit.
Personalized Medicine, 11(2), 143-153.
Duhachek, A., Coughlan, A. T., & Iacobucci, D. (2005). Results on the standard error of
the coefficient alpha index of reliability. Marketing Science, 24(2), 294-301.
Durbin, J. & Watson, G. S. (1951). Testing for serial correlation in least squares
regression. II. Biometrika Trust, 38(1/2), 159-177.
Eeles, R. A., Kote-Jarai, Z., Al Olama, A. A., Giles, G. G., Guy, M., Severi, G., et al.
(2009). Identification of seven new prostate cancer susceptibility loci through a
genome-wide association study. Nature Genetics, 41(10), 1116-1121.
Evans, W. E. & Relling, M. V. (1999). Pharmacogenomics: Translating functional
genomics into rational therapeutics. Science, 286(5439), 487-491.
Fargher, E. A., Eddy, C., Newman, W., Qasim, F., Tricker, K., Elliott, R. A., et al.
(2007). Patients’ and healthcare professionals’ views on pharmacogenetic testing
and its future delivery in the NHS. Pharmacogenomics, 8(11), 1511-1519.
Faul, F., Erdfelder, E., Buchner, A., & Lang, A. (2009). Statistical power analyses using
G*Power 3.1: Tests for correlation and regression analyses. Behavior Research
Methods, 41(4), 1149-1160.
Frankfort-Nachmias, C. & Leon-Guerrero, A. (2010). Social Statistics for a Diverse
Society (6th ed.). Thousand Oaks, CA: SAGE Publications, Inc.
Frueh, F. W., Amur, S., Mummaneni, P., Epstein, R. S., Aubert, R. E., DeLuca, T. M., et
al. (2008). Pharmacogenomic biomarker information in drug labels approved by
the United States food and drug administration: Prevalence of related drug use.
Pharmacotherapy, 28(8), 992-998.

143
Gandhi, T. K., Burstin, H. R., Cook, E. F., Puopolo, A. L., Haas, J. S., Brennan, T. A., et
al. (2000). Drug complications in outpatients. Journal of General Internal
Medicine, 15(3), 149-154.
Ghaddar, F., Cascorbi, I., & Zgheib, N. K. (2011). Clinical implementation of
pharmacogenetics: A nonrepresentative explorative survey to participants of
WorldPharma 2010. Pharmacogenomics, 12(7), 1051-1059.
Ginsburg, G. S. & McCarthy, J. J. (2001). Personalized medicine: Revolutionizing drug
discovery and patient care. Trends in Biotechnology, 19(12), 491-496.
Goodman, R. A., Posner, S. F., Huang, E. S., Parekh, A. K., & Koh, H. K. (2013).
Defining and measuring chronic conditions: Imperatives for research, policy,
program, and practice. Preventing Chronic Disease, 10.
Gordon, K., Smith, F., & Dhillon, S. (2007). Effective chronic disease management:
Patients’ perspectives on medication-related problems. Patient Education and
Counseling, 65(3), 407-415.
Green, D., Mummaneni, P., Kim, I., Oh, J., Pacanowski, M., & Burckart, G. (2016).
Pharmacogenomic information in FDA‐approved drug labels: Application to
pediatric patients. Clinical Pharmacology and Therapeutics, 99(6), 622-632.
Guengerich, F. P. (2007). Cytochrome P450 and chemical toxicology. Chemical
Research in Toxicology, 21(1), 70-83.
Haddy, C. A., Ward, H. M., Angley, M. T., & McKinnon, R. A. (2010). Consumers'
views of pharmacogenetics—a qualitative study. Research in Social and
Administrative Pharmacy, 6(3), 221-231.
Haga, S. B. & LaPointe, N. M. A. (2013). The potential impact of pharmacogenetic
testing on medication adherence. The Pharmacogenomics Journal, 13(6), 481483.
Haga, S. B., Barry, W. T., Mills, R., Ginsburg, G. S., Svetkey, L., Sullivan, J., et al.
(2013). Public knowledge of and attitudes toward genetics and genetic testing.
Genetic Testing and Molecular Biomarkers, 17(4), 327-335.
Haga, S. B., Burke, W., Ginsburg, G. S., Mills, R., & Agans, R. (2012a). Primary care
physicians' knowledge of and experience with pharmacogenetic testing. Clinical
Genetics, 82(4), 388-394.
Haga, S. B., O’Daniel, J. M., Tindall, G. M., Lipkus, I. R., & Agans, R. (2012b). Survey
of US public attitudes towards pharmacogenetic testing. The Pharmacogenomics
Journal, 12(3), 197-204.

144
Haga, S. B., Tindall, G., & O'Daniel, J. M. (2012c). Professional perspectives about
pharmacogenetic testing and managing ancillary findings. Genetic Testing and
Molecular Biomarkers, 16(1), 21-24.
Hagymási, K., Müllner, K., Herszényi, L., & Tulassay, Z. (2011). Update on the
pharmacogenomics of proton pump inhibitors. Pharmacogenomics, 12(6), 873888.
Helitzer, D., Heath, D., Maltrud, K., Sullivan, E., & Alverson, D. (2003). Assessing or
predicting adoption of telehealth using the diffusion of innovations theory: A
practical example from a rural program in New Mexico. Telemedicine Journal
and e-Health, 9(2), 179-187.
Henneman, L., Timmermans, D. R., & Van der Wal, G. (2004). Public experiences,
knowledge and expectations about medical genetics and the use of genetic
information. Public Health Genomics, 7(1), 33-43.
Henneman, L., Timmermans, D. R., & Wal, G. V. D. (2006). Public attitudes toward
genetic testing: Perceived benefits and objections. Genetic Testing, 10(2), 139145.
Hu, L. t. & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure
analysis: Conventional criteria versus new alternatives. Structural Equation
Modeling: A Multidisciplinary Journal, 6(1), 1-55.
Jarque, C. M. & Bera, A. K. (1987). A test for normality of observations and regression
residuals. International Statistical Review/Revue Internationale de Statistique,
55(2), 163-172.
Kadafour, M., Haugh, R., Posin, M., Kayser, S. R., & Shin, J. (2009). Survey on warfarin
pharmacogenetic testing among anticoagulation providers. Pharmacogenomics,
10(11), 1853-1860.
Kitzmiller, J. P., Groen, D. K., Phelps, M. A., & Sadee, W. (2011). Pharmacogenomic
testing: Relevance in medical practice: Why drugs work in some patients but not
in others. Cleveland Clinic Journal of Medicine, 78(4), 243.
Klitzman, R., Chung, W., Marder, K., Shanmugham, A., Chin, L. J., Stark, M., et al.
(2013). Attitudes and practices among internists concerning genetic testing.
Journal of Genetic Counseling, 22(1), 90-100.
Kobayashi, E. & Satoh, N. (2009). Public involvement in pharmacogenomics research: A
national survey on public attitudes towards pharmacogenomics research and the
willingness to donate DNA samples to a DNA bank in Japan. Cell and Tissue
Banking, 10(4), 281-291.

145
Kripalani, S., Yao, X., & Haynes, R. B. (2007). Interventions to enhance medication
adherence in chronic medical conditions: A systematic review. Archives of
Internal Medicine, 167(6), 540-549.
Kudzi, W., Addy, B., & Dzudzor, B. (2015). Knowledge of pharmacogenetics among
healthcare professionals and faculty members of health training institutions in
Ghana. Ghana Medical Journal, 49(1), 50-56.
Lachance, K., Korol, S., O'meara, E., Ducharme, A., Racine, N., Liszkowski, M., et al.
(2015). Opinions, hopes and concerns regarding pharmacogenomics: A
comparison of healthy individuals, heart failure patients and heart transplant
recipients. The Pharmacogenomics Journal, 15(1), 13-19.
Lanktree, M. B., Zai, G., VanderBeek, L. E., Giuffra, D. E., Smithson, D. S., Kipp, L. B.,
et al. (2014). Positive perception of pharmacogenetic testing for psychotropic
medications. Human Psychopharmacology, 29(3), 287-291.
Lazaridis, K. N. & Petersen, G. M. (2005). Genomics, genetic epidemiology, and
genomic medicine. Clinical Gastroenterology and Hepatology, 3(4), 320-328.
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions
in hospitalized patients: A meta-analysis of prospective studies. Journal of the
American Medical Association, 279(15), 1200-1205.
Lee, C. R., Goldstein, J. A., & Pieper, J. A. (2002). Cytochrome P450 2C9
polymorphisms: A comprehensive review of the in-vitro and human data.
Pharmacogenetics and Genomics, 12(3), 251-263.
Levene, H. (1960). Robust tests for equality of variances. In Contributions to Probability
and Statistics (Vol. 1). Palo Alto, CA: Stanford University Press.
Levin, K. A. (2006). Study design III: Cross-sectional studies. Evidence-Based Dentistry,
7(1), 24-25.
Ma, T. K., Lam, Y. Y., Tan, V. P., & Yan, B. P. (2011). Variability in response to
clopidogrel: How important are pharmacogenetics and drug interactions? British
Journal of Clinical Pharmacology, 72(4), 697-706.
Manolio, T. A., Brooks, L. D., & Collins, F. S. (2008). A HapMap harvest of insights into
the genetics of common disease. The Journal of Clinical Investigation, 118(5),
1590-1605.
McWilliam, A., Lutter, R., & Nardinelli, C. (2006). Health Care Savings from
Personalizing Medicine Using Genetic Testing: The Case of Warfarin.
Washington, D.C.: AEI-Brookings Joint Center for Regulatory Studies.

146
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P., Harshman, K., Tavtigian, S., et al.
(1994). A strong candidate for the breast and ovarian cancer susceptibility gene
BRCA1. Science, 266(5182), 66-71.
Mills, R., Voora, D., Peyser, B., & Haga, S. B. (2013). Delivering pharmacogenetic
testing in a primary care setting. Pharmacogenomics and Personalized Medicine,
6, 105-112.
Moaddeb, J. & Haga, S. B. (2013). Pharmacogenetic testing: Current evidence of clinical
utility. Therapeutic Advances in Drug Safety, 4(4), 155-169.
Moaddeb, J., Mills, R., & Haga, S. B. (2015). Community pharmacists’ experience with
pharmacogenetic testing. Journal of the American Pharmacists Association,
55(6), 587-594.
Morren, M., Rijken, M., Baanders, A. N., & Bensing, J. (2007). Perceived genetic
knowledge, attitudes towards genetic testing, and the relationship between these
among patients with a chronic disease. Patient Education and Counseling, 65(2),
197-204.
Murphy, S. L., Xu, J., & Kochanek, K. D. (2012). Deaths: Preliminary data for 2010.
Retrieved from https://pdfs.semanticscholar.org/3e72/c0cafc21400569b34331d2d
4fed8ae96d78b.pdf
Nalls, M. A., Saad, M., Noyce, A. J., Keller, M. F., Schrag, A., Bestwick, J. P., et al.
(2013). Genetic comorbidities in Parkinson's disease. Human Molecular Genetics,
23(3), 831-841.
National Center for Health Statistics (2011). Health, United States, 2010: With special
feature on death and dying. Retrieved from https://www.cdc.gov/nchs/data/hus
/hus10.pdf
Nebert, D. W. (1999). Pharmacogenetics and pharmacogenomics: Why is this relevant to
the clinical geneticist? Clinical Genetics, 56(4), 247-258.
Nielsen, L. F. & Moldrup, C. (2007). The diffusion of innovation: Factors influencing the
uptake of pharmacogenetics. Public Health Genomics, 10(4), 231-241.
Nunnally, J. & Bernstein, I. (1994). Psychometric Theory (3rd ed.). New York, NY:
McGraw-Hill, Inc.
Or, C. K. & Karsh, B.-T. (2009). A systematic review of patient acceptance of consumer
health information technology. Journal of the American Medical Informatics
Association, 16(4), 550-560.

147
Østbye, T., Yarnall, K. S., Krause, K. M., Pollak, K. I., Gradison, M., & Michener, J. L.
(2005). Is there time for management of patients with chronic diseases in primary
care? The Annals of Family Medicine, 3(3), 209-214.
Owczarek, J., Jasiñska, M., & Orszulak-Michalak, D. (2005). Drug-induced myopathies.
An overview of the possible mechanisms. Pharmacological Reports, 57(1), 2334.
Perlis, R. H., Patrick, A., Smoller, J. W., & Wang, P. S. (2009). When is
pharmacogenetic testing for antidepressant response ready for the clinic? A costeffectiveness analysis based on data from the STAR * D study.
Neuropsychopharmacology, 34(10), 2227-2236.
Powell, K. P., Cogswell, W. A., Christianson, C. A., Dave, G., Verma, A., Eubanks, S., et
al. (2012). Primary care physicians’ awareness, experience and opinions of directto-consumer genetic testing. Journal of Genetic Counseling, 21(1), 113-126.
Priest, V. L., Begg, E. J., Gardiner, S. J., Frampton, C. M., Gearry, R. B., Barclay, M. L.,
et al. (2006). Pharmacoeconomic analyses of azathioprine, methotrexate and
prospective pharmacogenetic testing for the management of inflammatory bowel
disease. Pharmacoeconomics, 24(8), 767-781.
Relling, M. & Klein, T. (2011). CPIC: Clinical pharmacogenetics implementation
consortium of the pharmacogenomics research network. Clinical Pharmacology
and Therapeutics, 89(3), 464-467.
Roden, D. M. & George Jr, A. L. (2002). The genetic basis of variability in drug
responses. Nature Reviews Drug Discovery, 1(1), 37-44.
Roden, D. M., Wilke, R. A., Kroemer, H. K., & Stein, C. M. (2011). Pharmacogenomics:
The genetics of variable drug responses. Circulation, 123(15), 1661-1670.
Roederer, M. W., Van Riper, M., Valgus, J., Knafl, G., & McLeod, H. (2012).
Knowledge, attitudes and education of pharmacists regarding pharmacogenetic
testing. Personalized Medicine, 9(1), 19-27.
Rogausch, A., Prause, D., Schallenberg, A., Brockmöller, J., & Himmel, W. (2006).
Patients’ and physicians’ perspectives on pharmacogenetic testing.
Pharmacogenomics, 7(1), 49-59.
Rogers, E. M. (2003). Diffusion of Innovations (5th ed.). New York, NY: Free Press.
Shah, J. (2004). Recent developments: Criteria influencing the clinical uptake of
pharmacogenomic strategies. British Medical Journal, 328(7454), 1482-1486.

148
Shaphiro, S. & Wilk, M. (1965). An analysis of variance test for normality. Biometrika
Trust, 52(3), 591-611.
Shaw, K., Amstutz, U., & Carleton, B. C. (2011). Using pharmacogenetics to understand
adverse drug reactions in children. Paediatrics and Child Health, 16(9), 537-538.
Shields, A. E., Blumenthal, D., Weiss, K. B., Comstock, C. B., Currivan, D., & Lerman,
C. (2005). Barriers to translating emerging genetic research on smoking into
clinical practice. Journal of General Internal Medicine, 20(2), 131-138.
Shiffman, D., Trompet, S., Louie, J. Z., Rowland, C. M., Catanese, J. J., Iakoubova, O.
A., et al. (2012). Genome-wide study of gene variants associated with differential
cardiovascular event reduction by pravastatin therapy. PLoS One, 7(5), e38240.
Shishko, I., Almeida, K., Silvia, R. J., & Tataronis, G. R. (2015). Psychiatric
pharmacists’ perception on the use of pharmacogenomic testing in the mental
health population. Pharmacogenomics, 16(9), 949-958.
Smith, K. L. & Isaacs, C. (2011). BRCA mutation testing in determining breast cancer
therapy. The Cancer Journal, 17(6), 492.
Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001). Clinical application of
pharmacogenetics. Trends in Molecular Medicine, 7(5), 201-204.
Srivastava, P. (2003). Drug metabolism and individualized medicine. Current Drug
Metabolism, 4(1), 33-44.
Stanek, E. J., Sanders, C. L., & Frueh, F. W. (2013). Physician awareness and utilization
of food and drug administration (FDA)-approved labeling for pharmacogenomic
testing information. Journal of Personalized Medicine, 3(2), 111-123.
Stanek, E., Sanders, C., Taber, K., Khalid, M., Patel, A., Verbrugge, R., et al. (2012).
Adoption of pharmacogenomic testing by US physicians: Results of a nationwide
survey. Clinical Pharmacology and Therapeutics, 91(3), 450-458.
Steiger, J. H. (2007). Understanding the limitations of global fit assessment in structural
equation modeling. Personality and Individual Differences, 42(5), 893-898.
Stevenson, F. A., Cox, K., Britten, N., & Dundar, Y. (2004). A systematic review of the
research on communication between patients and health care professionals about
medicines: The consequences for concordance. Health Expectations, 7(3), 235245.
Swen, J., Nijenhuis, M., Boer, A. d., Grandia, L., Maitland‐van der Zee, A.-H., Mulder,
H., et al. (2011). Pharmacogenetics: From bench to byte—an update of guidelines.
Clinical Pharmacology and Therapeutics, 89(5), 662-673.

149
Taber, K. A. J. & Dickinson, B. D. (2014). Pharmacogenomic knowledge gaps and
educational resource needs among physicians in selected specialties.
Pharmacogenomics and Personalized Medicine, 7, 145-162.
Table of pharmacogenomic biomarkers in drug labeling (2017). Retrieved from
https://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm0
83378.htm
Thompson, J., Man, M., Johnson, K., Wood, L., Lira, M., Lloyd, D., et al. (2005). An
association study of 43 SNPs in 16 candidate genes with atorvastatin response.
The Pharmacogenomics Journal, 5(6), 352.
Tomalik-Scharte, D., Lazar, A., Fuhr, U., & Kirchheiner, J. (2008). The clinical role of
genetic polymorphisms in drug-metabolizing enzymes. The Pharmacogenomics
Journal, 8(1), 4-15.
Tornatzky, L. G. & Klein, K. J. (1982). Innovation characteristics and innovation
adoption-implementation: A meta-analysis of findings. IEEE Transactions on
Engineering Management, 29(1), 28-45.
Trinidad, S. B., Coffin, T. B., Fullerton, S. M., Ralston, J., Jarvik, G. P., & Larson, E. B.
(2015). “Getting off the bus closer to your destination”: Patients’ views about
pharmacogenetic testing. The Permanente Journal, 19(3), 21-27.
Vacha-Haase, T., Kogan, L. R., & Thompson, B. (2000). Sample compositions and
variabilities in published studies versus those in test manuals: Validity of score
reliability inductions. Educational and Psychological Measurement, 60(4), 509522.
Vogel, F. (1959). Moderne probleme der humangenetik. In Ergebnisse der Iinneren
Medizin und Kinderheilkunde. Berlin, Heidelberg: Springer Berlin Heidelberg,
pp. 52-125.
Vogenberg, F. R., Barash, C. I., & Pursel, M. (2010). Personalized medicine, Part 1:
Evolution and development into theranostics. Pharmacy and Therapeutics,
35(10), 560-562.
Walden, L. M., Brandl, E. J., Changasi, A., Sturgess, J. E., Soibel, A., Notario, J. F. D., et
al. (2015). Physicians' opinions following pharmacogenetic testing for
psychotropic medication. Psychiatry Research, 229(3), 913-918.
Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011). Genomics and drug response.
New England Journal of Medicine, 364(12), 1144-1153.
Ward, B. W., Schiller, J. S., & Goodman, R. A. (2014). Multiple chronic conditions
among US adults: A 2012 update. Preventing Chronic Disease, 11.

150
Wen, M.-S. & Lee, M. T. M. (2013). Warfarin pharmacogenetics: New life for an old
drug. Acta Cardiologica Sinica, 29(3), 235-242.
World Health Organization (1994). The role of the pharmacist in the health care system.
Retrieved from http://apps.who.int/medicinedocs/en/d/Jh2995e/1.6. html
#Jh2995e.1.6
Wright, S. (1921). Correlation and causation. Journal of Agricultural Research, 20(7),
557-585.
Zhang, S. C., Bruce, C., Hayden, M., & Rieder, M. J. (2014). Public perceptions of
pharmacogenetics. Pediatrics, 133(5), e1258-e1267.
Zhang, X., Yu, P., Yan, J., & Spil, I. T. A. (2015). Using diffusion of innovation theory
to understand the factors impacting patient acceptance and use of consumer ehealth innovations: A case study in a primary care clinic. BMC Health Services
Research, 15(1), 71.

151

CURRICULUM VITAE 2017
SUHAIB M. MUFLIH
PERSONAL INFORMATION
Address:

Date of Birth:
Nationality:
Marital Status:

10237 SW 59 St, Cooper City, Florida
Tel: 954-395-6500
Email: sm2341@mynsu.nova.edu
January 22nd, 1985
Jordanian
Married

EDUCATION
Year

Institution

2012 - 2017

Doctor of Philosophy
Nova Southeastern University
Fort Lauderdale, Florida

2010 - 2012

Pharmacy Intern
Iowa University Hospital
Iowa City, Iowa

2003 - 2009

Doctor of Pharmacy
Jordan University of Science and Technology
Irbid - Jordan

2002 - 2003

General Secondary Certificate
Khalid Ibn AL-Waleed High School
Irbid - Jordan

SKILLS AND LANGUAGES
Computer Skills
Languages
Statistical Software

EXPERIENCES

Internet
Microsoft Word, Excel, Power point
English: Excellent
Arabic: Excellent
IBM SPSS®
Stata

152
2015 - 2016

Class Facilitator/ Microbiology and
Pharmacotherapy/ NSU, Florida

2014 - 2017

Primary Data Collection
Survey Construction and Validation
Statistical Analyses
Grant Review Experience

2011- 2012

Pharmacy internship, University of Iowa Hospitals
and Clinics:
- Training for providing clinical consultative
services to patients and therapeutic
recommendations to nurses and physicians
- Training for the sterile compounding and aseptic
techniques
Teaching Assistant, Department of Clinical
Pharmacy, Jordan University of Science and
Technology

2009 - 2010

2009 - 2010

Supervising PharmD and Msc Clinical Pharmacy
Students: Cardiology and Endocrinology Rotations
at King Abdullah University Hospital (KAUH)
and other local hospitals, Jordan

2008 - 2009

Community Pharmacy Training, Platinum
Pharmacy, Irbid - Jordan

2007 - 2008

Hospital Pharmacy Training, Princess Basma
Hospital, Irbid - Jordan

PROFESSIONAL MEMBERSHIPS
 The Jordanian Association of Pharmacy (JPA)
 Pharmacy Graduate PhD Association-SGA
 The Rho Chi Pharmacy Honor Society
 American Society of Health-System Pharmacists (ASHP)
 International Society For Pharmacoeconomics and Outcomes Research (ISPOR)
 American Association of Colleges of Pharmacy (AACP)
 Florida Society of Health-System Pharmacists (FSHP)
 The American Pharmacists Association (APhA)
 American College of Clinical Pharmacy (ACCP)
WORKSHOPS

153
January 2016

Faculty Development Workshops. NSU-Fort
Lauderdale, Florida

March 2014

Institutional Review Board Workshop. NSUFort Lauderdale, Florida

February 2014

Grant Workshop. NSU-Fort Lauderdale, Florida

April 2010

Updates in Therapeutics. American college of
clinical pharmacy (ACCP). Charlotte, North
Carolina

December 2009

Drug Information Resources, Jordan
Pharmaceutical Association. Amman - Jordan

ACTIVITIES AND COMMUNITY SERVICES
April 2016

Heart Walk/ NSU-Fort Lauderdale, Florida

February 2016

Conference Moderator at NSU Research Day.
Fort Lauderdale, Florida

February 2016

Community Festival. NSU-Fort Lauderdale,
Florida

August 2009 - January 2010

Primary Data Collector as a part of the Medicine
Transparency Alliance (MeTA) Project held by the
World Health Organization (WHO) and High
Health Council (HHC). Collecting data regarding
medicine availability, affordability, accessibility
and rational use among randomized sample of the
population. Amman - Jordan

SERVICES TO STUDENTS
2015 - 2016

President/International Society for
Pharmacoeconomics and Outcomes Research
(ISPOR)

2009 - 2016

Student Tutoring

RESEARCH OF INTEREST
 Pharmacogenetics

 Outcome Research

 Clinical Pharmacy

 Sociobehavioral aspects of Pharmacy

PUBLICATIONS

154

 Alameddine, S., Muflih, S., Hale, G., & Khanfar, N. M. (2016). Development
and Implementation of Customized Intravenous to Oral Conversion Protocol:
Cost-Saving Analysis. Value in Health, 19(3), A272. DOI:
10.1016/j.jval.2016.03.879.

 Halum, A. S., Bhinder, M. T. M., Shawaqfeh, M. S., & Muflih, S. M. (2016). An
In-Depth Look at the Clinical Relevance of Pharmacogenetic Testing
Ascertained. Journal of Molecular and Genetic Medicine, 2016. DOI:
10.4172/1747-0862.1000210.

 Shawaqfeh, M. S., Bhinder, M. T., Halum, A. S., Harrington, C., & Muflih, S.
(2015). Adverse Drug Events Related to Canagliflozin: A Meta-Analysis of
Randomized, Placebo-Controlled Trials. Advances Pharmacoepidemiology and
Drug Safety, 4(196), 2167-1052. DOI:10.4172/2167-1052.1000196.

 Bhinder, M. T. M., Halum, A. S., Muflih, S. M., & Shawaqfeh, M. (2015).
Pharmacogenetic Testing for Methotrexate Treatment in Leukemia Patients.
Journal of Biomolecular Research & Therapeutics, 4(134), 2.
DOI:10.4172/2167-7956.1000134.

 Al-Azzam, S. I., AlOmari, M., Khader, Y. S., AlMahasneh, F. A., Muflih, S. M.,
& Altawalbeh, S. (2012). Effects of pioglitazone add-on to gliclazide and
metformin on glycemic control in patients with type 2 diabetes. Endocrine
research, 37(1), 7-11. DOI: 10.3109/07435800.2011.566238.

POSTERS PRESENTED IN SCIENTIFIC MEETING
 Muflih, S., Bleidt, B., Popovici, I., & Khanfar, NM. (2017, November).
Community physicians’ knowledge and attitudes towards pharmacogenetic
testing. Poster session will be presented at the American Public Health
Association 145th Annual Meeting, Atlanta, GA.

 Muflih, S., Bleidt, B., Khanfar, NM., & Popovici, I. (2017, March).
Measuring knowledge and attitudes regarding the use of pharmacogenetic testing
among patients. Poster session presented at the American Pharmacists
Association 164th Annual Meeting, San Francisco, CA.

 Muflih, S., Bleidt, B., Khanfar, NM., & Popovici, I. (2016, December).
Measuring knowledge and attitudes regarding the use of pharmacogenetic testing
among physicians. Poster session presented at the American Society of HealthSystem Pharmacists 51st Annual Midyear Clinical Meeting, Las Vegas, NV.

155

 Sherbeny, F., Muflih, S., & Barry, B. (2016, December). Pharmacist’s Role in
HF Patient’s Transition of Care: RCT. Poster session presented at the American
Society of Health-System Pharmacists 51st Annual Midyear Clinical Meeting, Las
Vegas, NV.

 Muflih, S., Bleidt, B., Khanfar, NM., & Popovici, I. (2016, October). Measuring
Knowledge and Attitudes Regarding the Use of Pharmacogenetic Testing among
Patients and Prescribers: Diffusion of Innovation Theory. Poster session
presented at the American College of Clinical Pharmacy 45th Annual Meeting,
Hollywood, FL.

 Hale, G., Muflih, S., Alameddine, S., & Khanfar, NM. (2016,
October). Prescribing Patterns of Thiazide Diuretics. Poster session presented at
the American College of Clinical Pharmacy 45th Annual Meeting, Hollywood,
Florida.

 Muflih, S., Bleidt, B., Khanfar, NM., Popovici I., & Sanchez, J. (2016, August).
Knowledge and attitudes regarding the use of pharmacogenetic testing among
patients and physicians: a systematic review. Poster session presented at
the Florida Society of Health-System Pharmacists 50 th Annual Meeting, Orlando,
FL.

 Alameddine, S., Muflih, S., Hale, G., & Khanfar, N. M. (2016, May).
Development and Implementation of Customized Intravenous to Oral Conversion
Protocol: Cost-Saving Analysis. Poster session presented at the International
Society for Pharmacoeconomics and Outcomes Research 21 st Annual Meeting,
Washington, DC.

 Muflih, S., Khanfar, NM., Shawaqfeh, M., Bleidt, B., & Popovici I. (2016,
February). Knowledge and attitudes towards pharmacogenetic testing among a
cohort of patients and prescribers: diffusion of innovation theory. Poster session
presented at the NSU Research Day, Fort Lauderdale, FL.

 Muflih, S., Fore, J., Shawaqfeh, M., & Khanfar, NM. (2016, February).
Literature Based Evidence of the Clinical Relevance of Pharmacogenetic Testing
for Simvastatin. Poster session presented at the NSU Research Day, Fort
Lauderdale, FL.

 Muflih, S., Khanfar, NM., Shawaqfeh, M., Bleidt, B., & Popovici, I. (2015,
December). Knowledge and attitudes towards pharmacogenetic testing among a
cohort of patients and prescribers: diffusion of innovation theory. Poster session
presented at: American Society of Health-System Pharmacists 50 th Annual
Midyear Clinical Meeting, New Orleans, LA.

RESEARCH IN PROGRESS

156

 Measuring Patients’ Knowledge and Attitudes towards Pharmacogenetic Testing:
Diffusion of Innovation Theory

 Measuring Physicians’ Knowledge and Attitudes towards Pharmacogenetic
Testing: Diffusion of Innovation Theory

 Knowledge and Attitudes regarding the Use of Pharmacogenetic Testing Among
Patients: A Systematic Review

 Knowledge and Attitudes regarding the Use of Pharmacogenetic Testing among
Physicians: A Systematic Review

 Literature Based Evidence of the Clinical Relevance of Pharmacogenetic Testing
for Simvastatin”

 Prescribing Patterns of Thiazide Diuretics
 Impact Of IV to PO Antibiotic Conversion on Cost Saving
LOCAL CONFERENCES
 The 12th International Association for chronic fatigue syndrome/myalgic
encephalomyelitis Research and Clinical Conference: Emerging Science and
Clinical Care conference; October, 2016. Nova Southeastern University, Florida

 Future of Medicine Summit/ the 10th Anniversary; September, 2016; Palm Beach
County Convention Center, Florida

 Emerging Challenges in Primary Care/ the 15th Annual Conference; September,
2016. Fort Lauderdale Marriott Coral Springs

 The Medical Marijuana Program; August, 2016. Nova Southeastern University,
Florida

GRANTS
 October 2016: Awarded received from PanSGA Professional Development Grant
to present at the 2016 ACCP Annual Meeting, 10/23/2016 to 10/26/2016.
Measuring Knowledge and Attitudes Regarding the Use of Pharmacogenetic
Testing Among Patients and Prescribers: Diffusion of Innovation Theory

 June 2016: Awarded $4,990 by HPD Research Committee. Measuring knowledge
and attitudes regarding the use of pharmacogenetic testing among patients and
prescribers: diffusion of innovation theory

 February 2016: Awarded $450 from Pan SGA Professional Development Grant
to present at the 2015 ASHP Midyear Clinical Meeting, 12/06/2015-12/10/2015.
Knowledge and attitudes towards pharmacogenetic testing among a cohort of
patients and prescribers: diffusion of innovation theory (New Orleans, LA)

POINTS OF INTERESTS

157

 I am interested the outcomes of therapeutics using Pharmacogenetic testing.
 I am interested in continuing to learn more about pharmacoepidemiological
research and the outcomes of therapeutics

 I am interested in doing research about good pharmacy practice especially the
collaboration between physicians and pharmacists to choose the best healthcare
plan that decrease the economic burden on healthcare system

 I am interested in conducting more research on knowledge and attitudes towards
pharmacogenetic testing among patients, pharmacists, and prescribers using
diffusion of innovation theory

AWARDS AND HONORS
 February 2016: Award received for poster presentation, HPD Research Day. The
award is given for the outstanding poster presentation of my research
titled Knowledge and attitudes towards pharmacogenetic testing among a cohort of
patients and prescribers: diffusion of innovation theory, during NSU Research Day,
held on February 12, 2016
 September 2014: Member of Rho Chi national pharmacy honor society

HOBBIES
 Swimming, Kayaking, Biking, Ping Pong, Chess

